Á × Ì ÙÚ ŸÑÚäà Ý Í Ð Þ Ó Ð Ø ß Ó

202 Aetna Pharmacy Drug Guide
Advanced Control Plan - Aetna: S -1.75 Tc <8 36 68.64

Frequently asked questions

How can I save on prescriptions?

What is step therapy?

What are quantity limits?

What are generic drugs?

Dose efficiency edits

Maximum daily dose

What is precertification?

Quantity limits over time

How can your provider request a medical exception?

1-800-294-5979
1-866-814-5506

1-888-836-0730
1-866-249-6155

Can the formulary change during the year?

Pharmacy and Therapeutics (P&T) committee

Commercial 1557 Nondiscrimination Notice

Aetna is the brand name used for products and services provided by one or more of the Aetna group of subsidiary companies, including Aetna Life Insurance Company and their affiliates (Aetna).

(Kurdish)

(Marshallese)

(Micronesian-Pohnpeian)

në ID kard du kȍu. (Nilotic-Dinka)

Kardoi denwskujęcej (Polish)

identidade. (Portuguese)

(Romanian)

		Amtcp_ec Pcosgpckclrq _lb Jgkgrq ?J ; ?ec Jgkgr G@A ; Glbga_rgml @_qcb Amtcp_ec JEA ; Jmucqr Eclcpga Amn_w ?nnjgcq L/. ; Bpse Amtcp_ec dmp Qrsbclr Fc_jrf kck`cpq, L5 ; Bpse rgcp ufcl AC bmcq lmr _nnjw L6 ; Bpse Qncagdga Amtcp_ec N? ; Npgmp ?srfmpgx_rgml OJ ; Os_lrgrw Jgkgr OJP ; Os_lrgrw Jgkgr Pcqrpgargml @_qcb ml ?ec
	Bpse Rgcp AC ; Amn_w Cvacnrgml8 ?t_gj_`jc rm qmkc kck`cpq _r lm amqr ugrf _ npcqapgnrgml dpmk wmsp npmtgbcp ufcl m`r_glcb _r _l gl+lcrumpi nf_pk_aw, Acpr_gl jgkgr_rgmlq k_w _nnjw, LD ; Lml+dmpksj_pw* lmr amtcpcb sljcqq cvacnrgml pcoscqr ep_lrcb LN ; Lml+Npcdcppcb @p_lb _lb Eclcpga LNQN ; Lml+Npcdcppcb Qncag_jrw	Qcjcar MRA ; Qcjcar MRA Npmep_k gd wmsp nf_pk_aw nj_l glajsbcq rfgq npmep_k wms k_w f_tc amtcp_ec dmp npmbsarq lmrcb ugrf _ bmarmpq npcqapgnrgml, Njc_qc qcc wmsp nj_l `clcdgr gldmpk_rgml dmp qncagdga amtcp_ec bcr_gjq, QNA ; Qcjcar Nj_l Amtcp_ec8 Mljw _t_gj_`jc dmp qcjcar nj_lq, ĸĸPcdcp rm kck`cp nj_l bmaskclrq dmp amtcp_ec,ĸ
jmucpa_qc gr_jgaq ; Eclcpga bpseq SNNCPA?QC ; @p_lb l_kc bpseq	N@ ; Npcdcppcb @p_lb NE ; Npcdcppcb Eclcpga NQN ; Npcdcppcb Qncag_jrw	QR ; Qrcn Rfcp_nw QRV ; Q_dcp _lb-mp kmpc cddcargtc rpc_rkclrq _pc _t_gj_`jc

		ʒ γ ᴰ Ł -ɣ - ˡ

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
allopurinol oral tablet 200 mg	LD	
colchicine oral capsule 0.6 mg	LD	
colchicine oral tablet 0.6 mg	NE	OJ &/0. R?@JCRQ ncp 03 B?Wq'
colchicine-probenecid oral tablet 0.5-500 mg	NE	
AMJAPWQ MP?J R?@JCR .,4 KE &*colchicine*'	LD	
febuxostat oral tablet 40 mg, 80 mg	NE	
IPWQRCVV? GLRP?TCLMSQ QMJSRGML 6 KE-KJ &*pegloticase*'	LNQN	N?
KGRGE?PC MP?J A?NQSJC .,4 KE &*colchicine*'	N@	OJ &4. A?NQSJCQ ncp 03 b_wq'
probenecid oral tablet 500 mg	NE	
SJMPGA MP?J R?@JCR 2. KE*6. KE &*febuxostat*'	LD	
KGQACJJ?LCMSQ		
NPG?JR GLRP?RFCA?J QMJSRGML /.. KAE-KJ*3.. KAE-0.KJ*3.. KAE-3KJ &*ziconotide acetate*'	LNQN	
LML+MNGMGB ?L?JECQGAQ		
?JJXGR?J MP?J R?@JCR 03+103 KE &*butalbital-acetaminophen*'	LD	
butalbital-apap-caffeine &@_a Mp_j R_`jcr 3.+103+2. Ke'	NE	QRV9 OJ &26 r_`jcrq ncp 03 b_wq'
butalbital-acetaminophen &@sn_n Mp_j R_`jcr 3.+1.. Ke'	LD	
butalbital-acetaminophen oral capsule 50-300 mg	LD	
butalbital-acetaminophen oral tablet 50-325 mg	NE	QRV9 OJ &26 R?@JCRQ ncp 03 B?Wq'
butalbital-apap-caffeine oral capsule 50-300-40 mg, 50-325-40 mg	LD	
butalbital-apap-caffeine oral tablet 50-325-40 mg	NE	QRV9 OJ &26 R?@JCRQ ncp 03 b_wq'
butalbital-aspirin-caffeine oral capsule 50-325-40 mg	NE	QRV9 L6 &Jgqrgle bmcq lmr glajsbc acpr_gl LBAq'9 OJ &26 A?NQSJCQ ncp 03 B?Wq'
CQEGA MP?J R?@JCR 3.+103+2. KE &*butalbital-apap-caffeine*'	LN	QRV9 OJ &26 R?@JCRQ ncp 03 B?Wq'

0.01 Nf_pk_aw Bpse Esgbc+?bt_lacb Amlrpmj Nj_l+?crl_Qrsbclr Fc_jrf

Rfc dmpksj_pwgq snb_rcb _llsjjwgl HsjwK

.5-./-0.01

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jg] B ů b Ce_ se L_k

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
hydrocodone bitartrate er oral tablet er 24 hour abuse-deterrent 100 mg, 120 mg, 20 mg, 30 mg, 40 mg, 60 mg, 80 mg	LD	
hydrocodone-acetaminophen oral solution 7.5-325 mg/15ml	LN	$PO8;$PO9$e O$e O$e O$e O$e O$e O%6-48@ 6O$e O$e O$e O$e O$e O$e PO O$e O$e PL ð $PO8n BCVTF •NH NM I NH

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
methadone hcl oral solution 10 mg/5ml	NE	QR9 OJ &003 K J ncp 03 b_wq'
methadone hcl oral solution 5 mg/5ml	NE	QR9 OJ &23. K J ncp 03 B?Wq'
methadone hcl oral tablet 10 mg	NE	QR9 OJ &1. R?@JCRQ ncp 03 b_wq'
methadone hcl oral tablet 5 mg	NE	QR9 OJ &7. R?@JCRQ ncp 03 B?Wq'
methadone hcl oral tablet soluble 40 mg	NE	OJ &7 R?@JCRQ ncp 03 B?Wq'
methadone hcl oral table ʒ ! в † v Þ		
	NE	

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
morphine sulfate oral tablet 30 mg	NE	L6 &Qs`hcar rmglgrg_j jgkgr'9 OJ &7. R?@JCRQ ncp 03 b_wq'
KQ AMLRGL MP?J R?@JCR CVRCL BCB PCJC?QC /.. KE*0.. KE*4. KE &*morphine sulfate*'	LN	QR
KQ AMLRGL MP?J R?@JCR CVRCL BCB PCJC?QC /3 KE*1. KE &*morphine sulfate*'	LN	QR9 OJ &7. R?@JCRQ ncp 03 B?Wq'
nalocet oral tablet 2.5-300 mg	LD	

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
oxycodone-acetaminophen oral solution 10-300 mg/5ml, 5-325 mg/5ml	LD	

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
PMVW@ML B MP?J R?@JCR ?@SQC+BCRCPPCLR /3 KE*1. KE*3 KE &*oxycodone hcl*'	LD	
QCEJCLRGQ MP?J R?@JCR 34+22 KE &*celecoxib-tramadol hcl*'	LD	
QS@QWQ QS@JGLES?J JGOSGB /.. KAE*/0.. &4.. V 0' KAE*/4.. &6.. V 0' KAE*0.. KAE*2.. KAE*4.. KAE*6.. KAE &*fentanyl*'	LD	
tramadol hcl (er biphasic) oral capsule extended release 24 hour 100 mg, 200 mg, 300 mg	LD	
tramadol hcl (er biphasic) oral tablet extended release 24 hour 100 mg	NE	QR9 OJ &1. R?@JCRQ ncp 03 b_wq'
tramadol hcl (er biphasic) oral tablet extended release 24 hour 200 mg, 300 mg	NE	QR
tramadol hcl er oral tablet extended release 24 hour 100 mg	NE	QR9 OJ &1. R?@JCRQ ncp 03 b_wq'
tramadol hcl er oral tablet extended release 24 hour 200 mg, 300 mg	NE	QR
tramadol hcl oral solution 5 mg/ml	LD	
tramadol hcl oral tablet 100 mg	LD	
tramadol hcl oral tablet 50 mg	NE	L6 &Qs`hcar rmglgrg_j jgkgr'9 OJ &/6. R?@JCRQ ncp 03 b_wq'
tramadol-acetaminophen oral tablet 37.5-325 mg	NE	L6 &Qs`hcar rmglgrg_j jgkgr'9 OJ &2. R?@JCRQ ncp 03 b_wq'
VR?KNX? CP MP?J A?NQSJC CP /0 FMSP ?@SQC+ BCRCPPCLR /1,3 KE*/6 KE*05 KE*7 KE &*oxycodone*'	N@	QR9 OJ &4. A?NQSJCQ ncp 03 b_wq'
VR?KNX? CP MP?J A?NQSJC CP /0 FMSP ?@SQC+ BCRCPPCLR 14 KE &*oxycodone*'	N@	QR
MNGMGB N?PRG?J ?EMLGQRQ		
@CJ@SA? @SAA?J DGJK /3. KAE*1.. KAE*23. KAE*53 KAE &*buprenorphine hcl*'	N@	QR9 OJ &4. DGJKQ ncp 03 B?Wq'
@CJ@SA? @SAA?J DGJK 4.. KAE*53. KAE*7.. KAE &*buprenorphine hcl*'	N@	QR
buprenorphine transdermal patch weekly 10 mcg/hr, 5 mcg/hr, 7.5 mcg/hr	NE	QR9 OJ &2 N?RAF UCCIJW ncp 03 b_wq'
buprenorphine transdermal patch weekly 15 mcg/hr, 20 mcg/hr	NE	QR

0.01 Nf_pk_aw Bpse Esgbc+?bt_lacb Amlrpmj Nj_l+?crl_Qrsbclr Fc_jrf

Rfc dmpksj_pwgq snb_rcb _llsjjwgl HsjwK

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
@SRP?LQRP?LQBCPK?JN?RAF UCCIJW/. KAE-FP*/3 KAE-FP*0. KAE-FP*3 KAE-FP*5,3 KAE-FP &*buprenorphine*'	LD	
pentazocine-naloxone hcl oral tablet 50-0.5 mg	LN	QRV9 L6 &Qs`hcar rmglgrg_j jgkgr,'9 OJ &/0. R?@JCRQ ncp 03 b_wq'
QS@JMA?BC QS@ASR?LCMSQ QMJSRGML NPCDGJJCB QWPGLEC/.. KE-.,3KJ*1.. KE-/,3KJ &*buprenorphine*'	NQN	
Q?JGAWJ?RCQ		
aspirin childrens oral tablet chewable 81 mg	AC	L5 &Lmr Amtcpcb'9 OJ &/.. R?@JCRQ ncp 1. B?Wq'9 ?J &Kgl /0 Wc_pq_lb K_v 37 Wc_pq'
aspirin oral tablet delayed release 81 mg	AC	L5 &Lmr Amtcpcb'9 OJ &/.. R?@JCRQ ncp 1. B_wq'9 ?J &Kgl /0 Wc_pq_lb K_v 37 Wc_pq'
diflunisal oral tablet 500 mg	NE	L6 &Jgqrgle bmcq lmrglajsbc acpr_gl LBAq'
TGQAMQSNNJCKCLRQ		
BSPMJ?LCGLRP?+?PRGASJ?P NPCDGJJCB QWPGLEC4. KE-1KJ &*sodium hyaluronate (viscosup)*'	NQN	N?
CSDJCVV?GLRP?+?PRGASJ?P QMJSRGML NPCDGJJCB QWPGLEC0. KE-0KJ &*sodium hyaluronate (viscosup)*'	NQN	N?
ECJ+MLCGLRP?+?PRGASJ?P NPCDGJJCB QWPGLEC 1. KE-1KJ &*cross-linked hyaluronate*'	LD	
ECJQWL+1GLRP?+?PRGASJ?P QMJSRGML NPCDGJJCB QWPGLEC/4,6 KE-0KJ &*sodium hyaluronate (viscosup)*'	NQN	N?
ECLTGQA 63. GLRP?+?PRGASJ?P QMJSRGML NPCDGJJCB QWPGLEC03 KE-0,3KJ &*sodium hyaluronate (viscosup)*'	LD	
FW?JE?L GLRP?+?PRGASJ?P QMJSRGML 0. KE-0KJ &*sodium hyaluronate (viscosup)*'	LD	

0.01 Nf_pk_aw Bpse Esgbc+?bt_lacb Amlrpmj Nj_l+?crl_Qrsbclr Fc_jrf

Rfc dmpksj_pwgq snb_rcb _llsjjwgl HsjwK

.5-./-0.01

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
FW?JE?L GLRP?+?PRGASJ?P QMJSRGML NPCDGJJCB QWPGL EC 0. K E-0K J &*sodium hyaluronate (viscosup)*'	LD	
FWKMTGQ GLRP?+?PRGASJ?P QMJSRGML NPCDGJJCB QWPGL EC 02 K E-1K J &*hyaluronan*'	LD	
KMLMTGQA GLRP?+?PRGASJ?P QMJSRGML NPCDGJJCB QWPGL EC 66 K E-2K J &*hyaluronan*'	LD	
MPRFMTGQA GLRP?+?PRGASJ?P QMJSRGML NPCDGJJCB QWPGL EC 1. K E-0K J &*hyaluronan*'	LD	
QSN?PRX DV GLRP?+?PRGASJ?P QMJSRGML NPCDGJJCB QWPGL EC 03 K E-0,3K J &*sodium hyaluronate (viscosup)*'	NQN	N?
QWLMHMWLR GLRP?+?PRGASJ?P QMJSRGML NPCDGJJCB QWPGL EC 0. K E-0K J &*sodium hyaluronate (viscosup)*'	LD	
QWLTGQA GLRP?+?PRGASJ?P QMJSRGML NPCDGJJCB QWPGL EC /4 K E-0K J &*hylan*'	LD	
QWLTGQA MLC GLRP?+?PRGASJ?P QMJSRGML NPCDGJJCB QWPGL EC 26 K E-4K J &*hylan*'	LD	
RPGJSPML GLRP?+?PRGASJ?P QMJSRGML NPCDGJJCB QWPGL EC 0. K E-0K J &*sodium hyaluronate (viscosup)*'	LD	
RPGTGQA GLRP?+?PRGASJ?P QMJSRGML NPCDGJJCB QWPGL EC 03 K E-0,3K J &*sodium hyaluronate (viscosup)*'	LD	
TGQAM+1 GLRP?+?PRGASJ?P QMJSRGML NPCDGJJCB QWPGL EC 03 K E-0,3K J &*sodium hyaluronate (viscosup)*'	LD	
?LRG+GLDCARGTCQ+BPSEQ RM RPC?R GLDCARGMLQ		
?LRFCJKGLRGAQ+BPSEQ DMP UMPK GLDCARGML		
albendazole oral tablet 200 mg	LN	OJ &114 R?@JCRQ ncp 143 b_wq'
@GJRPGAGBC MP?J R?@JCR 4.. K E &*praziquantel*'	LN	OJ &02 R?@JCRQ ncp 143 B?Wq'
CKTCPK MP?J R?@JCR AFCU?@JC /.. K E &*mebendazole*'	LN	OJ &/0 R?@JCRQ ncp 143 b_wq'
ivermectin oral tablet 3 mg	NE	
praziquantel oral tablet 600 mg	NE	OJ &02 R?@JCRQ ncp 143 B?Wq'

0.01 Nf_pk_aw Bpse Esgbc+?bt_lacb Amlrpmj Nj_l+?crl_Qrsbclr Fc_jrf

Rfc dmpksj_pwgq snb_rcb _llsjjwgl HsjwK

.5-./-0.01
04

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
efavirenz oral capsule 200 mg, 50 mg	NE	OJ &7. A?NQSJCQ ncp 1. B?Wq'
efavirenz oral tablet 600 mg	NE	OJ &1. R?@JCRQ ncp 1. b_wq'
emtricitabine oral capsule 200 mg	NE	OJ &1. R?@JCRQ ncp 1. B?Wq'
CKRPGT? MP?J A?NQSJC 0.. KE &*emtricitabine*'	N@	OJ &1. A?NQSJCQ ncp 1. B?Wq'
CKRPGT? MP?J QMJSRGML /. KE-KJ &*emtricitabine*'	N@	OJ &46. KJ ncp 06 B?Wq'
CNGTGP MP?J QMJSRGML /. KE-KJ &*lamivudine*'	LN	OJ &7.. kjq ncp 1. b_wq'
CNGTGP MP?J R?@JCR /3. KE &*lamivudine*'	LN	OJ &4. r_`jcrq ncp 1. b_wq'
CNGTGP MP?J R?@JCR 1.. KE &*lamivudine*'	LN	OJ &1. r_`jcrq ncp 1. b_wq'
etravirine oral tablet 100 mg	NE	OJ &/0. R?@JCRQ ncp 1. B?Wq'
etravirine oral tablet 200 mg	NE	OJ &4. R?@JCRQ ncp 1. B?Wq'
fosamprenavir calcium oral tablet 700 mg	NE	OJ &/0. R?@JCRQ ncp 1. B?Wq'
DSXCML QS@ASR?LCMSQ QMJSRGML PCAMLQRGRSRCB 7. KE &*enfuvirtide*'	NQN	N?9 OJ &4. QMJSRGML PCAMLQRGRSRCB ncp 1. b_wq'
GLRCJCLAC MP?J R?@JCR /.. KE*03 KE &*etravirine*'	N@	OJ &/0. R?@JCRQ ncp 1. B?Wq'
GLRCJCLAC MP?J R?@JCR 0.. KE &*etravirine*'	N@	OJ &4. R?@JCRQ ncp 1. B?Wq'
GQCLRPCQQ FB MP?J R?@JCR 4.. KE &*raltegravir potassium*'	N@	OJ &4. R?@JCRQ ncp 1. B?Wq'
GQCLRPCQQ MP?J N?AICR /.. KE &*raltegravir potassium*'	N@	OJ &4. N?AICRQ ncp 1. b_wq'
GQCLRPCQQ MP?J R?@JCR 2.. KE &*raltegravir potassium*'	N@	OJ &/0. R?@JCRQ ncp 1. B?Wq'
GQCLRPCQQ MP?J R?@JCR AFCU?@JC /.. KE*03 KE &*raltegravir potassium*'	N@	OJ &/6. R?@JCRQ ncp 1. B?Wq'
lamivudine oral solution 10 mg/ml	NE	OJ &7.. KJ ncp 1. B?Wq'
lamivudine oral tablet 150 mg	NE	OJ &4. R?@JCRQ ncp 1. b_wq'

0.01 Nf_pk_aw Bpse Esgbc+?bt_lacb Amlrpmj Nj_l+?crl_Qrsbclr Fc_jrf

Rfc dmpksj_pwgq snb_rcb _llsjjwgl Hsjwk

.5-./-0.01

Npcqăpg Ğrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq _lb Jgkgrq
lamivudine oral tablet 300 mg	NE	OJ &1. R?@JCRQ ncp 1. b_wq'
JCVGT? MP?J QSQNCLQGML 3. KE-KJ &*fosamprenavir calcium*'	LD	
JCVGT? MP?J R?@JCR 5.. KE &*fosamprenavir calcium*'	LD	
maraviroc oral tablet 150 mg	NE	OJ &4. R?@JCRQ ncp 1. B?Wq'
maraviroc oral tablet 300 mg	NE	OJ &/0. R?@JCRQ ncp 1. B?Wq'
nevirapine er oral tablet extended release 24 hour 100 mg	NE	OJ &7. R?@JCRQ ncp 1. b_wq'
nevirapine er oral tablet extended release 24 hour 400 mg B?Wq ł	— " -Î ž Ğ-N ɞ ƷŤ ƙ NŃO-ɹ γ ɔ-ž Ğ-	

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
XG?ECL MP?J QMJSRGML 0. KE-KJ &*abacavir sulfate*'	LN	OJ &7.. KJ ncp 1. b_wq'
XG?ECL MP?J R?@JCR 1.. KE &*abacavir sulfate*'	LN	OJ &4. r_`jcrq ncp 1. b_wq'
zidovudine oral capsule 100 mg	NE	OJ &/6. A?NQSJCQ ncp 1. b_wq'
zidovudine oral syrup 50 mg/5ml	NE	OJ &/6.. KJ ncp 1. B?Wq'
zidovudine oral tablet 300 mg	NE	OJ &4. R?@JCRQ ncp 1. b_wq'
?LRGPCRPMTGP?J AMK@GL?RGML ?ECLRQ+BPSEQ RM QSNNPCQQ FGT-?GBQ GLDCARGML		
abacavir sulfate-lamivudine oral tablet 600-300 mg	NE	OJ &1. R?@JCRQ ncp 1. b_wq'OJ ŭ

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
CNXGAMK MP?J R?@JCR 4..+1.. K E &*abacavir sulfate-lamivudine*'	LN	OJ &1. R?@JCRQ ncp 1. B?Wq'
CTMR?X MP?J R?@JCR 1..+/3. K E &*atazanavir-cobicistat*'	N@	OJ &1. R?@JCRQ ncp 1. B?Wq'
ECLTMW? MP?J R?@JCR /3.+/3.+0..+/. K E &*elviteg-cobic-emtricit-tenofaf*'	N@	OJ &1. R?@JCRQ ncp 1. B?Wq'
HSJSA? MP?J R?@JCR 3.+03 K E &*dolutegravir-rilpivirine*'	LN	OJ &1. R?@JCRQ ncp 1. B?Wq'
I?JCRP? MP?J QMJSRGML 2..+/.. K E-3K J &*lopinavir-ritonavir*'	LN	OJ &26. K J ncp 1. b_wq'
I?JCRP? MP?J R?@JCR /..+03 K E &*lopinavir-ritonavir*'	LN	OJ &1.. R?@JCRQ ncp 1. b_wq'
I?JCRP? MP?J R?@JCR 0..+3. K E &*lopinavir-ritonavir*'	LN	OJ &/0. R?@JCRQ ncp 1. b_wq'
lamivudine-zidovudine oral tablet 150-300 mg	NE	OJ &4. R?@JCRQ ncp 1. b_wq'
lopinavir-ritonavir oral solution 400-100 mg/5ml	NE	OJ &26. K J ncp 1. b_wq'
lopinavir-ritonavir oral tablet 100-25 mg	NE	OJ &1.. R?@JCRQ ncp 1. b_wq'
lopinavir-ritonavir oral tablet 200-50 mg	NE	OJ &/0. R?@JCRQ ncp 1. B?Wq'
MBCDQCW MP?J R?@JCR 0..+03+03 K E &*emtricitab-rilpivir-tenofov af*'	N@	OJ &1. R?@JCRQ ncp 1. B?Wq'
NPCXAM@GV MP?J R?@JCR 6..+/3. K E &*darunavir-cobicistat*'	N@	OJ &1. R?@JCRQ ncp 1. B?Wq'
QRPG@GJB MP?J R?@JCR /3.+/3.+0..+1.. K E &*elviteg-cobic-emtricit-tenofdf*'	LD	
QWKDG JM MP?J R?@JCR 2..+1..+1.. K E &*efavirenz-lamivudine-tenofovir*'	LN	OJ &1. R?@JCRQ ncp 1. b_wq'
QWKDG MP?J R?@JCR 4..+1..+1.. K E &*efavirenz-lamivudine-tenofovir*'	LN	OJ &1. R?@JCRQ ncp 1. b_wq'
QWKRSX? MP?J R?@JCR 6..+/3.+0..+/. K E &*darun-cobic-emtricit-tenofaf*'	N@	OJ &1. R?@JCRQ ncp 1. b_wq'
RPGSKCO MP?J R?@JCR 4..+3.+1.. K E &*abacavir-dolutegravir-lamivud*'	N@	OJ &1. R?@JCRQ ncp 1. B?Wq'
RPGSKCO NB MP?J R?@JCR QMJS@JC 4.+3+1. K E &*abacavir-dolutegravir-lamivud*'	N@	OJ &/6. R?@JCRQ ncp 1. b_wq'

0.01 Nf_pk_aw Bpse Esgbc+?bt_lacb Amlrpmj Nj_l+?crl_Qrsbclr Fc_jrf

Rfc dmpksj_pwgq snb_rcb _llsjjwgl HsjwK

.5-./-0.01

50 mg/5ml

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
cefaclor oral suspension reconstituted 125 mg/5ml, 250 mg/5ml, 375 mg/5ml	NE	
cefadroxil oral capsule 500 mg	NE	
cefadroxil oral suspension reconstituted 250 mg/5ml, 500 mg/5ml	NE	
cefadroxil oral tablet 1 gm	NE	
cefdinir oral capsule 300 mg	NE	
cefdinir oral suspension reconstituted 125 mg/5ml, 250 mg/5ml	NE	
cefixime oral capsule 400 mg	LN	
cefixime oral suspension reconstituted 100 mg/5ml, 200 mg/5ml	LN	
cefpodoxime proxetil oral suspension reconstituted 100 mg/5ml, 50 mg/5ml	NE	
cefpodoxime proxetil oral tablet 100 mg, 200 mg	NE	
cefprozil oral suspension reconstituted 125 mg/5ml, 250 mg/5ml	NE	
cefprozil oral tablet 250 mg, 500 mg	NE	
cefuroxime axetil oral tablet 250 mg, 500 mg	" NE	
cephalexin oral capsule 250 mg, 500 mg	NE	L6 &Jgqrgle bmcq lmrglajsbc acpr_gl LBAq'
cephalexin oral capsule 750 mg	NE	
	NE	

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
clindamycin palmitate hcl oral solution reconstituted 75 mg/5ml	NE	
colistimethate sodium (cba) injection solution reconstituted 150 mg	NE	
dapsone oral tablet 100 mg, 25 mg	NE	
B?P?NPGK MP?J R?@JCR 03 KE &*pyrimethamine*'	LD	
DGPT?LO MP?J QMJSRGML PCAMLQRGRSRCB 03 KE-KJ*3. KE-KJ &*vancomycin hcl*'	LD	
linezolid oral suspension reconstituted 100 mg/5ml	NE	N?
linezolid oral tablet 600 mg	NE	N?9 L6 &Jgqrgle bmcq lmr glajsbc acpr_gl LBAq'
K?APMB?LRGL MP?J A?NQSJC /.. KE*03 KE*3. KE &*nitrofurantoin macrocrystal*'	LD	
KCNPML MP?J QSQNCLQGML 53. KE-3KJ &*atovaquone*'	N@	
methenamine hippurate oral tablet 1 gm	NE	
methenamine mandelate oral tablet 0.5 gm, 1 gm	NE	
metronidazole oral capsule 375 mg	NE	
metronidazole oral tablet 250 mg, 500 mg	NE	
nitazoxanide oral tablet 500 mg	NE	OJ &0. R?@JCRQ ncp 03 B?Wq'9 ?J &Kgl /0 Wc_pq'
nitrofurantoin macrocrystal oral capsule 100 mg, 25 mg, 50 mg	NE	
nitrofurantoin monohyd macro oral capsule 100 mg	NE	
nitrofurantoin oral suspension 25 mg/5ml	LN	L6 &Jgqrgle bmcq lmr glajsbc acpr_gl LBAq'
pentamidine isethionate inhalation solution reconstituted 300 mg	NE	
pyrimethamine oral tablet 25 mg	NE	
QGTCVRPM MP?J R?@JCR 0.. KE &*tedizolid phosphate*'	LN	N?
QMJMQCA MP?J N?AICR 0EK &*secnidazole*'	LD	
T?LAMAGL MP?J A?NQSJC /03 KE &*vancomycin hcl*'	LN	OJ &6. A?NQSJCQ ncp /. B_wq'
vancomycin hcl oral capsule 125 mg, 250 mg	LN	OJ &6. A?NQSJCQ ncp /. b_wq'
vancomycin hcl oral solution reconstituted 25 mg/ml, 50 mg/ml	LD	
vancomycin hcl oral solution reconstituted 250 mg/5ml	LN	OJ &23. KJ ncp /. B?Wq'
VGD?V?L MP?J R?@JCR 0.. KE &*rifaximin*'	LD	

0.01 Nf_pk_aw Bpse Esgbc+?bt_lacb Amlrpmj Nj_l+?crl_Qrsbclr Fc_jrf

Rfc dmpksj_pwgq snb_rcb _llsjjwgl HsjwK

.5-./-0.01

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
VGD?V?L MP?J R?@JCR 33. K E &*rifaximin*'	N@	N?

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
doxycycline hyclate oral tablet 20 mg	NE	L6&Jgqrgle bmcq lmrglajsbc acpr_gl LBAq'
doxycycline hyclate oral tablet delayed release 100 mg, 150 mg, 200 mg, 50 mg, 75 mg, 80 mg	LD	
doxycycline monohydrate oral capsule 100 mg, 50 mg	NE	
doxycycline monohydrate oral capsule 150 mg, 75 mg	LD	
doxycycline monohydrate oral suspension reconstituted 25 mg/5ml	NE	
doxycycline monohydrate oral tablet 100 mg, 150 mg, 50 mg, 75 mg	LN	
minocycline hcl er oral capsule extended release 24 hour 135 mg, 45 mg, 90 mg	LD	
minocycline hcl er oral tablet extended release 24 hour 105 mg, 115 mg, 135 mg, 45 mg, 55 mg, 65 mg, 80 mg, 90 mg	LD	
minocycline hcl oral capsule 100 mg, 50 mg, 75 mg	NE	
minocycline hcl oral tablet 100 mg, 50 mg, 75 mg	LN	
KGLMJGP? MP?J R?@JCR CVRCL BCB PCJC?QC 02 FMSP /.3 KE* /13 KE &*minocycline hcl*'	LD	
LSXWP? MP?J R?@JCR /3. KE &*omadacycline tosylate*'	LNQN	N?9OJ &1. R?@JCRQ ncp /2 B?Wq'
QCWQ?P? MP?J R?@JCR /.. KE* /3. KE* 4. KE &*sarecycline hcl*'	LD	
QMJMBWL MP?J R?@JCR CVRCL BCB PCJC?QC 02 FMSP /.3 KE* //3 KE* 33 KE* 43 KE* 6. KE &*minocycline hcl*'	LD	
doxycycline hyclate &R_pe_bmv Mp_j R_`jcr 3. Ke'	LD	
tetracycline hcl oral capsule 250 mg, 500 mg	NE	OJ &/0. A?NQSJCQ ncp 03 b_wq'
TG@P?KWAGL MP?J QSQNCLQGML PCAMLQRGRSRCB 03 KE-3KJ &*doxycycline monohydrate*'	LN	
VGKGLM MP?J A?NQSJC CVRCL BCB PCJC?QC 02 FMSP /13 KE* 23 KE* 7. KE &*minocycline hcl*'	LD	
?LRGLCMNJ?QRGA ?ECLRQ+BPSEQRM RPC?R A?LACP		
?JIWJ?RGLE ?ECLRQ		
?JICP?L MP?J R?@JCR 0 KE &*melphalan*'	AC	L5&LN'

0.01 Nf_pk_aw Bpse Esgbc+?bt_lacb Amlrpmj Nj_l+?crl_Qrsbclr Fc_jrf

Rfc dmpksj_pwgq snb_rcb _llsjjwgl HsjwK

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
cyclophosphamide oral capsule 25 mg, 50 mg	AC	L5&NE'
EJCMQRGLC MP?J A?NQSJC /. KE*/.. KE*2. KE &*lomustine*'	AC	L5&LNQN'
JCS ICP?L MP?J R?@JCR 0 KE &*chlorambucil*'	AC	L5&N@'
K?RSJ?LC MP?J A?NQSJC 3. KE &*procarbazine hcl*'	AC	L5&NQN'
melphalan oral tablet 2 mg	AC	L5&NE'
KWJCP?L MP?J R?@JCR 0 KE &*busulfan*'	AC	L5&N@'
temozolomide oral capsule 100 mg, 140 mg, 180 mg, 20 mg, 250 mg, 5 mg	AC	N?9 L5&NE'
?LRGKCR?@MJGRCQ		
capecitabine oral tablet 150 mg, 500 mg	AC	N?9 L5&NE'
GLOMTG MP?J R?@JCR 13+/.. KE &*decitabine-cedazuridine*'	AC	N?9 L5&LNQN'9OJ &3 R?@JCRQ ncp 06 b_wq'
JMLQSPD MP?J R?@JCR /3+4,/2 KE &*trifluridine-tipiracil*'	AC	N?9 L5&NQN'9OJ &/.. R?@JCRQ ncp 1. b_wq'
JMLQSPD MP?J R?@JCR 0.+6,/7 KE &*trifluridine-tipiracil*'	AC	N?9 L5&NQN'9OJ &6. R?@JCRQ ncp 1. b_wq'
mercaptopurine oral tablet 50 mg	AC	L5&NE'
methotrexate sodium (pf) injection solution 1 gm/40ml, 250 mg/10ml, 50 mg/2ml	NE	
methotrexate sodium injection solution 250 mg/10ml, 50 mg/2ml	NE	
methotrexate sodium injection solution reconstituted 1 gm	NE	
MLSPCE MP?J R?@JCR 0.. KE*1.. KE &*azacitidine*'	AC	N?9 L5&LNQN'9OJ &/2 R?@JCRQ ncp 06 b_wq'
NSPGV?L MP?J QSQNCLQGML 0... KE-/..KJ &*mercaptopurine*'	AC	N?9 L5&LNQN'
R?@JMGB MP?J R?@JCR 2. KE &*thioguanine*'	AC	L5&N@'
RPCV?JJ MP?J R?@JCR /. KE*/3 KE*3 KE*5,3 KE &*methotrexate sodium*'	AC	L5&N@'
V?RKCN MP?J QMJSRGML 0,3 KE-KJ &*methotrexate*'	AC	L5&LNQN'
VCJMB? MP?J R?@JCR /3. KE*3.. KE &*capecitabine*'	AC	N?9 QR9 L5&LNQN'
?LRGLCMNJ?QRGA*@AJ+0 GL FG@GRMPQ		
TCLAJCVR? MP?J R?@JCR /. KE*3. KE &*venetoclax*'	AC	N?9 L5&LNQN'9OJ &/0. R?@JCRQ ncp 1. b_wq'

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
TCLAJCVR? MP?J R?@JCR /.. KE &*venetoclax*'	AC	N?9 L5&LNQN'9 OJ &/6. R?@JCRQ ncp 1. b_wq'
TCLAJCVR? QR?PRGLE N?AI MP?J R?@JCR RFCP?NW N?AI /. $ 3. $ /.. KE &*venetoclax*'	AC	N?9 L5&LNQN'9 OJ &/ R?@JCR RFCP?NW N?AI ncp 06 b_wq'
@GMJMEGA PCQNMLQC KMBGDGCPQ		
@CQPCKG QS@ASR?LCMSQ QMJSRGML NPCDGJJCB QWPGLEC 3.. KAE-KJ &*ropeginterferon alfa-2b-njft*'	LNQN	N?9 OJ &0 QWPGLECQ ncp 06 b_wq'
B?SPGQKM MP?J R?@JCR /.. KE*03 KE &*glasdegib maleate*'	AC	L5&LD'
CPGTCBEC MP?J A?NQSJC /3. KE &*vismodegib*'	AC	N?9 L5&NQN'9 OJ &1. A?NQSJCQ ncp 1. b_wq'
NMK?JWQR MP?J A?NQSJC / KE*0 KE*1 KE*2 KE &*pomalidomide*'	AC	N?9 L5&LNQN'9 OJ &0/ A?NQSJCQ ncp 06 b_wq'
PCTJGKGB MP?J A?NQSJC /. KE* /3 KE*0,3 KE*3 KE &*lenalidomide*'	AC	N?9 L5&NQN'9 OJ &06 A?NQSJCQ ncp 06 b_wq'
PCTJGKGB MP?J A?NQSJC 0. KE*03 KE &*lenalidomide*'	AC	N?9 L5&NQN'9 OJ &0/ A?NQSJCQ ncp 06 b_wq'
RF?JMKGB MP?J A?NQSJC /.. KE*3. KE &*thalidomide*'	NQN	N?9 OJ &06 A?NQSJCQ ncp 06 b_wq'
RF?JMKGB MP?J A?NQSJC /3. KE*0.. KE &*thalidomide*'	NQN	N?9 OJ &34 A?NQSJCQ ncp 06 b_wq'
FMPKML?J ?LRGLCMNJ?QRGA ?ECLRQ		
abiraterone acetate oral tablet 250 mg	AC	N?9 L5&NQN'9 OJ &/0. R?@JCRQ ncp 1. b_wq'
abiraterone acetate oral tablet 500 mg	AC	N?9 L5&NQN'9 OJ &4. R?@JCRQ ncp 1. B?Wq'
anastrozole oral tablet 1 mg	AC	L5&NE'9 ?J &Kgl 13 Wc_pq'
bicalutamide oral tablet 50 mg	AC	L5&NE'
CJGE?PB QS@ASR?LCMSQ IGR 00,3 KE &*leuprolide acetate (3 month)*'	NQN	N?
CJGE?PB QS@ASR?LCMSQ IGR 1. KE &*leuprolide acetate (4 month)*'	NQN	N?
CJGE?PB QS@ASR?LCMSQ IGR 23 KE &*leuprolide acetate (6 month)*'	NQN	N?

0.01 Nf_pk_aw Bpse Esgbc+?bt_lacb Amlrpmj Nj_l+?crl_Qrsbclr Fc_jrf

Rfc dmpksj_pwgq snb_rcb _llsjjwgl HsjwK

.5-./-0.01

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq _lb Jgkgrq
CJGE?PB QS@ASR?LCMSQ IGR 5,3 KE &*leuprolide acetate*'	NQN	N?
CPJC?B? MP?J R?@JCR 02. KE &*apalutamide*'	AC	N?9 L5 &NQN'9 OJ &1. R?@JCRQ ncp 1. B?Wq'
CPJC?B? MP?J R?@JCR 4. KE &*apalutamide*'	AC	N?9 L5 &NQN'9 OJ &/0. R?@JCRQ ncp 1. b_wq'
CSJCVGL MP?J A?NQSJC /03 KE &*flutamide*'	AC	L5 &LD'
exemestane oral tablet 25 mg	AC	L5 &NE'9 ?J &Kgl 13 Wc_pq'
D?QJMBCV GLRP?KSQASJ?P QMJSRGML NPCDGJJCB QWPGL EC 03. KE-3KJ &*fulvestrant*'	LNQN	N?
DGPK?EML &02. KE BMQC' QS@ASR?LCMSQ QMJSRGML PCAMLQRGRSRCB /0. KE-TG?J &*degarelix acetate*'	LD	
DGPK?EML QS@ASR?LCMSQ QMJSRGML PCAMLQRGRSRCB 6. KE &*degarelix acetate*'	LD	
		NPCDGJJCB QWPG→ars)
?QJMBCV ص de		
tɹc M ᴰr		
ϗKP@γ/ ĩ		
		Ll'7l'(B q l' ᴬ. l' ɨtA ụ
		N˜ ᵐ γ v ᴰ ɔ ʒ. ᴰ/N l' ɨ
		QMJS "
		Ll'7l'(B q l' ᴬ. l' ɨtA
		N˜ ᵐ γ v ᴰ ɔ ʒ. ᴰ/ώ. ᴰ ɔ ʒ
		Ll'7l'(B q l' ᴬ
		NJCQ ŐV ᵐ γ
		QMJS "
		Ll'7l'(B q l'
		NJCQ ŐV
		PC ML O "
		LD l' l'
		NJCR ŐV
		PC ML O "
		Ll'7l'(B
		NJCT
		D?Q
		NJ "
		R
		ace ɒ at

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
L S@CO? MP?J R?@JCR 1.. K E &*darolutamide*'	AC	N?9 L5 &NQN'9 OJ &/0. R?@JCRQ ncp 1. b_wq'
MPEMTWV MP?J R?@JCR /0. K E &*relugolix*'	AC	N?9 L5 &LNQN'9 OJ &1. R?@JCRQ ncp 1. b_wq'
MPQCPBS MP?J R?@JCR 123 K E* 64 K E &*elacestrant hydrochloride*'	AC	L5 &LD'
tamoxifen citrate oral tablet 10 mg, 20 mg	AC	L5 &NE'9 ?J &Kgl 13 Wc_pq'
toremifene citrate oral tablet 60 mg	AC	L5 &NE'
RPCJQR?P KGVHCAR GLRP?K SQASJ?P QSQNCLQGML PCAMLQRGRSRCB //,03 K E* 00,3 K E* 1,53 K E &*triptorelin pamoate*'	LD	
VR?L BG MP?J A?NQSJC 2. K E &*enzalutamide*'	AC	N?9 L5 &NQN'9 OJ &/0. A?NQSJCQ ncp 1. b_wq'
VR?L BG MP?J R?@JCR 2. K E &*enzalutamide*'	AC	N?9 L5 &NQN'9 OJ &/0. R?@JCRQ ncp 1. B?Wq'
VR?L BG MP?J R?@JCR 6. K E &*enzalutamide*'	AC	N?9 L5 &NQN'9 OJ &4. R?@JCRQ ncp 1. B?Wq'
WMLQ? MP?J R?@JCR /03 K E &*abiraterone acetate micronized*'	AC	N?9 L5 &NQN'9 OJ &/0. R?@JCRQ ncp 1. b_wq'
XWRGE? MP?J R?@JCR 03. K E* 3.. K E &*abiraterone acetate*'	AC	L5 &LD'
IGL?QC GL FG@GRMPQ		
?DGLGRMP BGQNCPX MP?J R?@JCR QMJS@JC 0 K E* 1 K E* 3 K E &*everolimus*'	AC	L5 &Lmr Amtcpcb'
?DGLGRMP MP?J R?@JCR /. K E* 0,3 K E* 3 K E* 5,3 K E &*everolimus*'	AC	L5 &LD'
?JCACLQ? MP?J A?NQSJC /3. K E &*alectinib hcl*'	AC	N?9 L5 &NQN'9 OJ &02. A?NQSJCQ ncp 1. b_wq'
?JSL@PGE MP?J R?@JCR /6. K E* 7. K E &*brigatinib*'	AC	N?9 L5 &NQN'9 OJ &1. R?@JCRQ ncp 1. b_wq'
?JSL@PGE MP?J R?@JCR 1. K E &*brigatinib*'	AC	N?9 L5 &NQN'9 OJ &/0. R?@JCRQ ncp 1. b_wq'
?JSL@PGE MP?J R?@JCR RFCP?NW N?A I 7. $ /6. K E &*brigatinib*'	AC	N?9 L5 &NQN'9 OJ &1. R?@JCRQ ncp 1. b_wq'
?WT?IGR MP?J R?@JCR /.. K E* 0.. K E* 03 K E* 1.. K E* 3. K E &*avapritinib*'	AC	L5 &LD'

0.01 Nf_pk_aw Bpse Esgbc+?bt_lacb Amlrpmj Nj_l+?crl_Qrsbclr Fc_jrf

Rfc dmpksj_pwgq snb_rcb _llsjjwgl HsjwK

.5-./-0.01

Npcqapgnrgm l Bpse L_kc	Bpse Rgcp	

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
GLJWR? MP?J R?@JCR / K E &*axitinib*'	AC	N?9 L5 &NQN'9 OJ &02. R?@JCRQ ncp 1. b_wq'
GLJWR? MP?J R?@JCR 3 K E &*axitinib*'	AC	N?9 L5 &NQN'9 OJ &/0. R?@JCRQ ncp 1. b_wq'
GLPC@GA MP?J A?NQSJC /.. K E &*fedratinib hcl*'	AC	L5 &LD'
GPCQQ? MP?J R?@JCR 03. K E &*gefitinib*'	AC	N?9 L5 &NQN'9 OJ &1. R?@JCRQ ncp 1. b_wq'
MP?Ē?M ˢ ᵛ ɞ ⊿ ɞ Ủ ↳ N Ớ ₫ '		MP?Ē?M ˢ ᵛ ɞ ⊿ ɞ Ủ
		N?9 ₩ Þ G L P C@ñ ?@J ! MP?Ē?
Ø Ł Þ Ø ₩@ñ	*MP?Ē?M l'*	ç
l' l' ´ ╬ *MP?Ē?« ɕ RQĒ ŭ*		
N?9 ╬₩ ÞMP?Ē?« δ RQĒ ŭ ?@J !		
´ ╬ *MP?Ē?« ɋ RQĒ ?@J ayQ per 3*		

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq _lb Jgkgrq
JCLTGK?&0. KE B?GJW BMQC' MP?J A?NQSJC RFCP?NW N?A I 0 V /. K E &*lenvatin]*、	3	3 3
R F C P ? NW N ? A I Q 3 ɣ Þ/ '	3	3 U
R F C P ? NW N ? A I Q 3 ɣ Þ/ '		*A ? Nq ʎ M Q*
R F C P ? NW N ? A I Q 3 ɣ Þ/ ' *I'*		*ʎ M*

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
PCRCTKMMP?JA?NQSJC6. KE&Ŏ¸ ’ Ť		

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
RSP?JGM MP?J A?NQSJC /03 K E &*pexidartinib hcl*'	AC	L5&LD'
RW I CP@ MP?J R?@JCR 03. K E &*lapatinib ditosylate*'	AC	N?9 L5&LNQN'9 OJ &/6. R?@JCRQ ncp 1. b_wq'
TCPXCLGM MP?J R?@JCR /.. K E* /3. K E* 0.. K E* 3. K E &*abemaciclib*'	AC	N?9 L5&LNQN'9 OJ &34 R?@JCRQ ncp 06 b_wq'
TGRP? I TG MP?J A?NQSJC /.. K E &*larotrectinib sulfate*'	AC	N?9 L5&NQN'9 OJ &4. A?NQSJCQ ncp 1. b_wq'
TGRP? I TG MP?J A?NQSJC 03 K E &*larotrectinib sulfate*'	AC	N?9 L5&NQN'9 OJ &/6. A?NQSJCQ ncp 1. b_wq'
TGRP? I TG MP?J QMJSRGML 0. K E-K J &*larotrectinib sulfate*'	AC	N?9 L5&NQN'9 OJ &1.. K J ncp 1. b_wq'
TGXGK NPM MP?J R?@JCR /3 K E* 1. K E* 23 K E &*dacomitinib*'	AC	L5&LD'
TMLHM MP?J A?NQSJC /.. K E &*pacritinib citrate*'	AC	N?9 L5&LNQN'9 OJ &/0. A?NQSJCQ ncp 1. b_wq'
TMRPGCLR MP?J R?@JCR 0.. K E &*pazopanib hcl*'	AC	L5&LD'
V?J I MPG MP?J A?NQSJC 0.. K E* 03. K E &*crizotinib*'	AC	L5&LD'
VMQN?R? MP?J R?@JCR 2. K E &*gilteritinib fumarate*'	AC	N?9 L5&NQN'9 OJ &7. R?@JCRQ ncp 1. b_wq'
XCJ@MP?D MP?J R?@JCR 02. K E &*vemurafenib*'	AC	N?9 L5&NQN'9 OJ &02. R?@JCRQ ncp 1. b_wq'
XWBCJGE MP?J R?@JCR /.. K E* /3. K E &*idelalisib*'	AC	N?9 L5&NQN'9 OJ &4. R?@JCRQ ncp 1. b_wq'
XW I ?BG? MP?J R?@JCR /3. K E &*ceritinib*'	AC	N?9 L5&NQN'9 OJ &7. R?@JCRQ ncp 1. b_wq'
KGQACJJ?LCMSQ		
bexarotene oral capsule 75 mg	AC	N?9 L5&NQN'
hydroxyurea oral capsule 500 mg	AC	L5&NE'
GBFGD? MP?J R?@JCR /.. K E* 3. K E &*enasidenib mesylate*'	AC	N?9 L5&LNQN'9 OJ &1. R?@JCRQ ncp 1. b_wq'
I P?X?RG MP?J R?@JCR 0.. K E &*adagrasib*'	AC	L5&LD'
JSK? I P?Q MP?J R?@JCR /0. K E &*sotorasib*'	AC	N?9 L5&LNQN'9 OJ &02. R?@JCRQ ncp 1. b_wq'
JSK? I P?Q MP?J R?@JCR 10. K E &*sotorasib*'	AC	N?9 L5&LNQN'9 OJ &7. R?@JCRQ ncp 1. B?Wq'

0.01 Nf_pk_aw Bpse Esgbc+?bt_lacb Amlrpmj Nj_l+?crl_Qrsbclr Fc_jrf

Rfc dmpksj_pwgq snb_rcb _llsjjwgl HsjwK

.5-./-0.01

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq _lb Jgkgrq
JWLN?PX? MP?J R?@JCR /.. KE* /3. KE &*olaparib*'	AC	N?9 L5 &NQN'9 OJ &/0. R?@JCRQ ncp 1. b_wq'
MBMKXM MP?J A?NQSJC 0.. KE &*sonidegib phosphate*'	AC	N?9 L5 &NQN'9 OJ &1. A?NQSJCQ ncp 1. b_wq'
PCXJGBFG? MP?J A?NQSJC /3. KE &*olutasidenib*'	AC	L5 &LD'
PS@P?A? MP?J R?@JCR 0.. KE* 03. KE* 1.. KE &*rucaparib camsylate*'	AC	L5 &LD'
QWLPG@MQS@ASR?LCMSQQMJSRGML PCAMLQRGRSRCB 1,3 KE &*omacetaxine mepesuccinate*'	LNQN	N?
R?JXCLL? MP?J A?NQSJC .,03 KE* .,3 KE* .,53 KE* / KE &*talazoparib tosylate*'	AC	L5 &LD'
R?PEPCRGL MP?J A?NQSJC 53 KE &*bexarotene*'	AC	L5 &LD'
R?XTCPGI MP?J R?@JCR 0.. KE &*tazemetostat hbr*'	AC	L5 &LD'
RG@QMTM MP?J R?@JCR 03. KE &*ivosidenib*'	AC	N?9 L5 &LNQN'9 OJ &4. R?@JCRQ ncp 1. b_wq'
tretinoin oral capsule 10 mg N H N H		
tr l' l' ' b v b Þ ivosidenib)		*m ç*
enib) m " ü		

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq _lb Jgkgrq
XMJGLX? MP?J A?NQSJC /.. KE &*vorinostat*'	AC	N?9 L5 &NQN'9 OJ &/0. A?NQSJCQ ncp 1. b_wq'
NPMRC?QMKC GL FG@GRMPQ		
LGLJ?PM MP?J A?NQSJC 0,1 KE*1 KE*2 KE &*ixazomib citrate*'	AC	N?9 L5 &NQN'9 OJ &1 A?NQSJCQ ncp 06 b_wq'
NPMRCARGTC ?ECLRQ		
leucovorin calcium oral tablet 10 mg, 15 mg, 25 mg, 5 mg	AC	L5 &NE'
RMNMGQMKCP?QC GL FG@GRMPQ		
etoposide oral capsule 50 mg	AC	L5 &NE'
FWA?KRGL MP?J A?NQSJC .,03 KE*/ KE &*topotecan hcl*'	AC	N?9 L5 &LNQN'
A?PBGMT?QASJ?P+BPSEQRM RPC?R FC?PR ?LB AGPASJ?RGML AMLBGRGMLQ		
?AC GL FG@GRMP AMK@GL?RGMLQ+BPSEQRM RPC?R FGEF @JMMB NPCQQSPC		
amlodipine besy-benazepril hcl oral capsule 10-20 mg, 10-40 mg, 2.5-10 mg, 5-10 mg, 5-20 mg, 5-40 mg	NE	JEA
*benazepril-hydrochlor ! ä 2 ˙ WA ? K-10 mg, ń 5-20 mg, 5-40 m*ÆNE		

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
captopril oral tablet 100 mg, 12.5 mg, 25 mg, 50 mg	NE	JEA
enalapril maleate oral solution 1 mg/ml	NE	
enalapril maleate oral tablet 10 mg, 2.5 mg, 20 mg, 5 mg	NE	JEA
CN?LCB MP?J QMJSRGML / KE-KJ &*enalapril maleate*'	LD	
fosinopril sodium oral tablet 10 mg, 20 mg, 40 mg	NE	JEA
lisinopril oral tablet 10 mg, 2.5 mg, 20 mg, 30 mg, 40 mg, 5 mg	NE	JEA
moexipril hcl oral tablet 15 mg, 7.5 mg	NE	
perindopril erbumine oral tablet 2 mg, 4 mg, 8 mg	LN	
quinapril hcl oral tablet 10 mg, 20 mg, 40 mg, 5 mg	NE	JEA
ramipril oral capsule 1.25 mg, 10 mg, 2.5 mg, 5 mg	NE	JEA
trandolapril oral tablet 1 mg, 2 mg, 4 mg	NE	JEA
?JBMQRCPMLC PCACNRMP ?LR?EMLGQRQ+BPSEQ RM RPC?R FGEF @JMMB NPCQQSPC		
eplerenone oral tablet 25 mg, 50 mg	LN	
?JNF? @JMA ICPQ+BPSEQ RM RPC?R FGEF @JMMB NPCQQSPC		
doxazosin mesylate oral tablet 1 mg, 2 mg, 4 mg, 8 mg	NE	
prazosin hcl oral capsule 1 mg, 2 mg, 5 mg	NE	
terazosin hcl oral capsule 1 mg, 10 mg, 2 mg, 5 mg	NE	JEA9 L6 &Jgqrgle bmcq lmr glajsbc acpr_gl LBAq'
?LEGMRCLQGL GG PCACNRMP ?LR?EMLGQR AMK@GL?RGMLQ+BPSEQ RM RPC?R FGEF @JMMB NPCQQSPC		
amlodipine besylate-valsartan oral tablet 10-160 mg, 10-320 mg, 5-160 mg, 5-320 mg	NE	JEA
amlodipine-olmesartan oral tablet 10-20 mg, 10-40 mg, 5-20 mg, 5-40 mg	LN	
amlodipine-valsartan-hctz oral tablet 10-160-12.5 mg, 10-160-25 mg, 10-320-25 mg, 5-160-12.5 mg, 5-160-25 mg	NE	
?R?A?LB FAR MP?J R?@JCR /4+/0,3 KE*10+/0,3 KE*10+03 KE &*candesartan cilexetil-hctz*'	LD	
?XMP MP?J R?@JCR /.+0. KE*/.+2. KE*3+0. KE*3+2. KE &*amlodipine-olmesartan*'	LD	
@CLGA?P FAR MP?J R?@JCR 0.+/0,3 KE*2.+/0,3 KE*2.+03 KE &*olmesartan medoxomil-hctz*'	LD	

0.01 Nf_pk_aw Bpse Esgbc+?bt_lacb Amlrpmj Nj_l+?crl_Qrsbclr Fc_jrf

Rfc dmpksj_pwgq snb_rcb _llsjjwgl HsjwK

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
candesartan cilexetil-hctz oral tablet 16-12.5 mg, 32-12.5 mg, 32-25 mg	NE	
BGMT?L FAR MP?J R?@JCR /4.+/0,3 K E* /4.+03 K E* 10.+/0,3 K E* 10.+03 K E* 6.+/0,3 K E &*valsartan-hydrochlorothiazide*'	LD	
CB?P@WAJMP MP?J R?@JCR 2.+/0,3 K E* 2.+03 K E &*azilsartan-chlorthalidone*'	LD	
CVDMPEC FAR MP?J R?@JCR /.+/4.+/0,3 K E* /.+/4.+03 K E* /.+10.+03 K E* 3+/4.+/0,3 K E* 3+/4.+03 K E &*amlodipine-valsartan-hctz*'	LD	
CVDMPEC MP?J R?@JCR /.+/4. K E* /.+10. K E* 3+/4. K E* 3+10. K E &*amlodipine besylate-valsartan*'	LD	
FWX??P MP?J R?@JCR /..+/0,3 K E* /..+03 K E* 3.+/0,3 K E &*losartan potassium-hctz*'	LD	
irbesartan-hydrochlorothiazide oral tablet 150-12.5 mg, 300-12.5 mg	NE	JEA
losartan potassium-hctz oral tablet 100-12.5 mg, 100-25 mg, 50-12.5 mg	NE	JEA
KGA?PBGQ FAR MP?J R?@JCR 2.+/0,3 K E* 6.+/0,3 K E* 6.+03 K E &*telmisartan-hctz*'	LD	
olmesartan medoxomil-hctz oral tablet 20-12.5 mg, 40-12.5 mg, 40-25 mg	NE	
olmesartan-amlodipine-hctz oral tablet 20-5-12.5 mg, 40-10-12.5 mg, 40-10-25 mg, 40-5-12.5 mg, 40-5-25 mg	LN	
telmisartan-amlodipine oral tablet 40-10 mg, 40-5 mg, 80-10 mg, 80-5 mg	LN	
telmisartan-hctz oral tablet 40-12.5 mg, 80-12.5 mg, 80-25 mg	NE	
valsartan-hydrochlorothiazide oral tablet 160-12.5 mg, 160-25 mg, 320-12.5 mg, 320-25 mg, 80-12.5 mg	NE	JEA
?LEGMRCLQGL GG PCACNRMP ?LR?EMLGQRQ+BPSEQ RM RPC?R FGEF @JMMB NPCQQSPC		
?R?A?LB MP?J R?@JCR /4 K E* 10 K E* 2 K E* 6 K E &*candesartan cilexetil*'	LD	
@CLGA?P MP?J R?@JCR 0. K E* 2. K E* 3 K E &*olmesartan medoxomil*'	LD	
candesartan cilexetil oral tablet 16 mg, 32 mg, 4 mg, 8 mg	NE	JEA

0.01 Nf_pk_aw Bpse Esgbc+?bt_lacb Amlrpmj Nj_l+?crl_Qrsbclr Fc_jrf

Rfc dmpksj_pwgq snb_rcb _llsjjwgl Hsjwk

.5-./-0.01

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
AMX??P MP?J R?@JCR /.. KE*03 KE*3. KE &*losartan potassium*'	LD	
BGMT?L MP?J R?@JCR /4. KE*10. KE*2. KE*6. KE &*valsartan*'	LD	
CB?P@G MP?J R?@JCR 2. KE*6. KE &*azilsartan medoxomil*'	LD	
irbesartan oral tablet 150 mg, 300 mg, 75 mg	NE	JEA
losartan potassium oral tablet 100 mg, 25 mg, 50 mg	NE	JEA
KGA?PBGQ MP?J R?@JCR 0. KE*2. KE*6. KE &*telmisartan*'	LD	
olmesartan medoxomil oral tablet 20 mg, 40 mg, 5 mg	NE	
telmisartan oral tablet 20 mg, 40 mg, 80 mg	NE	JEA
valsartan oral solution 4 mg/ml	LD	
valsartan oral tablet 160 mg, 320 mg, 40 mg, 80 mg	NE	JEA
?LRG?PPFWRF KGAQ+BPSEQRM AMLRPMJ FC?PR PFWRF K		
amiodarone hcl oral tablet 100 mg, 200 mg, 400 mg	NE	
@CR?N?AC ?D MP?J R?@JCR /0. KE*/4. KE*6. KE &*sotalol hcl af*'	LD	
@CR?N?AC MP?J R?@JCR /0. KE*/4. KE*6. KE &*sotalol hcl*'	LD	
disopyramide phosphate oral capsule 100 mg, 150 mg	NE	
dofetilide oral capsule 125 mcg, 250 mcg, 500 mcg	NQN	N?
flecainide acetate oral tablet 100 mg, 150 mg, 50 mg	NE	
KSJR?O MP?J R?@JCR 2.. KE &*dronedarone hcl*'	LD	
LMPN?AC MP?J A?NQSJC /.. KE*/3. KE &*disopyramide phosphate*'	LD	
propafenone hcl er oral capsule extended release 12 hour 225 mg, 325 mg, 425 mg	NE	
propafenone hcl oral tablet 150 mg, 225 mg, 300 mg	NE	
qag'B 225 mg, 300 mg	LDTPUBMPM I SP IDM PSBI	

Npcqapgnrgm l Bpse L_kc	Bpse Rgcp	

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
fenofibrate oral tablet 145 mg, 160 mg, 48 mg, 54 mg	NE	
fenofibric acid oral capsule delayed release 135 mg, 45 mg	NE	
fenofibric acid oral tablet 105 mg, 35 mg	LN	
DCLMEJGBC MP?J R?@JCR /0. KE &*fenofibrate*'	LD	
DG@PGAMP MP?J R?@JCR /.3 KE &*fenofibric acid*'	LD	
gemfibrozil oral tablet 600 mg	NE	JEA
RPGAMP MP?J R?@JCR /23 KE* 26 KE &*fenofibrate*'	LD	
?LRGJGNCKGAQ* FKE+AM? PCBSAR?QCGL FG@GRMPQ +BPSEQ		

Npcqapgnrgm l Bpse L_kc	Bpse Rgcp	

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
metoprolol succinate er oral tablet extended release 24 hour 100 mg, 200 mg, 25 mg, 50 mg	NE	JEA
metoprolol tartrate oral tablet 100 mg, 25 mg, 50 mg	NE	JEA
metoprolol tartrate oral tablet 37.5 mg, 75 mg	NE	
nadolol oral tablet 20 mg, 40 mg, 80 mg	NE	
nebivolol hcl oral tablet 10 mg, 2.5 mg, 20 mg, 5 mg	LD	
pindolol oral tablet 10 mg, 5 mg	NE	
propranolol hcl er oral capsule extended release 24 hour 120 mg, 160 mg, 60 mg, 80 mg	NE	
propranolol hcl oral solution 20 mg/5ml, 40 mg/5ml	NE	
propranolol hcl oral tablet 10 mg, 20 mg, 40 mg, 80 mg	NE	JEA
propranolol hcl oral tablet 60 mg	NE	
timolol maleate oral tablet 10 mg, 20 mg, 5 mg	NE	
RMNPMJ VJ MP?J R?@JCR CVRCL BCB PCJC?QC 02 FMSP /.. KE*0.. KE*03 KE*3. KE &*metoprolol succinate*'	LD	
A?JAGSK AF?LLCJ @JMAICP-?LRGJGNCKGA AMK@GL?RGMLQ+BPSEQRM RPC?R FGEF @JMMB NPCQQSPC ?LB FC?PR A		

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
verapamil hcl er oral tablet extended release 180 mg, 240 mg	NE	
verapamil hcl oral tablet 120 mg, 40 mg, 80 mg	NE	JEA
BGEGR?JGQ EJWAMQGBCQ+ BPSEQ RM RPC?R FC?PR AMLBGRGMLQ		
digoxin oral solution 0.05 mg/ml	NE	
digoxin oral tablet 125 mg, 250 mg, 62.5 mg	NE	
J?LMVGL MP?J R?@JCR /03 KAE*03. KAE &*digoxin*'	LD	
BGPCAR PCLGL GL FG@GRMPQ-AMK@GL?RGMLQ+ BPSEQ RM RPC?R FC?PR AMLBGRGMLQ		
aliskiren fumarate oral tablet 150 mg, 300 mg	NE	
RC IRSPL? FAR MP?J R?@JCR 1..+/0,3 KE*1..+03 KE &*aliskiren-hydrochlorothiazide*'	N@	QR
BGSPCRGAQ+ BPSEQ RM RPC?R FC?PR AMLBGRGMLQ		
acetazolamide er oral capsule extended release 12 hour 500 mg	LN	
acetazolamide oral tablet 125 mg, 250 mg	NE	
amiloride hcl oral tablet 5 mg	NE	
amiloride-hydrochlorothiazide oral tablet 5-50 mg	NE	JEA
bumetanide oral tablet 0.5 mg, 1 mg, 2 mg	NE	
A?PMQNGP MP?J QSQNCLQGML 03 KE-3KJ &*spironolactone*'	LD	
chlorthalidone oral tablet 25 mg, 50 mg	NE	
dichlorphenamide oral tablet 50 mg	NQN	N?9OJ &/0. R?@JCRQ ncp 1. B?Wq'
BWPCLGSK MP?J A?NQSJC /.. KE*3. KE &*triamterene*'	LD	
ethacrynic acid oral tablet 25 mg	LN	
furosemide oral tablet 20 mg, 40 mg, 80 mg	NE	JEA
hydrochlorothiazide oral capsule 12.5 mg	NE	JEA
hydrochlorothiazide oral tablet 12.5 mg	NE	JEA
hydrochlorothiazide oral tablet 25 mg, 50 mg	NE	JEA9L6 &Jgqrglebmcq lmr glajsbc acpr_gl LBAq'
indapamide oral tablet 1.25 mg, 2.5 mg	NE	
ICTCWGQ MP?J R?@JCR 3. KE &*dichlorphenamide*'	LNQN	N?9OJ &/0. R?@JCRQ ncp 1. b_wq'

0.01 Nf_pk_aw Bpse Esgbc+ ?bt_lacb Amlrpmj Nj_l+ ?crl_Qrsbclr Fc_jrf

Rfc dmpksj_pwgq snb_rcb _llsjjwgl HsjwK

.5-./-0.01

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
PCT?RGM MP?J QSQNCLQGML PCAMLQRGRSRCB /. KE-KJ &*sildenafil citrate*'	LD	
PCT?RGM MP?J R?@JCR 0. KE &*sildenafil citrate*'	LD	
sildenafil citrate intravenous solution 10 mg/12.5ml	NQN	N?
sildenafil citrate oral suspension reconstituted 10 mg/ml	NQN	N?9 OJ &562 KJ ncp 1. b_wq'
sildenafil citrate oral tablet 20 mg	NE	N?9 OJ &14. R?@JCRQ ncp 1. b_wq'
tadalafil (pah) oral tablet 20 mg	NQN	N?9 OJ &4. R?@JCRQ ncp 1. b_wq'
R?BJGO MP?J QSQNCLQGML 0. KE-3KJ &*tadalafil (pah)*'	LD	
RP?AJCCP MP?J R?@JCR /03 KE* 40,3 KE &*bosentan*'	LD	
RP?AJCCP MP?J R?@JCR QMJS@JC 10 KE &*bosentan*'	LD	
treprostinil injection solution 100 mg/20ml, 20 mg/20ml, 200 mg/20ml, 50 mg/20ml	NQN	N?
RWT?QM BNG K?GLRCL?LAC IGR GL F?J?RGML NMUBCP /4 KAE* 10 KAE* 26 KAE* 42 KAE &*treprostinil*'	LD	
RWT?QM BNG RGRP?RGML IGR GL F?J?RGML NMUBCP //0 V /4KAE $ 62 V 10KAE* /4 $ 10 $ 26 KAE &*treprostinil*'	LD	
RWT?QM GL F?J?RGML QMJSRGML .,4 KE-KJ &*treprostinil*'	LNQN	N?9 OJ &06 KJ ncp 06 b_wq'
RWT?QM PCDGJJ GL F?J?RGML QMJSRGML .,4 KE-KJ &*treprostinil*'	LNQN	N?9 OJ &06 KJ ncp 06 b_wq'
RWT?QM QR?PRCP GL F?J?RGML QMJSRGML .,4 KE-KJ &*treprostinil*'	LNQN	N?9 OJ &06 KJ ncp 06 b_wq'
SNRP?TG MP?J R?@JCR /... KAE* /0.. KAE* /2.. KAE* /4.. KAE* 2.. KAE* 4.. KAE* 6.. KAE &*selexipag*'	NQN	N?9 OJ &4. R?@JCRQ ncp 1. b_wq'
SNRP?TG MP?J R?@JCR 0.. KAE &*selexipag*'	NQN	N?9 OJ &/2. R?@JCRQ ncp 06 b_wq'
SNRP?TG MP?J R?@JCR RFCP?NW N?AI 0.. $ 6.. KAE &*selexipag*'	NQN	N?9 OJ &/ R?@JCR RFCP?NW N?AI ncp 06 b_wq'

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
clomipramine hcl oral capsule 25 mg, 50 mg	NE	OJP &OJ _nnjgcq rm kck`cpq_ec 43_lb mjbcp'9 OJ &/3. A?NQSJCQ ncp 03 b_wq'9 ?J &K_v 43 Wc_pq'
clomipramine hcl oral capsule 75 mg	NE	OJP &OJ _nnjgcq rm kck`cpq_ec 43_lb mjbcp'9 OJ &7. A?NQSJCQ ncp 03 b_wq'9 ?J &K_v 43 Wc_pq'
fluvoxamine maleate er oral capsule extended release 24 hour 100 mg, 150 mg	NE	
fluvoxamine maleate oral tablet 100 mg, 25 mg, 50 mg	NE	
lorazepam &Jmp_xcn_k Glrclqmj Mp_j Amlaclrp_rc 0 Ke-Kj'	NE	OJ &/3. KJ ncp 03 B?Wq'
lorazepam oral tablet 0.5 mg	NE	OJ &/3. R?@JCRQ ncp 03 b_wq'
lorazepam oral tablet 1 mg, 2 mg	NE	OJ &/3. R?@JCRQ ncp 03 B?Wq'
JMPCCT VP MP?J A?NQSJC CP 02 FMSP QNPGL I JC / KE* /,3 KE* 0 KE &*lorazepam*'	LN	OJ &/3. A?NQSJCQ ncp 03 b_wq'
JMPCCT VP MP?J A?NQSJC CP 02 FMSP QNPGL I JC 1 KE &*lorazepam*'	LN	OJ &7. A?NQSJCQ ncp 03 b_wq'
oxazepam oral capsule 10 mg, 15 mg, 30 mg	NE	OJ &/0. A?NQSJCQ ncp 03 B?Wq'
V?L?V MP?J R?@JCR .,03 KE* .,3 KE* / KE* 0 KE &*alprazolam*'	LD	
V?L?V VP MP?J R?@JCR CVRCL BCB PCJC?QC 02 FMSP .,3 KE* / KE* 0 KE* 1 KE &*alprazolam*'	LD	
?LRGBCKCLRG?+BPSEQ RM RPC?R BCKCLRG? ?LB KCK MPW JMQQ		
?BJ?PGRW RP?LQBCP K?J N?RAF UCC I JW /. KE-B?W* 3 KE-B?W &*donepezil hcl*'	LD	
donepezil hcl oral tablet 10 mg, 5 mg	NE	
donepezil hcl oral tablet 23 mg	LN	
donepezil hcl oral tablet dispersible 10 mg, 5 mg	NE	
ergoloid mesylates oral tablet 1 mg	LN	QRV
CVCJML RP?LQBCP K?J N?RAF 02 FMSP /1,1 KE-02FP* 2,4 KE-02FP* 7,3 KE-02FP &*rivastigmine*'	LN	N?

0.01 Nf_pk_aw Bpse Esgbc+?bt_lacb Amlrpmj Nj_l+?crl_Qrsbclr Fc_jrf

Rfc dmpksj_pwgq snb_rcb_llsjjwgl HsjwK

.5-./-0.01

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
amitriptyline hcl oral tablet 50 mg	NE	OJP &OJ _nnjgcq rm kck`cpq_ec 43_lb mjbcp'9 OJ &1. R?@JCRQ ncp 03 b_wq'9 ?J &K_v 43 Wc_pq'
amoxapine oral tablet 100 mg, 25 mg, 50 mg	NE	OJP &OJ _nnjgcq rm kck`cpq_ec 43_lb mjbcp'9 OJ &7. R?@JCRQ ncp 03 b_wq'9 ?J &K_v 43 Wc_pq'
amoxapine oral tablet 150 mg	NE	OJP &OJ _nnjgcq rm kck`cpq_ec 43_lb mjbcp'9 OJ &4. R?@JCRQ ncp 03 b_wq'9 ?J &K_v 43 Wc_pq'
?STCJGRW MP?J R?@JCR CVRCL BCB PCJC?QC 23+ /.3 KE &*dextromethorphan-bupropion*'	LD	
bupropion hcl er (sr) oral tablet extended release 12 hour 100 mg, 150 mg, 200 mg	NE	
bupropion hcl er (xl) oral tablet extended release 24 hour 150 mg, 300 mg	NE	
bupropion hcl er (xl) oral tablet extended release 24 hour 450 mg	LD	
bupropion hcl oral tablet 100 mg, 75 mg	NE	
citalopram hydrobromide oral capsule 30 mg	LD	
citalopram hydrobromide oral solution 10 mg/5ml	NE	
citalopram hydrobromide oral tablet 10 mg, 20 mg, 40 mg	NE	JEA
AWK@?JR? MP?J A?NQSJC BCJ?WCB PCJC?QC N?PRGAJCQ 0. KE*1. KE*4. KE &*duloxetine hcl*'	LD	
desipramine hcl oral tablet 10 mg, 25 mg, 50 mg	NE	OJP &OJ _nnjgcq rm kck`cpq_ec 43_lb mjbcp'9 OJ &7. R?@JCRQ ncp 03 b_wq'9 ?J &K_v 43 Wc_pq'
desipramine hcl oral tablet 100 mg, 150 mg	NE	OJP &OJ _nnjgcq rm kck`cpq_ec 43_lb mjbcp'9 OJ &1. R?@JCRQ ncp 03 b_wq'9 ?J &K_v 43 Wc_pq'
desipramine hcl oral tablet 75 mg	NE	OJP &OJ _nnjgcq rm kck`cpq_ec 43_lb mjbcp'9 OJ &4. R?@JCRQ ncp 03 b_wq'9 ?J &K_v 43 Wc_pq'

0.01 Nf_pk_aw Bpse Esgbc+?bt_lacb Amlrpmj Nj_l+?crl_Qrsbclr Fc_jrf

Rfc dmpksj_pwgq snb_rcb_llsjjwgl HsjwK

.5-./-0.01

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
desvenlafaxine er oral tablet extended release 24 hour 100 mg, 50 mg	LD	
desvenlafaxine succinate er oral tablet extended release 24 hour 100 mg, 25 mg, 50 mg		

Npcqapgnrgm l Bpse L_kc		

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
paroxetine hcl oral suspension 10 mg/5ml	LD	
paroxetine hcl oral tablet 10 mg, 20 mg, 30 mg, 40 mg	NE	JEA9 L6 &Jgqrglebmcq lmr glajsbc acpr_gl LBAq'
N?VGJ AP MP?J R?@JCR CVRCLBCB PCJC?QC 02 FMSP /0,3 KE*03 KE*15,3 KE &*paroxetine hcl*'	LD	
N?VGJ MP?J QSQNCLQGML /. KE-3KJ &*paroxetine hcl*'	LD	
N?VGJ MP?J R?@JCR /. KE*0. KE*1. KE*2. KE &*paroxetine hcl*'	LD	
NCVCT? MP?J R?@JCR /. KE*0. KE*1. KE &*paroxetine mesylate*'	LD	
phenelzine sulfate oral tablet 15 mg	NE	
NPGQRGO MP?J R?@JCR CVRCLBCB PCJC?QC 02 FMSP /.. KE*03 KE*3. KE &*desvenlafaxine succinate*'	LD	
protriptyline hcl oral tablet 10 mg	NE	OJP &OJ _nnjgcq rm kck`cpq_ec 43 _lb mjbcp'9 OJ &4. R?@JCRQ ncp 03 b_wq'9 ?J &K_v 43 Wc_pq'
protriptyline hcl oral tablet 5 mg	NE	OJP &OJ _nnjgcq rm kck`cpq_ec 43 _lb mjbcp'9 OJ &7. R?@JCRQ ncp 03 b_wq'9 ?J &K_v 43 Wc_pq'
NPMX?A MP?J A?NQSJC /. KE*0. KE*2. KE &*fluoxetine hcl*'	LD	
sertraline hcl oral capsule 150 mg, 200 mg	LD	
sertraline hcl oral concentrate 20 mg/ml	NE	
sertraline hcl oral tablet 100 mg, 25 mg, 50 mg	NE	JEA
QNP?T?RM &34 KE BMQC' L?Q?J QMJSRGML RFCP?NW N?AI 06 KE-BCTGAC &*esketamine hcl*'	LNQN	N?
QNP?T?RM &62 KE BMQC' L?Q?J QMJSRGML RFCP?NW N?AI 06 KE-BCTGAC &*esketamine hcl*'	LNQN	N?
tranylcypromine sulfate oral tablet 10 mg	NE	
trazodone hcl oral tablet 100 mg, 150 mg, 300 mg, 50 mg	NE	

0.01 Nf_pk_aw Bpse Esgbc+?bt_lacb Amlrpmj Nj_l+?crl_Qrsbclr Fc_jrf

Rfc dmpksj_pwgq snb_rcb _llsjjwgl HsjwK

.5-./-0.01

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
trimipramine maleate oral capsule 100 mg	LN	OJP &OJ _nnjgcq rm kck`cpq_ec 43_lb mjbcp'9 L6&Jgqrgle bmcq lmrglajsbc acpr_gl LBAq'9 OJ &1. A?NQSJCQ ncp 03 b_wq'9 ?J&K_v 43 Wc_pq'
trimipramine maleate oral capsule 25 mg, 50 mg	LN	OJP &OJ _nnjgcq rm kck`cpq_ec 43_lb mjbcp'9 L6&Jgqrgle bmcq lmrglajsbc acpr_gl LBAq'9 OJ &4. A?NQSJCQ ncp 03 b_wq'9 ?J&K_v 43 Wc_pq'
RPGLRCJJGV MP?J R?@JCR /. KE*0. KE*3 KE *&vortioxetine hbr'*	N@	QR
venlafaxine besylate er oral tablet extended release 24 hour 112.5 mg	LD	
venlafaxine hcl er oral capsule extended release 24 hour 150 mg, 37.5 mg, 75 mg	NE	
venlafaxine hcl er oral tablet extended release 24 hour 150 mg, 37.5 mg, 75 mg	LD	
venlafaxine hcl er oral tablet extended release 24 hour 225 mg	LN	L6&Jgqrgle bmcq lmrglajsbc acpr_gl LBAq'
venlafaxine hcl oral tablet 100 mg, 25 mg, 37.5 mg, 50 mg, 75 mg	NE	
TGG@PWB MP?J R?@JCR /. KE*0. KE*2. KE *&vilazodone hcl'*	LD	
TGG@PWB QR?PRCP N?AI MP?J IGR /. $0. KE *&vilazodone hcl'*	LD	
vilazodone hcl oral tablet 10 mg, 20 mg, 40 mg	LD	
XMJMDR MP?J AMLACLRP?RC 0. KE-KJ *&sertraline hcl'*	LD	
XMJMDR MP?J R?@JCR /.. KE*03 KE*3. KE *&sertraline hcl'*	LD	
?LRGN?PIGLQMLG?L ?ECLRQ+BPSEQRM RPC?R N?PIGLQMLQ BGQC?QC		
amantadine hcl oral capsule 100 mg	NE	
amantadine hcl oral solution 50 mg/5ml	NE	L6&Jgqrgle bmcq lmrglajsbc acpr_gl LBAq'

0.01 Nf_pk_aw Bpse Esgbc+?bt_lacb Amlrpmj Nj_l+?crl_Qrsbclr Fc_jrf

Rfc dmpksj_pwgq snb_rcb _llsjjwgl HsjwK

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
amantadine hcl oral tablet 100 mg	NE	
?NMIWL QS@ASR?LCMSQQMJSRGML A?PRPGBEC 1. KE-1KJ &*apomorphine hcl*'	LD	
apomorphine hcl subcutaneous solution cartridge 30 mg/3ml	LD	
benztropine mesylate oral tablet 0.5 mg, 1 mg, 2 mg	NE	
bromocriptine mesylate oral capsule 5 mg	NE	
bromocriptine mesylate oral tablet 2.5 mg	NE	
carbidopa oral tablet 25 mg	NE	
carbidopa-levodopa oral tablet extended release 25-100 mg, 50-200 mg	NE	
carbidopa-levodopa oral tablet 10-100 mg, 25-100 mg, 25-250 mg	NE	
carbidopa-levodopa-entacapone oral tablet 12.5-50-200 mg, 18.75-75-200 mg, 25-100-200 mg, 31.25-125-200 mg, 37.5-150- *ä l' 5 al t ^*		

12.5-50-200 mg,-ثم "

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
rasagiline mesylate oral tablet 0.5 mg, 1 mg	NE	
ropinirole hcl er oral tablet extended release 24 hour 12 mg, 2 mg, 4 mg, 6 mg, 8 mg	LN	
ropinirole hcl oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg	NE	
PWR?PW MP?J A?NQSJC CVRCL BCB PCJC?QC 01,53+73 K E* 14,03+/23 K E* 26,53+/73 K E* 4/,03+023 K E &*carbidopa-levodopa*'	N@	
selegiline hcl oral capsule 5 mg	NE	
selegiline hcl oral tablet 5 mg	NE	
QGLCKCR MP?J R?@JCR /.+/.. K E* 03+/.. K E &*carbidopa-levodopa*'	LN	
tolcapone oral tablet 100 mg	LN	QRV
trihexyphenidyl hcl oral solution 0.4 mg/ml	NE	
trihexyphenidyl hcl oral tablet 2 mg, 5 mg	NE	
V?B?EM MP?J R?@JCR /.. K E* 3. K E &*safinamide mesylate*'	LD	
XCJ?N?P MP?J R?@JCR BGQNCPQG@JC /,03 K E &*selegiline hcl*'	LD	
?LRGNQWAFMRGAQ+BPSEQRM RPC?R NQWAFMQCQ		
?@GJGDW ?QGKRSDGG GLRP?K SQASJ?P NPCDGJJCB QWPGL EC 50. K E-0,2K J* 74. K E-1,0K J &*aripiprazole*'	LD	
?@GJGDW K?GLRCL?GLRP?K SQASJ?P NPCDGJJCB QWPGL EC 1.. K E* 2.. K E &*aripiprazole*'	N@	
?@GJGDW K?GLRCL?GLRP?K SQASJ?P QSQNCLQGML PCAMLQRGRSRCB CP 1.. K E* 2.. K E &*aripiprazole*'	N@	
?@GJGDW MP?J R?@JCR /. K E* /3 K E* 0 K E* 0. K E* 1. K E* 3 K E &*aripiprazole*'	LD	
aripiprazole oral solution 1 mg/ml	NE	
aripiprazole oral tablet 10 mg, 15 mg, 2 mg, 20 mg, 30 mg, 5 mg	NE	
aripiprazole oral tablet dispersible 10 mg, 15 mg	NE	
?PGQR?B?GLGRGM GLRP?K SQASJ?P NPCDGJJCB QWPGL EC 453 K E-0,2K J &*aripiprazole lauroxil*'	LN	

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
J?KGAR?J VP MP?J IGR 0/ V 03 KE $ 5 V 3. KE*03 $ 3. $ /.. KE*3. $ /.. $ 0.. KE &*lamotrigine*'	LD	
J?KGAR?J VP MP?J R?@JCR CVRCL BCB PCJC?QC 02 FMSP /.. KE*0.. KE*03 KE*03. KE*1.. KE*3. KE &*lamotrigine*'	LD	
lamotrigine er oral tablet extended release 24 hour 100 mg, 200 mg, 25 mg, 250 mg, 300 mg, 50 mg	NE	L6 &Jgqrgle bmcq lmrglajsbc acpr_gl LBAq'
lamotrigine oral kit 25 & 50 & 100 mg	NE	
lamotrigine oral tablet 100 mg, 150 mg, 200 mg, 25 mg	NE	
lamotrigine oral tablet chewable 25 mg, 5 mg	NE	
lamotrigine oral tablet dispersible 100 mg, 200 mg, 25 mg, 50 mg	LN	
lamotrigine starter kit-blue oral kit 35 x 25 mg	NE	
lamotrigine starter kit-green oral kit 84 x 25 mg & 14x100 mg	NE	
lamotrigine starter kit-orange oral kit 42 x 25 mg & 7 x 100 mg	NE	
levetiracetam er oral tablet extended release 24 hour 500 mg, 750 mg	NE	
levetiracetam oral solution 100 mg/ml	NE	
levetiracetam oral tablet 1000 mg, 250 mg, 500 mg, 750 mg	NE	
JWPGA? MP?J A?NQSJC /.. KE*/3. KE*0.. KE*003 KE*03 KE*1.. KE*3. KE*53 KE &*pregabalin*'	LD	
JWPGA? MP?J QMJSRGML 0. KE-KJ &*pregabalin*'	LD	
L?WXGJ?K L?Q?J QMJSRGML 3 KE-.,/KJ &*midazolam (anticonvulsant)*'	N@	OJ &/. QMJSRGML ncp 03 b_wq'
LCSPMLRGL MP?J A?NQSJC /.. KE*1.. KE*2.. KE &*gabapentin*'	LN	OJ &4 A?NQSJCQ ncp / b_w'
LCSPMLRGL MP?J QMJSRGML 03. KE-3KJ &*gabapentin*'	LN	OJ &50 KJ ncp / b_w'
LCSPMLRGL MP?J R?@JCR 4.. KE &*gabapentin*'	LN	OJ &4 R?@JCRQ ncp / b_w'
LCSPMLRGL MP?J R?@JCR 6.. KE &*gabapentin*'	LN	OJ &2 R?@JCRQ ncp / b_w'
MLDG MP?J QSQNCLQGML 0,3 KE-KJ &*clobazam*'	LD	
MLDG MP?J R?@JCR /. KE*0. KE &*clobazam*'	LD	
oxcarbazepine oral suspension 300 mg/5ml	NE	
oxcarbazepine oral tablet 150 mg, 300 mg, 600 mg	NE	

0.01 Nf_pk_aw Bpse Esgbc+?bt_lacb Amlrpmj Nj_l+?crl_Qrsbclr Fc_jrf

Rfc dmpksj_pwgq snb_rcb _llsjjwgl HsjwK

Npcqapgnrgm l Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
RCEPCRMJ+VP MP?J R?@JCR CVRCL BCB PCJC?QC /0 FMSP /.. KE*0.. KE*2.. KE &*carbamazepine*'	LD	
tiagabine hcl oral tablet 12 mg, 16 mg, 2 mg, 4 mg	NE	
topiramate er oral capsule er 24 hour sprinkle 100 mg, 150 mg, 200 mg, 25 mg, 50 mg	LD	
ttiagabine *ł 2 mg, 4 mg* *L 15Č*		

ke

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
TGKN?RMP?JR?@JCR/.. KE*/3. KE*0.. KE*3. KE &*lacosamide*'	LD	
VAMNPG&03. KE B?GJW BMQC' MP?JR?@JCR RFCP?NWN?AI /.. $ /3. KE &*cenobamate*'	N@	
VAMNPG&13. KE B?GJW BMQC' MP?JR?@JCR RFCP?NWN?AI /3. $ 0.. KE &*cenobamate*'	N@	
VAMNPG MP?JR?@JCR/.. KE*/3. KE*0.. KE*3. KE &*cenobamate*'	N@	
VAMNPG MP?JR?@JCR RFCP?NWN?AI /2 V /0,3 KE $ /2 V 03 KE*/2 V /3. KE $ /2 V0.. KE*/2 V 3. KE $ /2 V/.. KE &*cenobamate*'	N@	
XMLCEP?L MP?JA?NQSJC/.. KE*03 KE &*zonisamide*'	LD	
X@MLGQ?BC MP?JQSQNCLQG?Bċ ? KE Î *zonisamide*'	LD	

xÅP G JÎT B N-4 3B(⊖PÃ8 $½ÒDÓ$@3 (6ÐXTSEÒ9 ´z® ɵFÍ1@ @ LD°" lÍ4 * T K$E9`l@ 3 $nÅ4•b ý4 * T 0 à P `'

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
amphetamine-dextroamphetamine oral tablet 12.5 mg, 5 mg, 7.5 mg	NE	OJ &7. R?@JCRQ ncp 03 b_wq'
amphetamine-dextroamphetamine oral tablet 15 mg	NE	OJ &4. R?@JCRQ ncp 03 b_wq'
amphetamine-dextroamphetamine oral tablet 20 mg	NE	OJ &4. R?@JCRQ ncp 03 B?Wq'
amphetamine-dextroamphetamine oral tablet 30 mg	NE	OJ &1. R?@JCRQ ncp 03 B?Wq'
?NRCLQGM VP MP?J A?NQSJC CVRCL BCB PCJC?QC 02 FMSP /. KE* /3 KE* 0. KE* 1. KE* 2. KE* 3. KE* 4. KE &*methylphenidate hcl*'	LD	
atomoxetine hcl oral capsule 10 mg, 18 mg, 25 mg	NE	OJ &/0. A?NQSJCQ ncp 03 B?Wq'
atomoxetine hcl oral capsule 100 mg, 60 mg, 80 mg	NE	OJ &1. A?NQSJCQ ncp 03 B?Wq'
atomoxetine hcl oral capsule 40 mg	NE	OJ &4. A?NQSJCQ ncp 03 B?Wq'
?XQR?PWQ MP?J A?NQSJC 04,/+3,0 KE* 17,0+5,6 KE* 30,1+/.,2 KE &*serdexmethylphen-dexmethylphen*'	N@	OJ &1. A?NQSJCQ ncp 03 b_wq'
AMLACPR? MP?J R?@JCR CVRCL BCB PCJC?QC /6 KE* 05 KE* 14 KE* 32 KE &*methylphenidate hcl*'	LD	
AMRCKNJ? VP+MBR MP?J R?@JCR CVRCL BCB PCJC?QC BGQNCPQG@JC /5,1 KE* 03,7 KE* 6,4 KE &*methylphenidate*'	LD	
B?WRP?L? RP?LQBCPK?J N?RAF /. KE-7FP* /3 KE-7FP* 0. KE-7FP* 1. KE-7FP &*methylphenidate*'	LD	
BCQMVWL MP?J R?@JCR 3 KE &*methamphetamine hcl*'	LN	OJ &/3. R?@JCRQ ncp 03 b_wq'
BCVCBPGLC MP?J A?NQSJC CVRCL BCB PCJC?QC 02 FMSP /. KE &*dextroamphetamine sulfate*'	LN	QR9 OJ &/0. A?NQSJCQ ncp 03 b_wq'
BCVCBPGLC MP?J A?NQSJC CVRCL BCB PCJC?QC 02 FMSP /3 KE &*dextroamphetamine sulfate*'	LN	QR9 OJ &4. A?NQSJCQ ncp 03 b_wq'
dexmethylphenidate hcl er oral capsule extended release 24 hour 10 mg, 15 mg, 20 mg, 5 mg	NE	OJ &4. A?NQSJCQ ncp 03 B?Wq'
dexmethylphenidate hcl er oral capsule extended release 24 hour 25 mg, 30 mg, 40 mg	NE	OJ &1. A?NQSJCQ ncp 03 B?Wq'

0.01 Nf_pk_aw Bpse Esgbc+?bt_lacb Amlrpmj Nj_l+?crl_Qrsbclr Fc_jrf

Rfc dmpksj_pwgq snb_rcb _llsjjwgl HsjwK

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
dexmethylphenidate hcl er oral capsule extended release 24 hour 35 mg	NE	OJ &1. A?NQSJCQ ncp 03 b_wq'
dexmethylphenidate hcl oral tablet 10 mg	NE	OJ &4. R?@JCRQ ncp 03 b_wq'
dexmethylphenidate hcl oral tablet 2.5 mg, 5 mg	NE	OJ &/0. R?@JCRQ ncp 03 b_wq'
dextroamphetamine sulfate er oral capsule extended release 24 hour 10 mg, 5 mg	NE	OJ &/0. A?NQSJCQ ncp 03 b_wq'
dextroamphetamine sulfate er oral capsule extended release 24 hour 15 mg	NE	OJ &4. A?NQSJCQ ncp 03 b_wq'
dextroamphetamine sulfate oral solution 5 mg/5ml	NE	OJ &/0.. KJ ncp 03 B?Wq'
dextroamphetamine sulfate oral tablet 10 mg, 5 mg	NE	OJ &/0. R?@JCRQ ncp 03 B?Wq'
BW?L?TCJ VP MP?J QSQNCLQGML CVRCLBCB PCJC?QC 0,3 KE-KJ &*amphetamine*'	LD	
BW?L?TCJ VP MP?J R?@JCR AFCU?@JC CVRCLBCB PCJC?QC /. KE* /3 KE* 0. KE* 3 KE &*amphetamine*'	LD	
CTC ICM MBR MP?J R?@JCR BGQNCPQG@JC /. KE* /3 KE* 0. KE* 3 KE &*amphetamine sulfate*'	LD	
CTC ICM MP?J R?@JCR /. KE* 3 KE &*amphetamine sulfate*'	LD	
DMA?JGL MP?J R?@JCR /. KE &*dexmethylphenidate hcl*'	LN	OJ &4. R?@JCRQ ncp 03 B?Wq'
DMA?JGL MP?J R?@JCR 0,3 KE* 3 KE &*dexmethylphenidate hcl*'	LN	OJ &/0. R?@JCRQ ncp 03 B?Wq'
DMA?JGL VP MP?J A?NQSJC CVRCLBCB PCJC?QC 02 FMSP /. KE* /3 KE* 0. KE* 03 KE* 1. KE* 13 KE* 2. KE* 3 KE &*dexmethylphenidate hcl*'	LD	LD2. KE* 3 KE &*dexmethyl*'
guanfacine hcl er oral tablet extendeex		*oral*

Npcqapgnrgm l Bpse L_kc	Bpse Rgcp	

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
estazolam oral tablet 1 mg, 2 mg	NE	OJ &/3 R?@JCRQ ncp 03 B?Wq'
eszopiclone oral tablet 1 mg, 2 mg, 3 mg	NE	OJ &/3 R?@JCRQ ncp 03 B?Wq'
F?JAGML MP?J R?@JCR .,03 KE &*triazolam*'	LN	OJ &/. R?@JCRQ ncp 03 B?Wq'
FCRJGMX JO MP?J QSQNCLQGML 2 KE-KJ &*tasimelteon*'	LNQN	N?9 OJ &3 KJ ncp / b_w'
FCRJGMX MP?J A?NQSJC 0. KE &*tasimelteon*'	LNQN	N?9 OJ &1. A?NQSJCQ ncp 1. b_wq'
JSLCQR? MP?J R?@JCR / KE*0 KE*1 KE &*eszopiclone*'	LD	
midazolam hcl oral syrup 2 mg/ml	LN	
quazepam oral tablet 15 mg	LD	
OSTGTGO MP?J R?@JCR 03 KE*3. KE &*daridorexant hcl*'	LD	
ramelteon oral tablet 8 mg	NE Jgkgrq	
tazidorexant l'		

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
GKGRPCV L?Q?J QMJSRGML 3 KE-?AR &*sumatriptan*'	LN	QR9 OJ &02 QNP?WQ ncp 03 B?Wq'
GKGRPCV MP?J R?@JCR /.. KE*03 KE*3. KE &*sumatriptan succinate*'	LN	QR9 OJ &/0 R?@JCRQ ncp 03 B?Wq'
GKGRPCV QR?RBMQC PCDGJJ QS@ASR?LCMSQ QMJSRGML A?PRPGBEC 2 KE-.,3KJ &*sumatriptan succinate*'	LN	QR9 OJ &/6 QWPGLECQ ncp 03 B?Wq'
GKGRPCV QR?RBMQC PCDGJJ QS@ASR?LCMSQ QMJSRGML A?PRPGBEC 4 KE-.,3KJ &*sumatriptan succinate*'	LN	QR9 OJ &/0 A?PRPGBECQ ncp 03 b_wq'
GKGRPCV QR?RBMQC QWQRCK QS@ASR?LCMSQ QMJSRGML ?SRM+GLHCARMP 2 KE-.,3KJ &*sumatriptan succinate*'	LN	QR9 OJ &/6 QWPGLECQ ncp 03 B?Wq'
GKGRPCV QR?RBMQC QWQRCK QS@ASR?LCMSQ QMJSRGML ?SRM+GLHCARMP 4 KE-.,3KJ &*sumatriptan succinate*'	LN	QR9 OJ &/0 GLHCARGMLQ ncp 03 b_wq'
K?V?JR MP?J R?@JCR /. KE &*rizatriptan benzoate*'	LD	
K?V?JR+KJR MP?J R?@JCR BGQNCPQG@JC /. KE &*rizatriptan benzoate*'	LD	
KGECPEMR PCAR?J QSNNMQGRMPW 0+/.. KE &*ergotamine-caffeine*'	LD	
KGEP?L?J L?Q?J QMJSRGML 2 KE-KJ &*dihydroergotamine mesylate*'	LD	
naratriptan hcl oral tablet 1 mg, 2.5 mg	NE	OJ &/0 R?@JCRQ ncp 03 B?Wq'
LSPRCA MP?J R?@JCR BGQNCPQG@JC 53 KE &*rimegepant sulfate*''		
PCV Q?J R?@JCRU BGQNCP Î N		

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
rizatriptan benzoate oral tablet 10 mg, 5 mg	NE	OJ &/6 R?@JCRQ ncp 03 B?Wq'
rizatriptan benzoate oral tablet dispersible 10 mg, 5 mg	NE	OJ &/6 R?@JCRQ ncp 03 B?Wq'
sumatriptan nasal solution 20 mg/act	NE	OJ &/0 QNP?WQ ncp 03 B?Wq'
sumatriptan nasal solution 5 mg/act	NE	OJ &02 QNP?WQ ncp 03 B?Wq'
sumatriptan succinate oral tablet 100 mg, 25 mg, 50 mg	NE	OJ &/0 R?@JCRQ ncp 03 B?Wq'
sumatriptan succinate refill subcutaneous solution cartridge 4 mg/0.5ml	NE	OJ &/6 QWPGL ECQ ncp 03 b_wq'
sumatriptan succinate refill subcutaneous solution cartridge 6 mg/0.5ml	NE	OJ &/0 A?PRPGBECQ ncp 03 b_wq'
sumatriptan succinate subcutaneous solution 6 mg/0.5ml	NE	OJ &/0 KJ ncp 03 b_wq'
sumatriptan succinate subcutaneous solution auto-injector 4 mg/0.5ml	NE	OJ &/6 KJ ncp 03 b_wq'
sumatriptan succinate subcutaneous solution auto-injector 6 mg/0.5ml	NE	OJ &/0 KJ ncp 03 b_wq'
sumatriptan-naproxen sodium oral tablet 85-500 mg	LD	
RMQWKP? L?Q?J QMJSRGML /. KE-?AR &*sumatriptan*'	LD	
RPCVGKCR MP?J R?@JCR 63+3.. KE &*sumatriptan-naproxen sodium*'	LD	
RPSBFCQ? L?Q?J ?CPMQMJ QMJSRGML .,503 KE-?AR &*dihydroergotamine mesylate hfa*'	LN	OJ &1 N?AI?ECQ ncp 03 b_wq'
S@PCJTW MP?J R?@JCR /.. KE*3. KE &*ubrogepant*'	N@	QR9 OJ &/4 R?@JCRQ ncp 03 b_wq'
XCK@P?AC QWKRMSAF QS@ASR?LCMSQ QMJSRGML ?SRM+GLHCARMP 1 KE-.,3KJ &*sumatriptan succinate*'	LN	QR9 OJ &02 GLHCARMPQ ncp 03 B?Wq'
zolmitriptan nasal solution 5 mg	NE	OJ &/0 QNP?WQ ncp 03 B?Wq'
zolmitriptan oral tablet 2.5 mg, 5 mg	NE	OJ &/0 R?@JCRQ ncp 03 b_wq'
zolmitriptan oral tablet dispersible 2.5 mg, 5 mg	NE	OJ &/0 R?@JCRQ ncp 03 b_wq'

0.01 Nf_pk_aw Bpse Esgbc+?bt_lacb Amlrpmj Nj_l+?crl_Qrsbclr Fc_jrf

Rfc dmpksj_pwgq snb_rcb_llsjjwgl HsjwK

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
KMTCKCLR BGQMPBCPQ		
?SQRCBM MP?J R?@JCR /0 KE*7 KE &*deutetrabenazine*'	NQN	N?9 OJ &/0. R?@JCRQ ncp 1. b_wq'
?SQRCBM MP?J R?@JCR 4 KE &*deutetrabenazine*'	NQN	N?9 OJ &4. R?@JCRQ ncp 1. b_wq'
?SQRCBM VP MP?J R?@JCR CVRCL BCB PCJC?QC 02 FMSP /0 KE &*deutetrabenazine*'	NQN	N?9 OJ &/0. R?@JCRQ ncp 1. B?Wq'
?SQRCBM VP MP?J R?@JCR CVRCL BCB PCJC?QC 02 FMSP 02 KE &*deutetrabenazine*'	NQN	N?9 OJ &4. R?@JCRQ ncp 1. B?Wq'
?SQRCBM VP MP?J R?@JCR CVRCL BCB PCJC?QC 02 FMSP 4 KE &*deutetrabenazine*'	NQN	N?9 OJ &7. R?@JCRQ ncp 1. B?Wq'
GLEPCXX? MP?J A?NQSJC 2. KE*4. KE*6. KE &*valbenazine tosylate*'	NQN	N?9 OJ &1. A?NQSJCQ ncp 1. b_wq'
GLEPCXX? MP?J A?NQSJC RFCP?NW N?AI 2. $6. KE &*valbenazine tosylate*'	NQN	N?9 OJ &/ A?NQSJC RFCP?NW N?AI ncp 06 b_wq'
tetrabenazine oral tablet 12.5 mg	NQN	N?9 OJ &02. R?@JCRQ ncp 1. b_wq'
tetrabenazine oral tablet 25 mg	NQN	N?9 OJ &/0. R?@JCRQ ncp 1. b_wq'
VCL?XGLC MP?J R?@JCR /0,3 KE*03 KE &*tetrabenazine*'	LD	
KSJRGNJC QAJCPMQGQ ?ECLRQ+BPSEQ RM RPC?R KSJRGNJC QAJCPMQGQ		
?KNWP? MP?J R?@JCR CVRCL BCB PCJC?QC /0 FMSP /. KE &*dalfampridine*'	LNQN	N?9 QR9 OJ &4. R?@JCRQ ncp 1. b_wq'
?S@?EGM MP?J R?@JCR /2 KE*5 KE &*teriflunomide*'	LD	
?TMLCV NCL GLRP?KSQASJ?P ?SRM+GLHCARMP IGR 1. KAE-.,3KJ &*interferon beta-1a*'	NQN	N?9 OJ &2 QWPGL ECQ ncp 06 b_wq'
?TMLCV NPCDGJJCB GLRP?KSQASJ?P NPCDGJJCB QWPGL EC IGR 1. KAE-.,3KJ &*interferon beta-1a*'	NQN	N?9 OJ &2 QWPGL ECQ ncp 06 b_wq'
@?DGCPR?K MP?J A?NQSJC BCJ?WCB PCJC?QC 73 KE &*monomethyl fumarate*'	LD	
@CR?QCPML QS@ASR?LCMSQ IGR .,1 KE &*interferon beta-1b*'	NQN	N?9 OJ &/2 GLHCARGMLQ ncp 06 b_wq'
AMN?VMLC QS@ASR?LCMSQ QMJSRGML NPCDGJJCB QWPGL EC 0. KE-KJ &*glatiramer acetate*'	NQN	N?9 OJ &1. KJ ncp 1. b_wq'

0.01 Nf_pk_aw Bpse Esgbc+?bt_lacb Amlrpmj Nj_l+?crl_Qrsbclr Fc_jrf

Rfc dmpksj_pwgq snb_rcb _llsjjwgl HsjwK

Npcqapgnrgm l Bpse L_kc	Bpse Rgcp	

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Nrgăþ R_l_i Ämtcp_ec Pcosgpckčlrq_lb

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq _lb Jgkgrq
PC@GD PC@GBMQC RGRP?RGML N?AI QS@ASR?LCMSQ QMJSRGML ?SRM+GLHCARMP 4V6,6 $ 4V00 KAE &*interferon beta-1a*'	NQN	N?9 OJ &/ KJ ncp 06 b_wq'
PC@GD QS@ASR?LCMSQ QMJSRGML NPCDGJJCB QWPGLEC 00 KAE-.,3KJ* 22 KAE-.,3KJ &*interferon beta-1a*'	NQN	N?9 OJ &/0 QWPGLECQ ncp 06 B?Wq'
PC@GD RGRP?RGML N?AI QS@ASR?LCMSQ QMJSRGML NPCDGJJCB QWPGLEC 4V6,6 $ 4V00 KAE &*interferon beta-1a*'	NQN	N?9 OJ &/ KJ ncp 06 b_wq'
R?QACLQM MBR MP?J R?@JCR BGQNCPQG@JC .,03 KE* .,3 KE &*fingolimod lauryl sulfate*'	LD	
RCADGBCP? MP?J /0. $ 02. KE &*dimethyl fumarate*'	LD	
RCADGBCP? MP?J A?NQSJC BCJ?WCB PCJC?QC /0. KE* 02. KE &*dimethyl fumarate*'	LD	
teriflunomide oral tablet 14 mg, 7 mg	NQN	N?9 OJ &1. R?@JCRQ ncp 1. B?Wq'
RWQ?@PG GLRP?TCLMSQ AMLACLRP?RC 1.. KE-/3KJ &*natalizumab*'	NQN	N?9 OJ &/ KJ ncp 06 b_wq'
TSKCPGRW MP?J A?NQSJC BCJ?WCB PCJC?QC 01/ KE &*diroximel fumarate*'	NQN	N?9 OJ &/0. A?NQSJCQ ncp 1. b_wq'
XCNMQG? 5+B?W QR?PRCP N?AI MP?J A?NQSJC RFCP?NW N?AI 2V .,01KE $ 1V .,24KE &*ozanimod hcl*'	NQN	N?9 QR9 G@A &Npcdcppcb _eclr dmp Sjacp_rgtc Amjgrgq'9 OJ &/ N?AI ncp 5 b_wq'
XCNMQG? MP?J A?NQSJC .,70 KE &*ozanimod hcl*'	NQN	N?9 QR9 G@A &Npcdcppcb _eclr dmp Sjacp_rgtc Amjgrgq'9 OJ &1. A?NQSJCQ ncp 1. b_wq'
XCNMQG? QR?PRCP IGR MP?J A?NQSJC RFCP?NW N?AI .,01KE $.,24KE $.,70KE &*ozanimod hcl*'	NQN	N?9 QR9 G@A &Npcdcppcb _eclr dmp Sjacp_rgtc Amjgrgq'9 QJÏ&/ IGR pcp 1. bpwq' p

Npcqapgnrgm l Bpse L_kc	Bpse Rgcp	Amn pga gn

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
XS@QMJT QS@JGLES?J R?@JCR QS@JGLES?J //,2+ 0,7 KE &*buprenorphine hcl-naloxone hcl*'	N@	OJ &1. R?@JCRQ ncp 03 B?Wq'
XS@QMJT QS@JGLES?J R?@JCR QS@JGLES?J 6,4+ 0,/ KE &*buprenorphine hcl-naloxone hcl*'	N@	OJ &4. R?@JCRQ ncp 03 B?Wq'
MNGMGB ?LR?EMLGQR		
IJMVV?BM L?Q?J JGOSGB 6 KE-.,/ KJ &*naloxone hcl*'	LN	OJ &2 QNP?WQ ncp 03 b_wq'
naloxone hcl injection solution 0.4 mg/ml, 4 mg/10ml	NE	
naloxone hcl injection solution cartridge 0.4 mg/ml	NE	
naloxone hcl injection solution prefilled syringe 2 mg/2ml	NE	
naloxone hcl nasal liquid 4 mg/0.1ml	NE	OJ &2 QNP?WQ ncp 03 b_wq'
naltrexone hcl oral tablet 50 mg	AC	L5 &NE'
L?PA?L L?Q?J JGOSGB 2 KE-.,/ KJ &*naloxone hcl*'	LN	OJ &2 QNP?WQ ncp 03 b_wq'
TGTGRPMJ GLRP?KSQASJ?P QSQNCLQGML PCAMLQRGRSRCB 16. KE &*naltrexone*'	LNQN	OJ &16. KE ncp 06 b_wq'
XGK FG GLHCARGML QMJSRGML NPCDGJJCB QWPGLEC 3 KE-.,3KJ &*naloxone hcl*'	LD	
MNGMGB N?PRG?J ?EMLGQRQ		
buprenorphine hcl sublingual tablet sublingual 2 mg, 8 mg	AC	L5 &NE'9 OJ &7. R?@JCRQ ncp 03 B?Wq'
NMQRFCPNCRGA LCSP?JEG? &NFL'		
EP?JGQC MP?J R?@JCR 1.. KE &*gabapentin (once-daily)*'	N@	QR9 OJ &/3. R?@JCRQ ncp 03 b_wq'
EP?JGQC MP?J R?@JCR 23. KE &*gabapentin (once-daily)*'	N@	QR9 OJ &7. R?@JCRQ ncp 03 B?Wq'
EP?JGQC MP?J R?@JCR 4.. KE &*gabapentin (once-daily)*'	N@	QR9 OJ &7. R?@JCRQ ncp 03 b_wq'
EP?JGQC MP?J R?@JCR 53. KE*7.. KE &*gabapentin (once-daily)*'	N@	QR9 OJ &4. R?@JCRQ ncp 03 B?Wq'
FMPGX?LR MP?J R?@JCR CVRCL BCB PCJC?QC 1.. KE*4.. KE &*gabapentin enacarbil*'	LD	
JWPGA? AP MP?J R?@JCR CVRCL BCB PCJC?QC 02 FMSP /43 KE*11. KE*60,3 KE &*pregabalin*'	LD	
pregabalin er oral tablet extended release 24 hour 165 mg, 330 mg, 82.5 mg	LD	

0.01 Nf_pk_aw Bpse Esgbc+?bt_lacb Amlrpmj Nj_l+?crl_Qrsbclr Fc_jrf

Rfc dmpksj_pwgq snb_rcb _llsjjwgl HsjwK

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
NQWAFMRFCP?NCSRGA+KGQA		
?BBWG MP?J R?@JCR /.. KE &*flibanserin*'	LN	QNA
chlordiazepoxide-amitriptyline oral tablet 10-25 mg	LN	OJP &OJ _nnjgcq rm kck`cpq_ec 43_lb mjbcp'9 OJ &4. R?@JCRQ ncp 03 b_wq'9 ?J &K_v 43 Wc_pq'
chlordiazepoxide-amitriptyline oral tablet 5-12.5 mg	LN	OJP &OJ _nnjgcq rm kck`cpq_ec 43_lb mjbcp'9 OJ &/0. R?@JCRQ ncp 03 b_wq'9 ?J &K_v 43 Wc_pq'
fluoxetine hcl (pmdd) oral tablet 10 mg, 20 mg	LD	
JSACKWP? MP?J R?@JCR .,/6 KE &*lofexidine hcl*'	LD	
JW@?JTG MP?J R?@JCR /.+/. KE* /3+/. KE* 0.+/. KE* 3+/. KE &*olanzapine-samidorphan*'	LD	
LSCBCVR? MP?J A?NQSJC 0.+/. KE &*dextromethorphan-quinidine*'	LD	
olanzapine-fluoxetine hcl oral capsule 12-25 mg, 12-50 mg, 3-25 mg, 6-25 mg, 6-50 mg	LN	QRV
paroxetine mesylate oral capsule 7.5 mg	LD	
perphenazine-amitriptyline oral tablet 2-10 mg	NE	OJP &OJ _nnjgcq rm kck`cpq_ec 43_lb mjbcp'9 OJ &/3. R?@JCRQ ncp 03 b_wq'9 ?J &K_v 43 Wc_pq'
perphenazine-amitriptyline oral tablet 2-25 mg, 4-25 mg	NE	OJP &OJ _nnjgcq rm kck`cpq_ec 43_lb mjbcp'9 OJ &4. R?@JCRQ ncp 03 b_wq'9 ?J &K_v 43 Wc_pq'
perphenazine-amitriptyline oral tablet 4-10 mg	NE	OJP &OJ _nnjgcq rm kck`cpq_ec 43_lb mjbcp'9 OJ &/0. R?@JCRQ ncp 03 b_wq'9 ?J &K_v 43 Wc_pq'
perphenazine-amitriptyline oral tablet 4-50 mg	NE	OJP &OJ _nnjgcq rm kck`cpq_ec 43_lb mjbcp'9 OJ &1. R?@JCRQ ncp 03 b_wq'9 ?J &K_v 43 Wc_pq'
pimozide oral tablet 1 mg, 2 mg	LN	
TWJCCQG QS@ASR?LCMSQ QMJSRGML ?SRM+ GLHCARMP /,53 KE-.,1KJ &*bremelanotide acetate*'	LD	

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
LGAMRPMJ LQ L?Q?J QMJSRGML /. KE-KJ &*nicotine*'	AC	L5&LN'9 L6&". amn_w jgkgrcb rm 0 rpc_rkclr awajcq-wc_p'9 OJ &/46 B?WQ MD RPC?RKCLR ncp 143 b_wq'
varenicline tartrate oral tablet 0.5 mg, 1 mg	AC	L5&NE'9 L6&". jgkgrcb rm 0 rpc_rkclr awajcq-wc_p'9 OJ &0 RPC?RKCLR AWAJCQ ncp 143 b_wq'
/. KE*0. KE*1. *varenicline tartrate oral tablet therapy pack 0.5 mg x 11 & 1 mg x 42*	AC	L5&NE'9 L6&". amn_w jgkgrcb rm 0 rpc_rkclr awajcq-wc_p'9 OJ &0 RPC?RKCLR ncp 143 b_wq'
N?9 OJ (90 KJ		
NQN CLBMAPGLC?LB KCR?@MJGA+BPSEQ RM RPC?R BG?@CRCQ ?LB PCESJ?RC FMP KMLCQ		
?APMKCE?JW+BPSEQ RM RPC?R AMLBGRGMLQ RF?R A?SQC CVACQQGTC EPMURF		
lanreotide acetate subcutaneous solution 120 mg/0.5ml	LD	
KWA?NQQ? MP?J A?NQSJC BCJ?WCB PCJC?QC 0. KE &*octreotide acetate*'	LD	
octreotide acetate injection solution 100 mcg/ml, 50 mcg/ml, 500 mcg/ml	NE	N?9 OJ &7. KJ ncp 1. b_wq'
octreotide acetate injection solution 1000 mcg/ml	NE	N?9 OJ &23 KJ ncp 1. b_wq'
octreotide acetate injection solution 200 mcg/ml	NE	N?9 OJ &003 KJ ncp 1. b_wq'
octreotide acetate subcutaneous solution prefilled syringe 100 mcg/ml, 50 mcg/ml, 500 mcg/ml	NE	N?9 OJ &7. KJ ncp 1. b_wq'
Q?LBMQR?RGL GLHCARGML QMJSRGML /.. KAE-KJ* 3. KAE-KJ*3.. KAE-KJ &*octreotide acetate*'	LNQN	N?9 OJ &7. KJ ncp 1. B?Wq'
Q?LBMQR?RGL J?P BCNMR GLRP?KSQASJ?P IGR /. KE*0. KE*1. KE &*octreotide acetate*'	LD	
QMK?RSJGLC BCNMR QS@ASR?LCMSQ QMJSRGML /0. KE-."K = ή" p 1 ζ AE-KJ&		

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
?LBPMECLQ		
RJ?LBMMP?JA?NQSJC//0,3 KE &*testosterone undecanoate*'	LD	
?LBPMECLQ+BPSEQRMPCESJ?RC K?JC FMPKMLCQ		
?LBPMBCPK RP?LQBCPK?J N?RAF 02 FMSP 0 KE-02FP*2 KE-02FP &*testosterone*'	LN	N?
?LBPMECJNSKNRP?LQBCPK?J ECJ 0.,03 KE-?AR&/,40#' &*testosterone*'	LD	
?TCCB GLRP?KSQASJ?P QMJSRGML 53. KE-1KJ &*testosterone undecanoate*'	LNQN	N?
DMPRCQR?RP?LQBCPK?J ECJ /. KE-?AR&0#' &*testosterone*'	LD	
HRCLXMMP?JA?NQSJC /36 KE*/76 KE*015 KE &*testosterone undecanoate*'	LN	N?
IWX?RPCVMP?JA?NQSJC /.. KE*/3. KE*0.. KE &*testosterone undecanoate*'	LD	
methitest oral tablet 10 mg	LN	N?9QRV
methyltestosterone oral capsule 10 mg	NE	N?9QRV
L?RCQRML?Q?J ECJ 3,3 KE-?AR &*testosterone*'	N@	N?
oxandrolone oral tablet 10 mg, 2.5 mg	LN	N?
RCQRGK RP?LQBCPK?J ECJ 3. KE-3EK &/#' &*testosterone*'	LD	
testosterone cypionate injection solution 200 mg/ml	LD	
testosterone cypionate intramuscular solution 100 mg/ml, 200 mg/ml	NE	N?
testosterone enanthate intramuscular solution 200 mg/ml	NE	N?
testosterone transdermal gel 10 mg/act (2%), 20.25 mg/1.25gm (1.62%), 20.25 mg/act (1.62%), 25 mg/2.5gm (1%), 40.5 mg/2.5gm (1.62%)	NE	N?
testosterone transdermal gel 12.5 mg/act (1%), 50 mg/5gm (1%)	NE	N?9L6&JMqKIe bm }

NER l'

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
TMECJVM RP?LQBCPK?J ECJ 3. KE-3EK &/#' *&testosterone'*	LD	
M ~PWWQRCB QS@ASR?LCMSQPQMJSRGML ?SRM+ GLHCARMP /.. KE-.,3KJ*3. KE-.,3KJ*53 KE-.,3KJ *&testosterone enanthate'*	LN	N?
?LRGBG?@CRGAQ* ?JNF?+EJSAMQGB?QC GLFG@GRMPQ		
acarbose oral tablet 100 mg, 25 mg, 50 mg ,شي *p* GLHCA 00 KE/0.5KJ (	NLEN	L6 &Jgqrgle bmcq lmrglajsbc acpr_gl LBAq'
miglitol oral tablet 100 mg, 25 mg, 50 mg	NE LD	

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
?LRGBG?@CRGAQ* BGNCNRGBWJ NCNRGB?QC+2 GL FG@GRMPQ		
alogliptin benzoate oral tablet 12.5 mg, 25 mg, 6.25 mg	LD	
H?LSTG? MP?JR?@JCR /.. KE*03 KE*3. KE &*sitagliptin phosphate*'	LD	
LCQGL? MP?JR?@JCR /0,3 KE*03 KE*4,03 KE &*alogliptin benzoate*'	LD	
MLEJWX? MP?JR?@JCR 0,3 KE*3 KE &*saxagliptin hcl*'	LD	
RP?BHCLR? MP?JR?@JCR 3 KE &*linagliptin*'	N@	QR
?LRGBG?@CRGAQ* BMN?KGLC PCACNRMP ?EMLGQRQ		
AWAJMQCR MP?JR?@JCR .,6 KE &*bromocriptine mesylate*'	LD	
?LRGBG?@CRGAQ* BNN+2 GL FG@GRMP AMK@GL?RGMLQ		
alogliptin-metformin hcl oral tablet 12.5-1000 mg, 12.5-500 mg	LD	
alogliptin-pioglitazone oral tablet 12.5-30 mg, 25-15 mg, 25-30 mg, 25-45 mg	LD	
H?LSKCR MP?JR?@JCR 3.+/... KE*3.+3.. KE &*sitagliptin-metformin hcl*'	LD	
H?LSKCR VP MP?JR?@JCR CVRCL BCB PCJC?QC 02 FMSP /..+/... KE*3.+/... KE*3.+3.. KE &*sitagliptin-metformin hcl*'	LD	
HCLR?BSCRM MP?JR?@JCR 0,3+/... KE*0,3+3.. KE*0,3+63. KE &*linagliptin-metformin hcl*'	N@	QR
HCLR?BSCRM VP MP?JR?@JCR CVRCL BCB PCJC?QC 02 FMSP 0,3+/... KE*3+/... KE &*linagliptin-metformin hcl*'	N@	QR
I?X?LM MP?JR?@JCR /0,3+/... KE*/0,3+3.. KE &*alogliptin-metformin hcl*'	LD	
IMK@GEJWXC VP MP?JR?@JCR CVRCL BCB PCJC?QC 02 FMSP 0,3+/... KE*3+/... KE*3+3.. KE &*saxagliptin-metformin*'	LD	
MQCLG MP?JR?@JCR /0,3+1. KE*03+/3 KE*03+1. KE*03+23 KE &*alogliptin-pioglitazone*'	LD	
RPGH?PBW VP MP?JR?@JCR CVRCL BCB PCJC?QC 02 FMSP /.+3+/... KE*/0,3+0,3+/... KE*03+3+/... KE*3+0,3+/... KE &*empagliflozin-linaglip-metform*'	QR''	

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
?LRGBG?@CRGAQ*GLAPCRGL KGKCRGA ?ECLRQ		
@WBSPCML @AGQC QS@ASR?LCMSQ ?SRM+ GLHCARMP 0 KE-.,63KJ &*exenatide*'	LD	
@WCRR?/. KAE NCL QS@ASR?LCMSQ QMJSRGML NCL+GLHCARMP /. KAE-.,.2KJ &*exenatide*'	LD	
@WCRR?3 KAE NCL QS@ASR?LCMSQ QMJSRGML NCL+GLHCARMP 3 KAE-.,.0KJ &*exenatide*'	LD	
KMSLH?PM QS@ASR?LCMSQ QMJSRGML NCL+ GLHCARMP /. KE-.,3KJ*/0,3 KE-.,3KJ*/3 KE-.,3KJ* 0,3 KE-.,3KJ*3 KE-.,3KJ*5,3 KE-.,3KJ &*tirzepatide*'	LD	
MXCKNGA&.,03 MP .,3 KE-BMQC' QS@ASR?LCMSQ QMJSRGML NCL+GLHCARMP 0 KE-1KJ &*semaglutide*'	N@	N?9OJ &/ NCL ncp 06 B?Wq'
MXCKNGA&/ KE-BMQC' QS@ASR?LCMSQ QMJSRGML NCL+GLHCARMP 2 KE-1KJ &*semaglutide*'	N@	N?9OJ &/ NCL ncp 06 B?Wq'
MXCKNGA&0 KE-BMQC' QS@ASR?LCMSQ QMJSRGML NCL+GLHCARMP 6 KE-1KJ &*semaglutide*'	N@	N?9OJ &/ NCL ncp 06 b_wq'
PW@CJQSQ MP?J R?@JCR /2 KE*1 KE*5 KE &*semaglutide*'	N@	N?9OJ &1. R?@JCRQ ncp 1. b_wq'
RPSJGAGRW QS@ASR?LCMSQ QMJSRGML NCL+ GLHCARMP .,53 KE-.,3KJ*/,3 KE-.,3KJ*1 KE-.,3KJ* 2,3 KE-.,3KJ &*dulaglutide*'	N@	N?9OJ &2 NCLQ ncp 0/ B?Wq'
TGARMX? QS@ASR?LCMSQ QMJSRGML NCL+ GLHCARMP /6 KE-1KJ &*liraglutide*'	N@	N?9OJ &1 NCLQ ncp 03 B?Wq'
?LRGBG?@CRGAQ*GLAPCRGL KGKCRGA AMK@GL?RGML ?ECLRQ		
QMJGOS? QS@ASR?LCMSQ QMJSRGML NCL+ GLHCARMP /..+11 SLR+KAE-KJ &*insulin glargine-lixisenatide*'	N@	QR
VSJRMNFW QS@ASR?LCMSQ QMJSRGML NCL+ GLHCARMP /-ɻʿ ή θ > ˘ ˂		N ẘ r -ገ
QMJ = N@ QR		

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
LMTMJGL L DJCVNCL PCJGML QS@ASR?LCMSQ QSQNCLQGML NCL+GLHCARMP /.. SLGR-KJ &*insulin nph human (isophane)*'	LD	
LMTMJGL L DJCVNCL QS@ASR?LCMSQ QSQNCLQGML NCL+GLHCARMP /.. SLGR-KJ &*insulin nph human (isophane)*'	N@	
LMTMJGL L PCJGML QS@ASR?LCMSQ QSQNCLQGML /.. SLGR-KJ &*insulin nph human (isophane)*'	LD	
LMTMJGL L QS@ASR?LCMSQ QSQNCLQGML /.. SLGR-KJ &*insulin nph human (isophane)*'	N@	
LMTMJGL P DJCVNCL GLHCARGML QMJSRGML NCL+GLHCARMP /.. SLGR-KJ &*insulin regular human*'	N@	
LMTMJGL P DJCVNCL PCJGML GLHCARGML QMJSRGML NCL+GLHCARMP /.. SLGR-KJ &*insulin regular human*'	LD	
LMTMJGL P GLHCARGML QMJSRGML /.. SLGR-KJ &*insulin regular human*'	N@	
LMTMJGL P PCJGML GLHCARGML QMJSRGML /.. SLGR-KJ &*insulin regular human*'	LD	
LMTMJME 5.-1. DJCVNCL PCJGML QS@ASR?LCMSQ QSQNCLQGML NCL+GLHCARMP &5.+1.' /.. SLGR-KJ &*insulin aspart prot & aspart*'	LD	
LMTMJME DJCVNCL QS@ASR?LCMSQ QMJSRGML NCL+GLHCARMP /.. SLGR-KJ &*insulin aspart*'	N@	
LMTMJME GLHCARGML QMJSRGML /.. SLGR-KJ &*insulin aspart*'	N@	
LMTMJME KGV 5.-1. DJCVNCL QS@ASR?LCMSQ QSQNCLQGML NCL+GLHCARMP &5.+1.' /.. SLGR-KJ &*insulin aspart prot & aspart*'	N@	
LMTMJME KGV 5.-1. QS@ASR?LCMSQ QSQNCLQGML &5.+1.' /.. SLGR-KJ &*insulin aspart prot & aspart*'	N@	
LMTMJME NCLDGJJ QS@ASR?LCMSQ QMJSRGML A?PRPGBEC /.. SLGR-KJ &*insulin aspart*'	N@	
PCXTMEJ?P IUGINCL QS@ASR?LCMSQ QMJSRGML NCL+GLHCARMP /.. SLGR-KJ &*insulin glargine-aglr*'	LD	
QCKEJCC &WDEL' QS@ASR?LCMSQ QMJSRGML /.. SLGR-KJ &*insulin glargine-yfgn*'	LD	

0.01 Nf_pk_aw Bpse Esgbc+?bt_lacb Amlrpmj Nj_l+?crl_Qrsbclr Fc_jrf

Rfc dmpksj_pwgq snb_rcb _llsjjwgl HsjwK

.5-./-0.01

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
QCKEJCC &WDEL' QS@ASR?LCMSQ QMJSRGML NCL+ GLHCARMP /.. SLGR-KJ &*insulin glargine-yfgn*'	LD	
RMSHCM K?V QMJMQR?P QS@ASR?LCMSQ QMJSRGML NCL+GLHCARMP 1.. SLGR-KJ &*insulin glargine*'	N@	
RMSHCM QMJMQR?P QS@ASR?LCMSQ QMJSRGML NCL+GLHCARMP 1.. SLGR-KJ &*insulin glargine*'	N@	
RPCQG@? DJCVRMSAF QS@ASR?LCMSQ QMJSRGML NCL+GLHCARMP /.. SLGR-KJ*0.. SLGR-KJ &*insulin degludec*'	N@	
RPCQG@? QS@ASR?LCMSQ QMJSRGML /.. SLGR-KJ &*insulin degludec*'	N@	
?LRGBG?@CRGAQ*GLQSJGL QCLQGRGXCP		
?ARMQ MP?J R?@JCR /3 KE*1. KE*23 KE &*pioglitazone hcl*'	LD	
pioglitazone hcl oral tablet 15 mg, 30 mg, 45 mg	NE	JEA
?LRGBG?@CRGAQ*GLQSJGL QCLQGRGXCP-@GES?LGBC AMK@GL?RGML		
pioglitazone hcl-metformin hcl oral tablet 15-500 mg, 15-850 mg	NE	
?LRGBG?@CRGAQ*GLQSJGL QCLQGRGXCP-QSJDMLWJSPC? AMK@GL?RGML		
pioglitazone hcl-glimepiride oral tablet 30-2 mg, 30-4 mg	NE	
?LRGBG?@CRGAQ* KCEJGRGLGBC		
nateglinide oral tablet 120 mg, 60 mg	NE	JEA
repaglinide oral tablet 0.5 mg, 1 mg, 2 mg	LN	
?LRGBG?@CRGAQ* KGQACJJ?LCMSQ		
IMPJWK MP?J R?@JCR 1.. KE &*mifepristone*'	LD	
?LRGBG?@CRGAQ*QMBGSK+EJSAMQC AMRP?LQNMPRCP+0 &QEJR0'GLFG@GRMP AMK@GL?RGMLQ		
GLTMI?KCR MP?J R?@JCR /3.+/... KE*/3.+3.. KE* 3.+/... KE*3.+3.. KE &*canagliflozin-metformin hcl*'	LD	
GLTMI?KCR VP MP?J R?@JCR CVRCL BCB PCJC?QC 02 FMSP /3.+/... KE*/3.+3.. KE*3.+/... KE*3.+3.. KE &*canagliflozin-metformin hcl*'	LD	

0.01 Nf_pk_aw Bpse Esgbc+?bt_lacb Amlrpmj Nj_l+?crl_Qrsbclr Fc_jrf

Rfc dmpksj_pwgq snb_rcb _llsjjwgl HsjwK

.5-./-0.01
//4

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
?LRGM@CQGRW		
?BGNCV+N MP?J A?NQSJC 15,3 K E &*phentermine hcl*'	LN	N?9QNA
?BGNCV+N MP?J R?@JCR 15,3 K E &*phentermine hcl*'	LN	N?9QNA
benzphetamine hcl oral tablet 50 mg	NE	N?9QNA
AMLRP?TC MP?J R?@JCR CVRCL BCB PCJC?QC /0 FMSP 6+7. K E &*naltrexone-bupropion hcl*'	LD	
diethylpropion hcl er oral tablet extended release 24 hour 75 mg	NE	N?9QNA 9 L6 &Jgqrgle bmcq lmrglajsbc acpr_gl L BAq'
diethylpropion hcl oral tablet 25 mg	NE	N?9QNA
JMK?GP? MP?J R?@JCR 6 K E &*phentermine hcl*'	LD	
orlistat oral capsule 120 mg	NE	N?9QNA
phendimetrazine tartrate er oral capsule extended release 24 hour 105 mg	LD	
phendimetrazine tartrate oral tablet 35 mg	NE	N?9QNA
phentermine hcl oral capsule 15 mg, 30 mg, 37.5 mg	NE	N?9QNA
phentermine hcl oral tablet 37.5 mg	NE	N?9QNA
OQWKG? MP?J A?NQSJC CVR= α - C QC 02		

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
		Ü Ç ÏẠ Ç Ỵ Ç ń
		Ş η

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
norethin ace-eth estrad-fe &@jgqmtg Dc /,3-1. Mp_j R_`jcr /,3+1. Ke+Kae'	AC	L5&NE'
norethin ace-eth estrad-fe &@jgqmtg Dc /-0. Mp_j R_`jcr /+0. Ke+Kae'	AC	L5&NE'
norethindrone &A_kgj_ Mp_j R_`jcr .,13 Ke'	AC	L5&NE'
levonorgest-eth estrad 91-day &A_kpcqc Jm Mp_j R_`jcr .,/+ .,.0 $.,./ Ke'	AC	L5&NE' &= 3 l 4

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
L?R?XG? MP?J R?@JCR 1-0+0-0+1-/ K E &*estradiol valerate-dienogest*'	AC	L5&N@'
norethindrone-eth estradiol &Lcaml .,3-13 &06' Mp_j R_`jcr .,3+13 Ke+Kae'	AC	L5&NE'
LCVNJ?LML QS@ASR?LCMSQGKNJ?LR 46 K E &*etonogestrel*'	AC	L5&LN'9OJ&/GKNJ?LR ncp 1.. b_wq'
LCVRQRCJJGQ MP?J R?@JCR 1+/2,0 K E &*drospirenone-estetrol*'	AC	L5&LD'
norethin ace-eth estrad-fe oral capsule 1-20 mg-mcg(24)	AC	L5&NE'
norethin ace-eth estrad-fe oral tablet 1-20 mg-mcg	AC	L5&NE'
norethin ace-eth estrad-fe oral tablet chewable 1-20 mg-mcg(24)	AC	L5&NE'
norethindrone acet-ethinyl est oral tablet 1-20 mg-mcg	AC	L5&NE'
norethindrone oral tablet 0.35 mg	AC	L5&NE'
norethin-eth estradiol-fe oral tablet chewable 0.4-35 mg-mcg, 0.8-25 mg-mcg	ACcfgl+crf cqrp_bmlc mp_j r_`jcr	
norethindrhin-eth estrablet *norethindrhin-eth estrablet*		
noretace-eth est C e o r h		OPSFU

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
UGBC+QC?J BG?NFP?EK 53 T?EGL?J BG?NFP?EK 0 # &*diaphragm wide seal*'	AC	L5&LN'9OJ &/ BG?NFP?EK ncp 1.. b_wq'
UGBC+QC?J BG?NFP?EK 6. T?EGL?J BG?NFP?EK 0 # &*diaphragm wide seal*'	AC	L5&LN'9OJ &/ BG?NFP?EK ncp 1.. b_wq'
UGBC+QC?J BG?NFP?EK 63 T?EGL?J BG?NFP?EK 0 # &*diaphragm wide seal*'	AC	L5&LN'9OJ &/ BG?NFP?EK ncp 1.. b_wq'
UGBC+QC?J BG?NFP?EK 7. T?EGL?J BG?NFP?EK 0 # &*diaphragm wide seal*'	AC	L5&LN'9OJ &/ BG?NFP?EK ncp 1.. b_wq'
UGBC+QC?J BG?NFP?EK 73 T?EGL?J BG?NFP?EK 0 # &*diaphragm wide seal*'	AC	L5&LN'9OJ &/ BG?NFP?EK ncp 1.. b_wq'
norelgestromin-eth estradiol &Vsj_lc Rp_lqbcpk_j N_raf Uccijw /3.+13 Kae-02Fp'	AC	L5&NE'
W?QKGL 06 MP?J R?@JCR 1+.,.1 KE &*drospirenone-ethinyl estradiol*'	LD	
W?X MP?J R?@JCR 1+.,.0 KE &*drospirenone-ethinyl estradiol*'	LD	
AMPRGQMJ QWLRFCQGQ GL FG@GRMPQ		
GQRSPGQ? MP?J R?@JCR / KE*/. KE*3 KE &*osilodrostat phosphate*'	LD	
PCAMPJCT MP?J R?@JCR /3. KE &*levoketoconazole*'	LD	
BG?@CRGA QSNNJGCQ		
?AAS+AFCI ?TGT? NJSQ GL TGRPM QRPGN &*glucose blood*'	N@	OJ &/3. RCQR QRPGNQ ncp 03 b_wq'
?AAS+AFCI D?QRAJGV J?LACRQ &*lancets*'	LN	
?AAS+AFCI ESGBC GL TGRPM QRPGN &*glucose blood*'	N@	OJ &/3. RCQR QRPGNQ ncp 03 b_wq'
?AAS+AFCI QK?PRTGCU GL TGRPM QRPGN &*glucose blood*'	N@	OJ &/3. RCQR QRPGNQ ncp 03 b_wq'
?AAS+AFCI QMDRAJGV J?LACRQ &*lancets*'	LN	
?AASRPCLB EJSAMQC GL TGRPM QRPGN &*glucose blood*'	LD	

0.01 Nf_pk_aw Bpse Esgbc+?bt_lacb Amlrpmj Nj_l+?crl_Qrsbclr Fc_jrf

Rfc dmpksj_pwgq snb_rcb _llsjjwgl HsjwK

.5-./-0.01
/04

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
?BT?LAC GLRSGRGML RCQR GL TGRPM QRPGN &*glucose blood*'	LD	
?BT?LAC KGAPM+BP?U RCQR GL TGRPM QRPGN &*glucose blood*'	LD	
?BTMA?RC PCBG+AMBC GL TGRPM QRPGN &*glucose blood*'	LD	
?BTMA?RC PCBG+AMBC) RCQR GL TGRPM QRPGN &*glucose blood*'	LD	
?BTMA?RC RCQR GL TGRPM QRPGN &*glucose blood*'	LD	
?E?K?RPGV ?KN RCQR GL TGRPM QRPGN &*glucose blood*'	LD	
?E?K?RPGV H?XX RCQR GL TGRPM QRPGN &*glucose blood*'	LD	
?E?K?RPGV ICWLMRC RCQR GL TGRPM QRPGN &*glucose blood*'	LD	
?E?K?RPGV NPCQRM RCQR GL TGRPM QRPGN &*glucose blood*'	LD	
alcohol swabs pad	LN	
?QQSPC 1 RCQR GL TGRPM QRPGN &*glucose blood*'	LD	
?QQSPC 2 RCQR GL TGRPM QRPGN &*glucose blood*'	LD	
?QQSPC GG AFCA I GL TGRPM QRPGN &*glucose blood*'	LD	
?QQSPC GG GL TGRPM QRPGN &*glucose blood*'	LD	
?QQSPC J?LAC J?LACRQ &*lancets*'	LN	
?QQSPC NJ?RGLSK GL TGRPM QRPGN &*glucose blood*'	LD	
?QQSPC NPGQK KSJRG RCQR GL TGRPM QRPGN &*glucose blood*'	LD	
?QQSPC NPM RCQR GL TGRPM QRPGN &*glucose blood*'	LD	
@B GLQSJGL QWPGLEC S+3..1/E V4KK .,3 KJ &*insulin syringe/needle u-500*'	N@	L6 &@B qwpglecq_lb lccbjcq _pc rfc mljw npcdcppcb mnrgmlq'
@B J?LACR SJRP?DGLC 1.E &*lancets*'	LN	
@B J?LACR SJRP?DGLC 11E &*lancets*'	LN	
@B KGAPMR?GLCP J?LACRQ &*lancets*'	LN	

0.01 Nf_pk_aw Bpse Esgbc+?bt_lacb Amlrpmj Nj_l+?crl_Qrsbclr Fc_jrf

Rfc dmpksj_pwgq snb_rcb_llsjjwgl HsjwK

.5-./-0.01

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
CTMJSRGML ?SRMAMBC GL TGRPM QRPGN &*glucose blood*'	LD	
DGDRW3. EJSAMQC RCQR 0,. GL TGRPM QRPGN &*glucose blood*'	LD	
DGL ECPQRGV J?LACRQ &*lancets*'	LN	
DMP? 4 AML LCAR GL TGRPM QRPGN &*glucose blood*'	LD	
DMP? @JMMB EJSAMQC RCQR GL TGRPM QRPGN &*glucose blood*'	LD	
DMP? B/3E @JMMB EJSAMQC RCQR GL TGRPM QRPGN &*glucose blood*'	LD	
DMP? B0. @JMMB EJSAMQC RCQR GL TGRPM QRPGN &*glucose blood*'	LD	
DMP? B2.-E1/ @JMMB EJSAMQC GL TGRPM QRPGN &*glucose blood*'	LD	
DMP? E0. @JMMB EJSAMQC RCQR GL TGRPM QRPGN &*glucose blood*'	LD	
D ʻ ʼ ʻ ʼ ķŃ lγ/w̄ l' א k &*glucose blood*' LD	l' LD	l'

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
DMP?A?PC NPCKGSK T/. RCQR GL TGRPM QRPGN &*glucose blood*'	LD	
DMP?A?PC RCQR L EM RCQR GL TGRPM QRPGN &*glucose blood*'	LD	
DMPRGQA?PC RCQR GL TGRPM QRPGN &*glucose blood*'	LD	
DPCCQRWJC GLQSJGLV RCQR GL TGRPM QRPGN &*glucose blood*'	LD	
DPCCQRWJC J?LACRQ &*lancets*'	LN	
DPCCQRWJC JG@PC /2 B?W QCLQMP &*continuous blood gluc sensor*'	LD	
DPCCQRWJC JG@PC 0 QCLQMP &*continuous blood gluc sensor*'	LD	
freestyle libre 3 sensor	LD	
DPCCQRWJC JG@PC PC?BCP BCTGAC &*continuous blood gluc receiver*'	LD	
DPCCQRWJC JGRC RCQR GL TGRPM QRPGN &*glucose blood*'	LD	
DPCCQRWJC NPCAGQGML LCM RCQR GL TGRPM QRPGN &*glucose blood*'	LD	
DPCCQRWJC RCQR GL TGRPM QRPGN &*glucose blood*'	LD	
ge100 blood glucose test in vitro strip	LD	
ECLSJRGK?RC RCQR GL TGRPM QRPGN &*glucose blood*'	LD	
ght test in vitro strip	LD	
EJSAM NCPDCAR 1 RCQR GL TGRPM QRPGN &*glucose blood*'	LD	
EJSAMA?PB ./ QCLQMP NJSQ GL TGRPM QRPGN &*glucose blood*'	LD	
EJSAMA?PB CVNPCQQGML RCQR GL TGRPM QRPGN &*glucose blood*'	LD	
EJSAMA?PB QFGLC RCQR GL TGRPM QRPGN &*glucose blood*'	LD	
EJSAMA?PB TGR?J RCQR GL TGRPM QRPGN &*glucose blood*'	LD	
EJSAMA?PB V+QCLQMP GL TGRPM QRPGN &*glucose blood*'	LD	
EJSAMAMK RCQR GL TGRPM QRPGN &*glucose blood*'	LD	

0.01 Nf_pk_aw Bpse Esgbc+?bt_lacb Amlrpmj Nj_l+?crl_Qrsbclr Fc_jrf

Rfc dmpksj_pwgq snb_rcb_llsjjwgl HsjwK

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
EJSAML?TGG@JMMB EJSAMQC RCQR GL TGRPM QRPGN &*glucose blood*'	LD	
glucose control in vitro solution	LN	
glucose meter test in vitro strip	LD	
gl	LD	

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
KCGHCP RPSCRCQR RCQR GL TGRPM QRPGN &*glucose blood*'	LD	
KCGHCP RPSCRP?AI RCQR GL TGRPM QRPGN &*glucose blood*'	LD	
KGAPMBMR RCQR GL TGRPM QRPGN &*glucose blood*'	LD	
KGAPMJCR J?LACRQ &*lancets*'	LN	
KWEJSAMFC?JRF RCQR GL TGRPM QRPGN &*glucose blood*'	LD	
LCSRCI 0RCI RCQR GL TGRPM QRPGN &*glucose blood*'	LD	
LMT? K?V EJSAMQC RCQR GL TGRPM QRPGN &*glucose blood*'	LD	
MKLGNMB 3 E4 GLRPM &ECL 3' IGR &*insulin disposable pump*'	N@	
MKLGNMB 3 E4 NMB &ECL 3' &*insulin disposable pump*'	N@	
MKLGNMB AJ?QQGA NMBQ &ECL 1' &*insulin disposable pump*'	N@	
MKLGNMB B?QF GLRPM &ECL 2' IGR &*insulin disposable pump*'	N@	
MKLGNMB B?QF NBK &ECL 2' IGR &*insulin disposable pump*'	N@	
MKLGNMB B?QF NMBQ &ECL 2' &*insulin disposable pump*'	N@	
MKLGNMB EM IGR /. SLGR-02FP* /3 SLGR-02FP* 0. SLGR-02FP* 03 SLGR-02FP* 1. SLGR-02FP* 13 SLGR-02FP* 2. SLGR-02FP &*insulin disposable pump*'	LD	
one drop test in vitro strip	LD	
MLCRMSAF BCJGA? NJSQ J?LACR1.E &*lancets*'	N@	
MLCRMSAF BCJGA? Q?DCRW J?LAGLE &*lancet devices*'	N@	
MLCRMSAF SJRP? GL TGRPM QRPGN &*glucose blood*'	N@	OJ &/3. RCQR QRPGNQ ncp 03 b_wq'
MLCRMSAF SJRP?QMDR 0 J?LACRQ &*lancets*'	N@	
MLCRMSAF TCPGM GL TGRPM QRPGN &*glucose blood*'	N@	OJ &/3. RCQR QRPGNQ ncp 03 b_wq'
MNRGS KCX RCQR GL TGRPM QRPGN &*glucose blood*'	LD	
NF?PK?AGQR AFMGAC ?SRMAMBC GL TGRPM QRPGN &*glucose blood*'	LD	

0.01 Nf_pk_aw Bpse Esgbc+?bt_lacb Amlrpmj Nj_l+?crl_Qrsbclr Fc_jrf

Rfc dmpksj_pwgq snb_rcb _llsjjwgl HsjwK

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq _lb Jgkgrq
A?P@?EJS MP?J R?@JCR QMJS@JC 0.. KE *&carglumic acid'*	LD	
carglumic acid oral tablet soluble 200 mg	NQN	N?
ACPBCJE? MP?J A?NQSJC 62 KE *&eliglustat tartrate'*	NQN	N?9 OJ &34 A?NQSJCQ ncp 06 b_wq'
ACPCXWKC GLRP?TCLMSQ QMJSRGML PCAML QRGRSRCB 2.. SL GR &		

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
P?TGARG MP?J JGOSGB /,/ E K-K J &*glycerol phenylbutyrate*'	LD	
sapropterin dihydrochloride oral packet 100 mg, 500 mg	NQN	N?
sapropterin dihydrochloride oral tablet 100 mg	NQN	N?
sodium phenylbutyrate oral powder 3 gm/tsp	NQN	N?9 OJ &4.. E ncp 1. b_wq'
sodium phenylbutyrate oral tablet 500 mg	NQN	

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
BGTGECJ RP?LQBCPK?J ECJ .,03 KE-.,03E K* .,3 KE-.,3E K* .,53 KE-.,53E K* / KE-E K* /,03 KE-/,03E K &*estradiol*'	N@	
BS?TCC MP?J R?@JCR .,23+0. KE &*conj estrogens-bazedoxifene*'	LD	L/. &LN*N? _nnjgcq'
CJCQRPGL RP?LQBCPK?J ECJ .,30 KE-.,65 E K &.,.4#' &*estradiol*'	LD	
estradiol oral tablet 0.5 mg, 1 mg, 2 mg	NE	
estradiol transdermal gel 0.25 mg/0.25gm, 0.5 mg/0.5gm, 0.75 mg/0.75gm, 1 mg/gm, 1.25 mg/1.25gm	NE	
estradiol transdermal patch twice weekly 0.025 mg/24hr, 0.0375 mg/24hr, 0.05 mg/24hr, 0.075 mg/24hr, 0.1 mg/24hr	NE	
estradiol transdermal patch weekly 0.025 mg/24hr, 0.0375 mg/24hr, 0.05 mg/24hr, 0.06 mg/24hr, 0.075 mg/24hr, 0.1 mg/24hr	NE	
estradiol vaginal cream 0.1 mg/gm	NE	
estradiol vaginal tablet 10 mcg	LD	
estradiol valerate intramuscular oil 20 mg/ml, 40 mg/ml	NE	
estradiol-norethindrone acet oral tablet 0.5-0.1 mg	NE	
CQRPGLE T?EGL?J PGLE 0 KE &*estradiol*'	LD	
CQRPMECJ RP?LQBCPK?J ECJ .,53 KE-/,03 E K &.,.4#' &*estradiol*'	LD	
CT?KGQR RP?LQBCPK?J QMJSRGML /,31 KE-QNP?W &*estradiol*'	N@	
norethindrone-eth estradiol &Dw_tmjt Mp_jR_`jcr .,3+0,3 Ke+ Kae* /+3 Ke+Kae'	NE	
GKTCVVW K?GLRCL?LAC N?AI T?EGL?J GLQCPR /. KAE*2 KAE &*estradiol*'	N@	
GKTCVVW QR?PRCP N?AI T?EGL?J GLQCPR /. KAE*2 KAE &*estradiol*'	N@	
norethindrone-eth estradiol &Hglrcjg Mp_jR_`jcr /+3 Ke+Kae'	NE	
KCLCQR MP?J R?@JCR .,1 KE* .,403 KE* /,03 KE*0,3 KE &*esterified estrogens*'	LD	
KCLMQR?P RP?LQBCPK?J N?RAF UCCI JW/2 KAE-02FP &*estradiol*'	LD	
estradiol-norethindrone acet &Kgk tcw Mp_jR_`jcr /+.,3 Ke'	NE	

0.01 Nf_pk_aw Bpse Esgbc+?bt_lacb Amlrpmj Nj_l+?crl_Qrsbclr Fc_jrf

Rfc dmpksj_pwgq snb_rcb _llsjjwgl HsjwK

.5-./-0.01

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
JSRCGLGXGLE FMPKMLC+PCJC?QGLE FMPKMLC &JFPF' ?EMLGQRQ		
DCLQMJTG&4 KMLRF'QS@ASR?LCMSQ IGR 23 KE &*leuprolide acetate (6 month)*'	NQN	N?
JSNPML BCNMR+NCB &/+KMLRF'GLRP?KSQASJ?P IGR //,03 KE*/3 KE*5,3 KE &*leuprolide acetate*'	NQN	N?
JSNPML BCNMR+NCB &1+KMLRF'GLRP?KSQASJ?P IGR //,03 KE &NCB'*1. KE &*leuprolide acetate (3 month)*'	NQN	N?
JSNPML BCNMR+NCB &4+KMLRF'GLRP?KSQASJ?P IGR 23 KE &*leuprolide acetate (6 month)*'	NQN	N?
QWL?PCJ L?Q?J QMJSRGML 0 KE-KJ &*nafarelin acetate*'	LN	N?
RPGNRMBSP GLRP?KSQASJ?P QSQNCLQGML PCAMLQRGRSRCB CP 00,3 KE &*triptorelin pamoate*'	NQN	N?
KGLCP?JMAMPRGAMGB PCACNRMP ?LR?EMLGQRQ+ BPSEQ RM RPC?R AFPMLGA IGBLCW BGQC?QC ?QQMAG?RCB UGRF RWNC 0 BG?@CRCQ		
ICPCLBG? MP?JR?@JCR /. KE*0. KE &*finerenone*'	N@	
KGQACJJ?LCMSQ		
?ARF?P GLHCARGML ECJ 6. SLGR-KJ &*corticotropin*'	LNQN	N?9 OJ &13 KJ ncp 0/ b_wq'
cabergoline oral tablet 0.5 mg	NE	
calcitonin (salmon) nasal solution 200 unit/act	NE	
AMPRPMNFGL GLHCARGML ECJ 6. SLGR-KJ &*corticotropin*'	LNQN	N?9 OJ &13 KJ ncp 0/ b_wq'
CTCLGRW QS@ASR?LCMSQ QMJSRGML NPCDGJJCB QWPGLEC /.3 KE-/,/5KJ &*romosozumab-aqqg*'	LD	
DMPRCM QS@ASR?LCMSQ QMJSRGML NCL+ GLHCARMP 4.. KAE-0,2KJ &*teriparatide (recombinant)*'	NQN	N?9 OJ &/ NCL ncp 06 B_wq'
E?J?DMJB MP?J A?NQSJC /01 KE &*migalastat hcl*'	LNQN	N?9 OJ &/2 A?NQSJCQ ncp 06 b_wq'
GKAGTPCC QS@ASR?LCMSQ QMJSRGML /. KE-KJ &*setmelanotide acetate*'	LD	
GLAPCJCV QS@ASR?LCMSQ QMJSRGML 2. KE-2KJ &*mecasermin*'	LNQN	N?
GLRP?PMQ? T?EGL?JGLQCPR 4,3 KE &*prasterone*'	LD	
HWL?POSC MP?JR?@JCR /3 KE*1. KE &*tolvaptan*'	LD	

0.01 Nf_pk_aw Bpse Esgbc+?bt_lacb Amlrpmj Nj_l+?crl_Qrsbclr Fc_jrf

Rfc dmpksj_pwgq snb_rcb _llsjjwgl HsjwK

.5-./-0.01

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
HWL?POSC MP?J R?@JCR RFCP?NW N?A I /3 K E* 1. $ /3 K E* 23 $ /3 K E* 4. $ 1. K E* 7. $ 1. K E &*tolvaptan*'	LD	
methylergonovine maleate &K crfcpeglc Mp_j R_`jcr .,0 Ke'	NE	OJ &2 R?@JCRQ ncp / b_w'
methylergonovine maleate oral tablet 0.2 mg	NE	OJ &2 R?@JCRQ ncp / B?W'
MQNFCL? MP?J R?@JCR 4. K E &*ospemifene*'	LD	L/. &LN*N? _nnjgcq'
NPMJG? QS@ASR?LCMSQ QMJSRGML NPCDGJJCB QWPGL EC 4. K E-K J &*denosumab*'	NQN	N?9 OJ &4. K J ncp /46 b_wq'
raloxifene hcl oral tablet 60 mg	AC	L5 &NE'9 ?J &Kgl 13 Wc_pq'
Q?KQA? MP?J R?@JCR /3 K E* 1. K E &*tolvaptan*'	LNQN	N?
QGELGDMP J?P GLRP?K SQASJ?P QSQNCLQGML PCAMLQRGRSRCB CP /. K E* 0. K E* 1. K E* 2. K E* 4. K E &*pasireotide pamoate*'	LD	
QGELGDMP QS@ASR?LCMSQ QMJSRGML .,1 K E-K J* .,4 K E-K J* .,7 K E-K J &*pasireotide diaspartate*'	LNQN	N?9 OJ &4. K J ncp 1. b_wq'
teriparatide (recombinant) subcutaneous solution pen-injector 620 mcg/2.48ml	LD	
tolvaptan oral tablet 15 mg, 30 mg	NQN	N?
RWK JMQ QS@ASR?LCMSQ QMJSRGML NCL+ GLHCARMP 1/0. KAE-/,34K J &*abaloparatide*'	NQN	N?9 OJ &/ NCL ncp 1. B?Wq'
TGHMGAC MP?J R?@JCR RFCP?NW N?A I /03 K E* 0.. $ 3. K E* 3. K E &*alpelisib*'		

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
DMQPCLMJ MP?J N?AICR /... KE*53. KE &*lanthanum carbonate*'	LD	
DMQPCLMJ MP?J R?@JCR AFCU?@JC /... KE*3.. KE*53. KE &*lanthanum carbonate*'	LD	
lanthanum carbonate oral tablet chewable 1000 mg, 500 mg, 750 mg	LD	
PCLTCJ? MP?J N?AICR .,6 EK*0,2 EK &*sevelamer carbonate*'	LD	
PCLTCJ? MP?J R?@JCR 6.. KE &*sevelamer carbonate*'	LD	
sevelamer carbonate oral packet 0.8 gm, 2.4 gm	NE	
sevelamer carbonate oral tablet 800 mg	NE	
sevelamer hcl oral tablet 400 mg, 800 mg	NE	
TCJNFMPM MP?J R?@JCR AFCU?@JC3.. KE &*sucroferric oxyhydroxide*'	N@	
NMJWLCSPMN?RFW		
RCEQCBG QS@ASR?LCMSQ QMJSRGML NPCDGJJCB QWPGL EC062 KE-/,3KJ &*inotersen sodium*'	NQN	N?9OJ &2 qwpglecq ncp 06 b_wq'
NPMECQRGLQ+BPSEQ RM PCESJ?RC DCK?JC FMPKMLCQ		
APGLMLC T?EGL?J ECJ 2 #*6 # &*progesterone*'	LD	
medroxyprogesterone acetate oral tablet 10 mg, 2.5 mg, 5 mg	NE	
megestrol acetate oral suspension 625 mg/5ml	AC	L5&LN'
norethindrone acetate oral tablet 5 mg	NE	
progesterone oral capsule 100 mg, 200 mg	NE	
NPMKCRPGSK MP?J A?NQSJC /.. KE*0.. KE &*progesterone*'	LD	
RFWPMGB ?ECLRQ+BPSEQ RM PCESJ?RC RFWPMGB JCTCJQ		
?BRFWX? MP?J R?@JCR /1. KE*/4,03 KE*10,3 KE*43 KE*75,3 KE &*thyroid*'	LD	
AWRMKCJ MP?J R?@JCR 03 KAE*3 KAE*3. KAE &*liothyronine sodium*'	LD	
CPKCX? MP?J QMJSRGML /3. KAE-3KJ &*levothyroxine sodium*'	LD	

0.01 Nf_pk_aw Bpse Esgbc+?bt_lacb Amlrpmj Nj_l+?crl_Qrsbclr Fc_jrf

Rfc dmpksj_pwgq snb_rcb _llsjjwgl HsjwK

.5-./-0.01

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
levothyroxine sodium oral capsule 100 mcg, 112 mcg, 125 mcg, 13 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, 25 mcg, 50 mcg, 75 mcg, 88 mcg	LD	
levothyroxine sodium oral tablet 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, 25 mcg, 300 mcg, 50 mcg, 75 mcg, 88 mcg	NE	
liothyronine sodium oral tablet 25 mcg, 5 mcg, 50 mcg	NE	
methimazole oral tablet 10 mg, 5 mg	NE	
propylthiouracil oral tablet 50 mg	NE	
RFWOSGBGRW MP?J QMJSRGML /.. KAE-3KJ &*levothyroxine sodium*'	LD	
RGPMQGLR MP?J A?NQSJC /.. KAE*//0 KAE*/03 KAE*/1 KAE*/15 KAE*/3. KAE*/53 KAE*0.. KAE*03 KAE*15,3 KAE*22 KAE*3. KAE*40,3 KAE*53 KAE*66 KAE &*levothyroxine sodium*'	LD	
RGPMQGLR+QMJ MP?J QMJSRGML /.. KAE-KJ*//0 KAE-KJ*/03 KAE-KJ*/1 KAE-KJ*/15 KAE-KJ*/3. KAE-KJ*/53 KAE-KJ*0.. KAE-KJ*03 KAE-KJ*15,3 KAE-KJ*22 KAE-KJ*3. KAE-KJ*40,3 KAE-KJ*53 KAE-KJ*66 KAE-KJ &*levothyroxine sodium*'	LD	
T?QMNPCQQGLQ+BPSEQRM PCESJ?RC NGRSGR?PW FMPKMLCQ		
BB?TN MP?J R?@JCR .,/ KE*.,0 KE &*desmopressin acetate*'	LN	
desmopressin ace spray refrig nasal solution 0.01 %	NE	
desmopressin acetate nasal solution 1.5 mg/ml	LNQN	N?
desmopressin acetate oral tablet 0.1 mg, 0.2 mg	NE	
desmopressin acetate spray nasal solution 0.01 %	NE	
LMABSPL? QS@JGLES?J R?@JCR QS@JGLES?J 05,5 KAE*33,1 KAE &*desmopressin acetate*'	LN	N?
TGR?KGLQ+TGR?KGLQ?LB QSNNJCKCLRQ		
P?W?JBCC MP?J A?NQSJC CVRCLBCB PCJC?QC 1. KAE &*calcifediol*'	LN	QR

0.01 Nf_pk_aw Bpse Esgbc+?bt_lacb Amlrpmj Nj_l+?crl_Qrsbclr Fc_jrf

Rfc dmpksj_pwgq snb_rcb _llsjjwgl HsjwK

Npcqapgnrgm l Bpse L_kc	Bpse Rgcp	

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
aprepitant oral capsule 80 mg	NE	OJ &2 A?NQSJCQ ncp 0/ b_wq'
prochlorperazine &Amknpm Pcar_j Qsnnmqgrmpw 03 Ke'	NE	
doxylamine-pyridoxine oral tablet delayed release 10-10 mg	NE	
dronabinol oral capsule 10 mg, 2.5 mg, 5 mg	LN	N?9 OJ &/0. A?NQSJCQ ncp 03 B?Wq'
CKCLB MP?J A?NQSJC 6. KE &*aprepitant*'	LD	
CKCLB MP?J QSQNCLQGML PCAMLQRGRSRCB /03 KE-3KJ &*aprepitant*'	LD	
CKCLB RPG+N?AI MP?J A?NQSJC 6. $ /03 KE &*aprepitant*'	LD	
granisetron hcl oral tablet 1 mg	LN	OJ &/0 R?@JCRQ ncp 0/ b_wq'
K?PGLMJ MP?J A?NQSJC 0,3 KE &*dronabinol*'	LN	N?9 OJ &/0. A?NQSJCQ ncp 03 b_wq'
metoclopramide hcl oral solution 10 mg/10ml	NE	L6 &Jgqrglebmcq lmrglajsbc acpr_gl LBAq'
metoclopramide hcl oral solution 5 mg/5ml	NE	
metoclopramide hcl oral tablet 10 mg, 5 mg	NE	
metoclopramide hcl oral tablet dispersible 5 mg	NE	
ondansetron hcl oral solution 4 mg/5ml	NE	OJ &0.. KJ ncp 0/ B?Wq'
ondansetron hcl oral tablet 24 mg	NE	OJ &0 R?@JCRQ ncp 0/ b_wq'
ondansetron hcl oral tablet 4 mg, 8 mg	NE	OJ &/6 R?@JCRQ ncp 0/ B?Wq'
ondansetron oral tablet dispersible 4 mg, 8 mg	NE	OJ &/6 R?@JCRQ ncp 0/ B?Wq'
prochlorperazine maleate oral tablet 10 mg, 5 mg	NE	
promethazine hcl oral syrup 6.25 mg/5ml	NE	
promethazine hcl oral tablet 12.5 mg, 25 mg, 50 mg	NE	
promethazine hcl rectal suppository 12.5 mg, 25 mg	NE	
NPMKCRFCE?L PCAR?J QSNNMQGRMPW 3. KE &*promethazine hcl*'	NE	
Q?LASQMRP?LQBCPK?J N?RAF 1,/ KE-02FP &*granisetron*'	N@	OJ &0 N?RAFCQ ncp 0/ b_wq'

0.01 Nf_pk_aw Bpse Esgbc+?bt_lacb Amlrpmj Nj_l+?crl_Qrsbclr Fc_jrf

Rfc dmpksj_pwgq snb_rcb _llsjjwgl HsjwK

.5-./-0.01
/3.

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
scopolamine transdermal patch 72 hour 1 mg/3days	NE	
QWL BPMQ MP?J QM,JSRGML 3 KE-KJ &*dronabinol*' qamnmj_kglrc p !	LDLD	
RP?LQBCPK+QAMN RP?LQBCPK?JN?RAF 50 F ЧQMQ&		

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
N?LAPC?RGA CLXWKCQ		
APCML MP?J A?NQSJC BCJ?WCB PCJC?QC N?PRGAJCQ /0...+16... SLGR* 02...+54... SLGR* 1...+ 73.. SLGR* 14...+//2... SLGR* 4...+/7... SLGR &*pancrelipase (lip-prot-amyl)*'	N@	
N?LAPC?XC MP?J A?NQSJC BCJ?WCB PCJC?QC N?PRGAJCQ /.3..+133.. SLGR* /46..+346.. SLGR* 0/...+ 325.. SLGR* 04..+66.. SLGR* 15...+751.. SLGR* 20..+ /20.. SLGR &*pancrelipase (lip-prot-amyl)*'	LD	
NCPRXWC MP?J A?NQSJC BCJ?WCB PCJC?QC N?PRGAJCQ /4...+353.. SLGR* 02...+6403. SLGR* 2...+ /2153 SLGR* 6...+0653. SLGR &*pancrelipase (lip-prot-amyl)*'	LD	
TGMI?AC MP?J R?@JCR /.22.+17/3. SLGR* 0.66.+ 561.. SLGR &*pancrelipase (lip-prot-amyl)*'	N@	
XCLNCN MP?J A?NQSJC BCJ?WCB PCJC?QC N?PRGAJCQ /....+10... SLGR* /3...+25... SLGR* 0....+ 41... SLGR* 03...+57... SLGR* 1...+/.... SLGR* 2....+ /04... SLGR* 3...+02... SLGR &*pancrelipase (lip-prot-amyl)*'	N@	
NPMRML NSKNGLFG@GRMPQ+BPSEQDMP SJACPQ ?LB QRMK?AF ?AGB		
?AGNFCV MP?J R?@JCR BCJ?WCB PCJC?QC 0. KE &*rabeprazole sodium*'	LD	
BCVGJ?LR MP?J A?NQSJC BCJ?WCB PCJC?QC 1. KE* 4. KE &*dexlansoprazole*'	LD	
dexlansoprazole oral capsule delayed release 30 mg, 60 mg	LD	
esomeprazole magnesium oral capsule delayed release 20 mg, 40 mg	NE	OJ &7. A?NQSJCQ ncp 143 B?Wq'
esomeprazole magnesium oral packet 10 mg, 20 mg, 40 mg	NE	OJ &7. N?AICR ncp 143 B?Wq'
esomeprazole magnesium oral tablet delayed release 20 mg	NE	Qcjcar MRA9 OJ &7. R?@JCRQ ncp 143 B?Wq'
IMLTMKCN MP?J QSQNCLQGML PCAMLQRGRSRCB 0+ 62 KE-KJ &*omeprazole-sodium bicarbonate*'	LD	
lansoprazole oral capsule delayed release 30 mg	NE	OJ &7. A?NQSJCQ ncp 143 B?Wq'
lansoprazole oral tablet delayed release dispersible 30 mg	LD	

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
ra omeprazole oral tablet delayed release 20 mg	NE	Qcjcar MRA9 OJ &7. R?@JCRQ ncp 143 b_wq'
rabeprazole sodium oral capsule sprinkle 10 mg	LN	OJ &7. A?NQSJCQ ncp 143 B?Wq'
rabeprazole sodium oral tablet delayed release 20 mg	NE	OJ &7. R?@JCRQ ncp 143 b_wq'
XCECPGB MP?J A?NQSJC¢	ɞ NEmkĈ½ d	↑ ú ĈB l″ ve

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
K SQC SPCRFP?J NCJJCR /... KAE*03. KAE*3.. KAE &*alprostadil (vasodilator)*'	N@	QNA 9 OJ &4 QSNNMQGRMPGCQ ncp 03 b_wq'
phenylephrine hcl intracavernosal solution 2 mg/2ml	LD	
quad-mix intracavernosal solution reconstituted 150-10-0.1-1 mg	LD	
sildenafil citrate oral tablet 100 mg, 25 mg, 50 mg	NE	QNA 9 OJ &4 R?@JCRQ ncp 03 B?Wq'
QRCL BP? MP?J R?@JCR /.. KE*0.. KE*3. KE &*avanafil*'	LD	
super quad-mix intracavernosal solution reconstituted 150-20-0.2-2 mg	LD	
tadalafil oral tablet 10 mg, 20 mg	NE	QNA 9 OJ &4 R?@JCRQ ncp 03 B?Wq'
tadalafil oral tablet 2.5 mg	NE	QNA 9 OJ &1. R?@JCRQ ncp 03 B?Wq'
tadalafil oral tablet 5 mg	NE	QNA 9 OJ &1. R?@JCRQ ncp 03 b_wq'
vardenafil hcl oral tablet 10 mg, 2.5 mg, 20 mg, 5 mg	NE	QNA 9 OJ &4 R?@JCRQ ncp 03 b_wq' QNA 9 OJ &4 R?@C&4 R?@ QRCL BP? P 03 B?Wq

Npcqapgnrgm l Bpse L_kc		

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
enoxaparin sodium injection solution prefilled syringe 100 mg/ml, 120 mg/0.8ml, 150 mg/ml, 30 mg/0.3ml, 40 mg/0.4ml, 60 mg/0.6ml, 80 mg/0.8ml	NE	
fondaparinux sodium subcutaneous solution 10 mg/0.8ml, 2.5 mg/0.5ml, 5 mg/0.4ml, 7.5 mg/0.6ml	LN	
DP?EKGL QS@ASR?LCMSQQMJSRGML /.... SLGR-2KJ*73... SLGR-1,6KJ &*dalteparin sodium*'	LD	
DP?EKGL QS@ASR?LCMSQQMJSRGML NPCDGJJCB QWPGLEC /.... SLGR-KJ*/03.. SLGR-.,3KJ*/3... SLGR-.,4KJ*/6... SLR-.,50KJ*03.. SLGR-.,0KJ*3... SLGR-.,0KJ*53.. SLGR-.,1KJ &*dalteparin sodium*'	LD	
heparin sodium (porcine) injection solution 1000 unit/ml, 10000 unit/ml, 20000 unit/ml, 5000 unit/ml	NE	
heparin sodium (porcine) pf injection solution 5000 unit/0.5ml	NE	
NP?B?V? MP?JA?NQSJC //. KE*/3. KE*53 KE &*dabigatran etexilate mesylate*'	LD	
NP?B?V? MP?JN?AICR //. KE*/3. KE*0. KE*1. KE*2. KE*3. KE &*dabigatran etexilate mesylate*'	LD	
Q?T?WQ? MP?JR?@JCR /3 KE*1. KE*4. KE &*edoxaban tosylate*'	LD	
warfarin sodium oral tablet 1 mg, 10 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg l' ثھ l' g */ l*		

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
AMPGD?AR GLRP?TCLMSQ IGR /...+/4.. SLGR &*factor xiii concentrate human*'	LNQN	N?
DCG@? GLRP?TCLMSQ QMJSRGML PCAMLQRGRSRCB /... SLGR*03.. SLGR*3.. SLGR &*antiinhibitor coagulant cmplx*'	LD	
DG@PWE? GLRP?TCLMSQ QMJSRGML PCAMLQRGRSRCB &*fibrinogen concentrate (human)*'	LNQN	N?
FSK?RC+N GLRP?TCLMSQ QMJSRGML PCAMLQRGRSRCB /...+02.. SLGR*03.+4.. SLGR*3..+ /0.. SLGR &*antihemophilic factor-vwf*'	LNQN	N?
IACLRP? GLRP?TCLMSQ IGR /... SLGR*3.. SLGR &*prothrombin complex conc human*'	LNQN	N?
LMTMQCTCL PR GLRP?TCLMSQ QMJSRGML PCAMLQRGRSRCB / KE*0 KE*3 KE*6 KE &*coagulation factor viia recomb*'	NQN	N?
PG?QR?N GLRP?TCLMSQ QMJSRGML PCAMLQRGRSRCB &*fibrinogen concentrate (human)*'	LNQN	N?
QCTCLD?AR GLRP?TCLMSQ QMJSRGML PCAMLQRGRSRCB / KE*3 KE &*coagulation factor viia-jncw*'	NQN	N?
RPCRRCL GLRP?TCLMSQ QMJSRGML PCAMLQRGRSRCB 0...+1/03 SLGR &*coagulation factor xiii a-sub*'	LNQN	N?
TMLTCLBG GLRP?TCLMSQ QMJSRGML PCAMLQRGRSRCB /1.. SLGR*43. SLGR &*von willebrand factor (recomb)*'	LD	
UGJ?RC GLRP?TCLMSQ IGR /...+/... SLGR*3..+3.. SLGR &*antihemophilic factor-vwf*'	LNQN	N?
FCK?RMNMGCRGA EPMURF D?ARMPQ		
?P?LCQN&?J@SKGL DPCC'GLHCARGML QMJSRGML /.. KAE-KJ*0.. KAE-KJ*03 KAE-KJ*2. KAE-KJ*4. KAE-KJ &*darbepoetin alfa*'	NQN	N?
?P?LCQN&?J@SKGL DPCC'GLHCARGML QMJSRGML NPCDGJJCB QWPGLEC /. KAE-.,2KJ*/.. KAE-.,3KJ*/3. KAE-.,1KJ*0.. KAE-.,2KJ*03 KAE-.,20KJ*1.. KAE-.,4KJ*2. KAE-.,2KJ*3.. KAE-KJ*4. KAE-.,1KJ &*darbepoetin alfa*'	NQN	N?

0.01 Nf_pk_aw Bpse Esgbc+?bt_lacb Amlrpmj Nj_l+?crl_Qrsbclr Fc_jrf

Rfc dmpksj_pwgq snb_rcb _llsjjwgl Hsjwk

.5-./-0.01

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
LWTCNPG? QS@ASR? LCMSQ QMJSRGML NPCDGJJCB QWPGL EC 4 K E-.,4 K J &*pegfilgrastim-apgf*'	LD	
MPMAPGR GLMCARGML QMJSRGML /.... SLGR-K J*0... SLGR-K J*0.... SLGR-K J*1... SLGR-K J*2... SLGR-K J*2.... SLGR-K J &*epoa*		

pl filgrastim½l a L D L D l' E d' L l' L D

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
GBCJTGML GLRP?TCLMSQ QMJSRGML PCAMLQRGRSRCB /... SLGR*0... SLGR*03. SLGR* 13.. SLGR*3.. SLGR &*coagulation factor ix (rix-fp)*'	LNQN	N?
GVGLGRW GLRP?TCLMSQ QMJSRGML PCAMLQRGRSRCB /... SLGR* /3.. SLGR*0... SLGR* 03. SLGR*1... SLGR*3.. SLGR &*coagulation factor ix (recomb)*'	LD	
NPMDGJLGLC GLRP?TCLMSQ QMJSRGML PCAMLQRGRSRCB /... SLGR* /3.. SLGR*3.. SLGR &*factor ix complex*'	LNQN	N?
PC@GLWL GLRP?TCLMSQ QMJSRGML PCAMLQRGRSRCB /... SLGR*0... SLGR*1... SLGR* 3.. SLGR &*coagulation factor ix glycopeg*'	NQN	N?
rixubis intravenous solution reconstituted 1000 unit, 2000 unit, 250 unit, 3000 unit, 500 unit	LD	
KGQACJJ?LCMSQ		

KGp ml pc= SL5 ľ S S ľ N-Î

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
TGR?KGLQ+TGR?KGLQ?LB QSNNJCKCLRQ		
L?QAM@?J L?Q?J QMJSRGML 3.. KAE-.,/KJ &*cyanocobalamin*'	LD	
GK K SLMJMEGA ?ECLRQ+BPSEQ RM RPC?R BGQMPBCPQ MD RFC GK K SLC QWQRCK		
?JJCPECLGA CVRP?ARQ		
EP?QRC I QS@JGL ES?J R?@JCR QS@JGL ES?J 06.. @?S &*timothy grass pollen allergen*'	N@	N?
MB?ARP? QS@JGL ES?J R?@JCR QS@JGL ES?J /0 QO+F B K &*dust mite mixed allergen ext*'	LN	N?
MP?J?GP QS@JGL ES?J R?@JCR QS@JGL ES?J 1.. GP &*grass mix pollens allergen ext*'	NQN	N?
N?JDMPXG? &/0 K E B?GJW BMQC' MP?J 0 V / K E $ /. K E &*peanut powder-dnfp*'	LD	
N?JDMPXG? &/0. K E B?GJW BMQC' MP?J 0. K E $ /.. K E &*peanut powder-dnfp*'	LD	
N?JDMPXG? &/4. K E B?GJW BMQC' MP?J 1 V 0. K E $ /.. K E &*peanut powder-dnfp*'	LD	
N?JDMPXG? &0. K E B?GJW BMQC' MP?J 0. K E &*peanut powder-dnfp*'	LD	
N?JDMPXG? &0.. K E B?GJW BMQC' MP?J 0 V /.. K E &*peanut powder-dnfp*'	LD	
N?JDMPXG? &02. K E B?GJW BMQC' MP?J 0 V 0. K E $ 0 V /.. K E &*peanut powder-dnfp*'	LD	
N?JDMPXG? &1 K E B?GJW BMQC' MP?J 1 V / K E &*peanut powder-dnfp*'	LD	
N?JDMPXG? &1.. K E K?GLRCL?LAC' MP?J N?A I CR 1.. K E &*peanut powder-dnfp*'	LD	
N?JDMPXG? &1.. K E RGRP?RGML' MP?J N?A I CR 1.. K E &*peanut powder-dnfp*'	LD	
N?JDMPXG? &2. K E B?GJW BMQC' MP?J 0 V 0. K E &*peanut powder-dnfp*'	LD	
N?JDMPXG? &4 K E B?GJW BMQC' MP?J 4 V / K E &*peanut powder-dnfp*'	LD	
N?JDMPXG? &6. K E B?GJW BMQC' MP?J 2 V 0. K E &*peanut powder-dnfp*'	LD	

0.01 Nf_pk_aw Bpse Esgbc+?bt_lacb Amlrpmj Nj_l+?crl_Qrsbclr Fc_jrf

Rfc dmpksj_pwgq snb_rcb _llsjjwgl HsjwK

.5-./-0.01
/5.

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq _lb Jgkgrq
N?JDMPXG? GLGRG?J CQA?J?RGML MP?J .,3 $ / $ /,3 $ 1 $ 4 K E &*peanut powder-dnfp*'	LD	
P?EUGRC I QS@JGLES?J R?@JCR QS@JGLES?J /0 ?K@ ? /+S &*short ragweed pollen ext*'	N@	N?
?SRMGK K SLC ?ECLRQ &NFWQGAG?L+ ?B KGLGQRCPCB'		
?ARCKP? GLRP?TCLMSQ QMJSRGML 0.. K E-/.K J* 2.. K E-0.K J* 6. K E-2K J &*tocilizumab*'	LD	
?TQMJ? GLRP?TCLMSQ QMJSRGML PCAMLQRGRSRCB /.. K E &*infliximab-axxq*'	LD	
CLRWTGM GLRP?TCLMSQ QMJSRGML PCAMLQRGRSRCB 1.. K E &*vedolizumab*'	LD	G@A &?t_gj_`jc _q LNQN ugrf N? dmp Sjacp_rgtc Amjgrgq'
GJSKW? QS@ASR?LCMSQ QMJSRGML NPCDGJJCB QWPGLEC /.. K E-K J &*tildrakizumab-asmn*'	NQN	N?9 OJ &/ QWPGLEC ncp 7. b_wq'
GLDJCARP? GLRP?TCLMSQ QMJSRGML PCAMLQRGRSRCB /.. K E &*infliximab-dyyb*'	LD	
Infliximab intravenous solution reconstituted 100 mg /	*LD*	
LD@MPCLAG? GLRP?TCLMSQ QMJSRGML PCAMLQRGRSRCB 03. K E &*abatacept*'		

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq _lb Jgkgrq
AMQCLRWV QCLQMPC?BW NCL QS@ASR?LCMSQ QMJSRGML ?SRM+GLHCARMP /3. KE-KJ &*secukinumab*'	NQN	N?9 QR9 G@A &Npcdcppcb _eclr dmp ?liwjmqgle Qnmlbwjgrgq* Nqmpg_rga ?prfpgrgq _lb Lml+ p_bgmep_nfga_j ?vg_j Qnmlbwjm_prfpgrgq, Lmr amtcpcb dmp Nqmpg_qgq'9 OJ &/ @MV ncp 06 b_wq'
AMQCLRWV QS@ASR?LCMSQ QMJSRGML NPCDGJJCB QWPGLEC /3. KE-KJ &*secukinumab*'	NQN	N?9 QR9 G@A &Npcdcppcb _eclr dmp ?liwjmqgle Qnmlbwjgrgq* Nqmpg_rga ?prfpgrgq _lb Lml+ p_bgmep_nfga_j ?vg_j Qnmlbwjm_prfpgrgq, Lmr amtcpcb dmp Nqmpg_qgq'9 OJ &/ @MV ncp 06 b_wq'
AMQCLRWV QS@ASR?LCMSQ QMJSRGML NPCDGJJCB QWPGLEC 53 KE-.,3KJ &*secukinumab*'	NQN	N?9 QR9 G@A &Npcdcppcb _eclr dmp ?liwjmqgle Qnmlbwjgrgq* Nqmpg_rga ?prfpgrgq _lb Lml+ p_bgmep_nfga_j ?vg_j Qnmlbwjm_prfpgrgq, Lmr amtcpcb dmp Nqmpg_qgq'9 OJ &/ QWPGLEC ncp 06 b_wq'
CL@PCJ KGLG QS@ASR?LCMSQ QMJSRGML A?PRPGBEC 3. KE-KJ &*etanercept*'	NQN	N?9 QR9 G@A &Npcdcppcb _eclr dmp _jj amlbgrgmlq cvacnr Nqmpg_qgq'9 OJ &2 A?PRPGBECQ ncp 06 b_wq'
CL@PCJ QS@ASR?LCMSQ QMJSRGML 03 KE-.,3KJ &*etanercept*'	NQN	N?9 QR9 G@A &Npcdcppcb _eclr dmp _jj amlbgrgmlq cvacnr Nqmpg_qgq'9 OJ &6 TG?JQ ncp 06 b_wq'
CL@PCJ QS@ASR?LCMSQ QMJSRGML NPCDGJJCB QWPGLEC 03 KE-.,3KJ &*etanercept*'	NQN	N?9 QR9 G@A &Npcdcppcb _eclr dmp _jj amlbgrgmlq cvacnr Nqmpg_qgq'9 OJ &6 QWPGLECQ ncp 06 b_wq'

0.01 Nf_pk_aw Bpse Esgbc+?bt_lacb Amlrpmj Nj_l+?crl_Qrsbclr Fc_jrf

Rfc dmpksj_pwgq snb_rcb _llsjjwgl HsjwK

.5-./-0.01

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq _lb Jgkgrq
PGLTMO MP?J R?@JCR CVRCLBCB PCJC?QC 02 FMSP 23 KE &*upadacitinib*'	NQN	N?9G@A &Npcdcppcb _eclr dmp Sjacp_rgtc Amjgrgq'9 OJ &34 R?@JCRQ ncp 34 B?Wq'
QGJGO QS@ASR?LCMSQ QMJSRGML NPCDGJJCB QWPGLEC 0/. KE-/,3KJ &*brodalumab*'	LD	
QGKNMLG QS@ASR?LCMSQ QMJSRGML ?SRM+ GLHCARMP /.. KE-KJ*3. KE-.,3KJ &*golimumab*'	LD	
QGKNMLG QS@ASR?LCMSQ QMJSRGML NPCDGJJCB QWPGLEC /.. KE-KJ*3. KE-.,3KJ &*golimumab*'	LD	
QIWPGXG NCL QS@ASR?LCMSQ QMJSRGML ?SRM+ GLHCARMP /3. KE-KJ &*risankizumab-rzaa*'	NQN	N?9G@A &Npcdcppcb _eclr dmp Nqmpg_qgq _lb Nqmpg_rga ?prfpgrgq'9 OJ &/ QWPGLEC ncp 62 b_wq'
QIWPGXG QS@ASR?LCMSQ QMJSRGML A?PRPGBEC /6. KE-/,0KJ &*risankizumab-rzaa*'	NQN	N?9G@A &Npcdcppcb _eclr dmp Apmfl¦q Bgqc_qc'9 OJ &/ A?PRPGBEC ncp 34 B?Wq'
QIWPGXG QS@ASR?LCMSQ QMJSRGML A?PRPGBEC 14. KE-0,2KJ &*risankizumab-rzaa*'	NQN	N?9G@A &Npcdcppcb _eclr dmp Apmfl¦q Bgqc_qc'9 OJ &/ A?PRPGBEC ncp 34 b_wq'
QIWPGXG QS@ASR?LCMSQ QMJSRGML NPCDGJJCB QWPGLEC /3. KE-KJ &*risankizumab-rzaa*'	NQN	N?9G@A &Npcdcppcb _eclr dmp Nqmpg_qgq _lb Nqmpg_rga ?prfpgrgq'9 OJ &/ QWPGLEC ncp 62 b_wq'
QRCJ?P? QS@ASR?LCMSQ QMJSRGML 23 KE-.,3KJ &*ustekinumab*'	NQN	N?9G@A &Npcdcppcb _eclr dmp Apmfl¦q Bgqc_qc* Nqmpg_qgq* Nqmpg_rga ?prfpgrgq* Sjacp_rgtc Amjgrgq'9 OJ &/ QWPGLEC ncp 62 b_wq'
QRCJ?P? QS@ASR?LCMSQ QMJSRGML NPCDGJJCB QWPGLEC 23 KE-.,3KJ &*ustekinumab*'	NQN	N?9G@A &Npcdcppcb _eclr dmp Apmfl¦q Bgqc_qc* Nqmpg_qgq* Nqmpg_rga ?prfpgrgq* Sjacp_rgtc Amjgrgq'9 OJ &/ QWPGLEC ncp 62 b_wq'

0.01 Nf_pk_aw Bpse Esgbc+?bt_lacb Amlrpmj Nj_l+?crl_Qrsbclr Fc_jrf

Rfc dmpksj_pwgq snb_rcb _llsjjwgl HsjwK

Npcqapgnrgm l Bpse ls_kc u u s u ő

Npcqapgnrgm l Bpse L_kc		

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
VCJH?LX MP?J R?@JCR /. KE*3 KE &*tofacitinib citrate*'	NQN	N?9 QR9 G@A &Npcdcppcb _eclr dmp Pfcsk_rmgb ?prfpgrgq* Sjacp_rgtc Amjgrgq, Lmr amtcpcb dmp Nqmpg_rga ?prfpgrgq* ?liwjmqgle Qnmlbwjgrgq'9 OJ &4. R?@JCRQ ncp 1. b_wq'
VCJH?LX VP MP?J R?@JCR CVRCL BCB PCJC?QC 02 FMSP // KE*00 KE &*tofacitinib citrate*'	NQN	N?9 QR9 G@A &Npcdcppcb _eclr dmp Pfcsk_rmgb ?prfpgrgq* Sjacp_rgtc Amjgrgq, Lmr amtcpcb dmp Nqmpg_rga ?prfpgrgq* ?liwjmqgle Qnmlbwjgrgq'9 OJ &1. R?@JCRQ ncp 1. b_wq'
BGQC?QC+KMBGDWGLE ?LRG+PFCSK?RGA BPSEQ &BK?PBQ' + BPSEQ RM RPC?R PFCSK?RMGB ?PRFPGRGQ		
hydroxychloroquine sulfate oral tablet 200 mg	NE	
leflunomide oral tablet 10 mg, 20 mg	NE	
methotrexate oral tablet 2.5 mg	AC	L5 &NE'
MRPCVSN QS@ASR?LCMSQ QMJSRGML ?SRM+ GLHCARMP /. KE-.,2KJ* /0,3 KE-.,2KJ* /3 KE-.,2KJ* /5,3 KE-.,2KJ*0. KE-.,2KJ*00,3 KE-.,2KJ*03 KE-.,2KJ &*methotrexate (anti-rheumatic)*'	LD	
P?QSTM QS@ASR?LCMSQ QMJSRGML ?SRM+ GLHCARMP /. KE-.,0KJ* /0,3 KE-.,03KJ* /3 KE-.,1KJ* /5,3 KE-.,13KJ*0. KE-.,2KJ*00,3 KE-.,23KJ*03 KE-.,3KJ*1. KE-.,4KJ*5,3 KE-.,/3KJ &*methotrexate (anti-rheumatic)*'	NQN	N?9 OJ &2 KJ ncp 06 b_wq'
PCBGRPCV QS@ASR?LCMSQ QMJSRGML NPCDGJJCB QWPGLEC /. KE-.,2KJ* /0,3 KE-.,3KJ* /3 KE-.,4KJ* /5,3 KE-.,5KJ*0. KE-.,6KJ*00,3 KE-.,7KJ*03 KE-KJ*5,3 KE-.,1KJ &*methotrexate (anti-rheumatic)*'	LD	
FCPCBGR?PW?LEGMCBCK?		
@CPGLCPR GLRP?TCLMSQ IGR3.. SLGR &*c1 esterase inhibitor (human)*'	LD	
AGLPWXC GLRP?TCLMSQ QMJSRGML PCAMLQRGRSRCB 3.. SLGR &*c1 esterase inhibitor (human)*'	LD	

0.01 Nf_pk_aw Bpse Esgbc + ?bt_lacb Amlrpmj Nj_l + ?crl_Qrsbclr Fc_jrf

Rfc dmp k sj_pw gq snb_rcb _l ls_jjw gl HsjwK

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq _lb Jgkgrq
DGP?XWP QS@ASR?LCMSQ QMJSRGML NPCDGJJCB QWPGLEC 1. KE-1KJ &*icatibant acetate*'	LD	
F?CE?PB? QS@ASR?LCMSQ QMJSRGML PCAMLQRGRSRCB 0... SLGR* 1... SLGR &*c1 esterase inhibitor (human)*'	LNQN	N?9OJ &0. TG?JQ ncp 1. b_wq'
icatibant acetate subcutaneous solution prefilled syringe 30 mg/3ml	NQN	N?9OJ &23 QWPGLECQ ncp 7. b_wq'
I?J@GRMP QS@ASR?LCMSQ QMJSRGML /. KE-KJ &*ecallantide*'	LNQN	N?9OJ &1. KJ ncp 7. b_wq'
MPJ?BCWM MP?J A?NQSJC //. KE* /3. KE &*berotralstat hcl*'	NQN	N?9OJ &06 A?NQSJCQ ncp 06 b_wq'
PSAMLCQR GLRP?TCLMSQ QMJSRGML PCAMLQRGRSRCB 0/.. SLGR &*c1 esterase inhibitor (recomb)*'	NQN	N?9OJ &4. TG?JQ ncp 7. b_wq'
R?IFXWPM QS@ASR?LCMSQ QMJSRGML 1.. KE-0KJ &*lanadelumab-flyo*'	NQN	N?9OJ &0 KJ ncp 06 b_wq'
R?IFXWPM QS@ASR?LCMSQ QMJSRGML NPCDGJJCB QWPGLEC /3. KE-KJ* 1.. KE-0KJ &*lanadelumab-flyo*'	NQN	N?9OJ &0 QWPGLECQ ncp 06 B?Wq'
GKKSLMEJM@SJGL		
?QACLGT GLRP?TCLMSQ QMJSRGML 3EK-3.KJ &*immune globulin (human)-slra*'	LD	
@GTGE?K GLRP?TCLMSQ QMJSRGML /. EK-/..KJ* 3 EK-3.KJ &*immune globulin (human)*'	LNQN	N?
ASR?OSGE QS@ASR?LCMSQ QMJSRGML /EK-4KJ* /,43 EK-/.KJ* 0 EK-/0KJ* 1,1 EK-0.KJ* 2 EK-02KJ* 6 EK-26KJ &*immune globulin (human)-hipp*'	NQN	N?
ASTGRPS QS@ASR?LCMSQ QMJSRGML /EK-3KJ* /. EK-3.KJ* 0 EK-/.KJ* 2 EK-0.KJ* 6 EK-2.KJ &*immune globulin (human)*'	LD	
DJC@ME?KK? BGD GLRP?TCLMSQ QMJSRGML .,3 EK-/.KJ* /. EK-/..KJ* /. EK-0..KJ* 0,3 EK-3.KJ* 0. EK-0..KJ* 0. EK-2..KJ* 3 EK-/..KJ* 3 EK-3.KJ &*immune globulin (human)*'	LNQN	N?
E?KK?E?PB GLHCARGML QMJSRGML /EK-/.KJ* /. EK-/..KJ* 0,3 EK-03KJ* 0. EK-0..KJ* 1. EK-1..KJ* 3 EK-3.KJ &*immune globulin (human)*'	LNQN	N?

0.01 Nf_pk_aw Bpse Esgbc+?bt_lacb Amlrpmj Nj_l+?crl_Qrsbclr Fc_jrf

Rfc dmpksj_pwgq snb_rcb _llsjjwgl HsjwK

.5-./-0.01

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
E?KK?E?PB Q-B JCQQGE?GLRP?TCLMSQ QMJSRGML PCAMLQRGRSRCB /. EK*3EK &*immune globulin (human)*'	LNQN	N?
E?KK?ICB GLHCARGML QMJSRGML /EK-/.KJ*/. EK-/..KJ*0. EK-0..KJ*3EK-3.KJ &*immune globulin (human)*'	LNQN	N?
E?KK?NJCV GLRP?TCLMSQ QMJSRGML /. EK-/..KJ*/. EK-0..KJ*0. EK-0..KJ*0. EK-2..KJ*3EK-/..KJ*3EK-3.KJ &*immune globulin (human)*'	LNQN	N?
E?KSLCV+A GLHCARGML QMJSRGML /EK-/.KJ*/. EK-/..KJ*0,3EK-03KJ*0. EK-0..KJ*2. EK-2..KJ*3EK-3.KJ &*immune globulin (human)*'	LNQN	N?
FGXCLRP? QS@ASR?LCMSQ QMJSRGML /EK-3KJ*/. EK-3.KJ*0EK-/.KJ*2EK-0.KJ &*immune globulin (human)*'	LNQN	N?
FGXCLRP? QS@ASR?LCMSQ QMJSRGML NPCDGJJCB QWPGLEC /EK-3KJ*0EK-/.KJ*2EK-0.KJ &*immune globulin (human)*'	LNQN	N?
FWNCPPFM Q-B GLRP?KSQASJ?P QMJSRGML NPCDGJJCB QWPGLEC /3.. SLGR*03. SLGR &*rho d immune globulin*'	LNQN	
FWNCPRCR GLRP?KSQASJ?P QMJSRGML NPCDGJJCB QWPGLEC 03. SLGR-KJ &*tetanus immune globulin*'	LNQN	
FWOTG? QS@ASR?LCMSQ IGR /. EK-/..KJ*0,3 EK-03KJ*0. EK-0..KJ*1. EK-1..KJ*3EK-3.KJ &*immune globulin-hyaluronidase*'	LD	
GKME?K P?@GCQ+FR GLHCARGML QMJSRGML 1.. SLGR-0KJ &*rabies immune globulin*'	LNQN	
kedrab injection solution 1500 unit/10ml, 300 unit/2ml	LNQN	
KGAPFME?K SJRP?+DGJRCPCB NJSQ GLRP?KSQASJ?P QMJSRGML NPCDGJJCB QWPGLEC 03. SLGR &*rho d immune globulin*'	LNQN	
MAR?E?K GLRP?TCLMSQ QMJSRGML /EK-0.KJ*/. EK-/..KJ*/. EK-0..KJ*0EK-0.KJ*0,3EK-3.KJ*0. EK-0..KJ*1. EK-1..KJ*3EK-/..KJ*3EK-3.KJ &*immune globulin (human)*'	LNQN	N?

0.01 Nf_pk_aw Bpse Esgbc+?bt_lacb Amlrpmj Nj_l+?crl_Qrsbclr Fc_jrf

Rfc dmpksj_pwgq snb_rcb _llsjjwgl HsjwK

.5-./-0.01
/6.

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
N?LXWE?GLRP?TCLMSQQMJSRGML / EK-/.KJ*/. EK-/..KJ*0,3EK-03KJ*0. EK-0..KJ*1. EK-1..KJ* 3EK-3.KJ &*immune globulin (human)-ifas*'	LD	
NPGTGECL GLRP?TCLMSQQMJSRGML /. EK-/..KJ* 0. EK-0..KJ*2. EK-2..KJ*3EK-3.KJ &*immune globulin (human)*'	LNQN	N?
PFME?K SJRP?+DGJRCPCB NJSQ GLRP?KSQASJ?P QMJSRGML NPCDGJJCB QWPGLEC /3.. SLGR &*rho d immune globulin*'	LNQN	
PFMNFWJ?AGLHCARGML QMJSRGML NPCDGJJCB QWPGLEC /3.. SLGR-0KJ &*rho d immune globulin*'	LNQN	
T?PGXGE GLRP?KSQASJ?P QMJSRGML /03 SLGR-/,0KJ &*varicella-zoster immune glob*'	LNQN	
UGLPFMQBDGLHCARGML QMJSRGML /3.. SLGR-/,1KJ*/3... SLGR-/1KJ*03.. SLGR-0,0KJ*3... SLGR-2,2KJ &*rho d immune globulin*'	LNQN	
VCK@GDWQS@ASR?LCMSQQMJSRGML / EK-3KJ*/. EK-3.KJ*0EK-/.KJ*2EK-0.KJ &*immune globulin (human)-klhw*'	LD	
SLGĪ .		

k ?ȳ†

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
DMJGT?LC+M@ MP?J A?NQSJC 63+/ KE &*prenat w/o a vit-fefum-fepo-fa*'	LD	
GL?R?J ER MP?J R?@JCR &*prenatal vit-dss-fe cbn-fa*'	NE	
jenliva prenatal/postnatal oral capsule 1 mg	LD	
kosher prenatal plus iron oral tablet 30-1 mg	LD	
multi-mac oral tablet 15-0.75-1 mg	LD	
L?R?AFCU MP?J R?@JCR AFCU?@JC 06+/ KE &*prenatal vit-fe fum-fe bisg-fa*'	LD	
natal pnv oral tablet 6-0.5 mg	LD	
L?R?JTGR MP?J R?@JCR &*prenatal vit-fe fumarate-fa*'	LD	
LCCTM BF? MP?J A?NQSJC 05+/,/1 KE &*prenat w/oa-fefum-methf-omegas*'	LD	
neonatal + dha oral 29-1 & 200 mg	LD	
neonatal 19 oral tablet 1 mg	LD	
neonatal fe oral tablet 90-1 mg	LD	
LCQR?@Q BF? MP?J 10+/ KE &*prenat-w/oa-fe bisgly-fa-omega*'	LD	
LCQR?@Q MLC MP?J A?NQSJC 16+/+003 KE &*prenat-fe-methylfol-dha w/o a*'	LD	
LCQR?@Q MP?J R?@JCR 10+/ KE &*prenat-fe bisgly-fa-w/o vit a*' M@QRCR l' X p`A ' ЂƵON ɑ ˬ ş	LD	
M@ AMKNJCRC MLC MP?J A?NQSJC 3.+/+254 KE &*prenat-fecbn-feaspgl-fa-fish*'	LD	
M@ AMKNJCRC MP?J R?@JCR 3.+/,03 KE &*prenatal vit-iron carbonyl-fa*'	LD	
M@ AMKNJCRC NCRGRC MP?J A?NQSJC 13+3+/+0.. KE &*prenat-fecbn-feaspgl-fa-omega*'	LD	
M@ AMKNJCRC NPCKGCP MP?J R?@JCR 1.+0.+/ KE &*prenatal-fe cbn-fe asp gly-fa*'	LD	
M@ AMKNJCRC-BF? MP?J A?NQSJC 1.+/.+/+0.. KE &*prenat-fecbn-feaspgl-fa-omega*'	LD	

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
pnv prenatal plus multivit+dha oral 27-1 & 312 mg	LD	
pnv tabs 20-1 oral tablet 20-1 mg	LD	
pnv-dha oral capsule 27-0.6-0.4-300 mg	NE	
pnv-dha+docusate oral capsule 27-1.25-300 mg	LD	
pnv-omega oral capsule 28-0.6-0.4-340 mg	LD	
pregen dha oral capsule 28-1-35 mg	LD	
pregenna oral tablet 20-1 mg	LD	
prena 1 true oral 30-1.4 & 300 mg	LD	
prenaissance oral capsule 29-1.25-325 mg	LD	
prenaissance plus oral capsule 28-1-250 mg	LD	
NPCL?R?J+S MP?J A?NQSJC /.4,3+/ KE &*prenatal w/o a vit-fe fum-fa*'	LD	
NPCL?RC?K MP?J R?@JCR / KE &*prenatal ca-b6-b12-fa-ginger*'	LD	
NPCL?RC BF? MP?J A?NQSJC /6+.,4+.,2+1.. KE &*prenat-feasp-meth-fa-dha w/o a*'	LD	
NPCL?RC CJGRC MP?J R?@JCR 0.+.,4+.,2 KE &*prenatal-feaspgly-methylfol-fa*'	LD	
NPCL?RC CLF?LAC MP?J A?NQSJC 06+.,4+.,2+2.. KE &*prenat w/o a-fe-methfol-fa-dha*'	LD	
NPCL?RC KGLG MP?J A?NQSJC /6+.,4+.,2+13. KE &*prenat-fecbn-feasp-meth-fa-dha*'	LD	
NPCL?RC MP?J R?@JCR AFCU?@JC .,4+.,2 KE &*prenat mv-min-methylfolate-fa*'	LD	
NPCL?RC NGVGC MP?J A?NQSJC /.+.,4+.,2+0.. KE &*prenat-feasp-meth-fa-dha w/o a*'	LD	
NPCL?RC JPCQRMPC MP?J A?NQSJC 05+.,4+.,2+2.. KE &*prenat w/o a-fe-methfol-fa-dha*'	LD	
prenatvite plus oral tablet 1 mg	LD	
NPGK?A?PC MP?J A?NQSJC 1.+/+25. KE &		

Npcqapgnrgm l Bpse L_kc	Bpse Rgcp	

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
zalvit oral tablet 13-1 mg	LD	
TGR?KGLQ+TGR?KGLQ?LB QSNNJCKCLRQ		
?AAPSDCP MP?J A?NQSJC 1. KE &*ferric maltol*'	LD	
?QAMP GLRP?TCLMSQ QMJSRGML 03... KE-3. KJ &*ascorbic acid*'	LD	
calcitriol oral capsule 0.25 mcg, 0.5 mcg	NE	
calcitriol oral solution 1 mcg/ml	NE	
cyanocobalamin injection solution 1000 mcg/ml	NE	
b complex-c-folic acid &Bcvgdmj Mp_j R_`jcr 3 Ke'	LD	
doxercalciferol oral capsule 0.5 mcg, 1 mcg, 2.5 mcg	NE	L6 &Jgqrgle bmcq lmr glajsbc acpr_gl LBAq'
D?+6 MP?J A?NQSJC .,6 KE &*folic acid*'	AC	L5 &Lmr Amtcpcb'9 OJ &/.. A?NQSJCQ ncp 1. b_wq'9 ?J &K_v 33 Wc_pq'
DCPPM+NJCV MP?J R?@JCR //3+/ KE &*fe fum-fa-c-e-b12-intrins fact*'	LD	
DJMPGT? MP?J JGOSGB .,03+2.. KE+SLGR-KJ &*sodium fluoride-vitamin d*'	LD	
DJMPGT? MP?J R?@JCR AFCU?@JC .,03 KE* .,3 KE* / KE &*ped multiple vit-minerals-fl*'	LD	
folbee plus oral tablet	NE	
DMJE?PB MQ MP?J R?@JCR 3..+/,/ KE &*multiple vit-min-calcium-fa*'	LD	
folic acid oral tablet 400 mcg	AC	L5 &Lmr Amtcpcb'9 OJ &/.. r_`jcrq ncp 1. b_wq'9 ?J &K_v 33 Wc_pq'
folic acid oral tablet 800 mcg	AC	L5 &Lmr Amtcpcb'9 OJ &/.. R?@JCRQ ncp 1. B?Wq'9 ?J &K_v 33 Wc_pq'
na ferric gluc cplx in sucrose intravenous solution 12.5 mg/ml	NE	
LCNFNJCV PV MP?J R?@JCR &*b complex-c-zn-folic acid*'	LD	
LGAMKGBC MP?J R?@JCR 53.+05+0+.,3 KE &*niacinamide-zn-cu-methfo-se-cr*'	LD	
nicotinamide oral tablet 750-27-2-0.5 mg	LD	
paricalcitol oral capsule 1 mcg, 2 mcg, 4 mcg	NE	

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
QGK@PGLX? MNFRF?JKGA QSQNCLQGML /+.1 os _k	Ń e L_^	= l’ e ľ

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
NPCB DMPRC MNFRF?JKGA QSQNCLQGML / # &*prednisolone acetate*'	LD	
NPCB KGJB MNFRF?JKGA QSQNCLQGML .,/0 # &*prednisolone acetate*'	LD	
prednisolone acetate ophthalmic suspension 1 %	NE	
NPMJCLQ? MNFRF?JKGA QMJSRGML .,.5 # &*bromfenac sodium*'	LD	
BPW CWC BGQC?QC		
ACOS? MNFRF?JKGA QMJSRGML .,.7 # &*cyclosporine*'	LD	
cyclosporine ophthalmic emulsion 0.05 %	LD	
PCQR?QGQ KSJRGBMQC MNFRF?JKGA CKSJQGML .,.3 # &*cyclosporine*'	N@	
PCQR?QGQ MNFRF?JKGA CKSJQGML .,.3 # &*cyclosporine*'	N@	
VGGBP? MNFRF?JKGA QMJSRGML 3 # &*lifitegrast*'	N@	
KGQACJJ?LCMSQ		
atropine sulfate ophthalmic solution 1 %	NE	
AWQR?BPMNQ MNFRF?JKGA QMJSRGML .,15 # &*cysteamine hcl*'	LD	
AWQR?P?L MNFRF?JKGA QMJSRGML .,22 # &*cysteamine hcl*'	LNQN	N?9OJ &2 @MRRJCQ ncp 06 b_wq'
J?APGQCPR MNFRF?JKGA GLQCPR 3 KE &*artificial tear insert*'	LD	
MVCPT?RC MNFRF?JKGA QMJSRGML .,..0 # &*cenegermin-bkbj*'	LNQN	N?9OJ &0 KJ ncp 5 B?Wq'
tropicamide ophthalmic solution 0.5 %, 1 %	NE	
RWPT?W? L?Q?J QMJSRGML .,.1 KE-?AR &*varenicline tartrate*'	LD	
SNLCCO MNFRF?JKGA QMJSRGML .,/ # &*oxymetazoline hcl*'	LD	
TCP I ?XG? MNFRF?JKGA CKSJQGML .,/ # &*cyclosporine*'	LD	
TGQSBWLC GLRP?TCLMSQ QMJSRGML PCAMLQRGRSRCB /3 KE &*verteporfin*'	LNQN	N?

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
PCRGL?J BGQMPBCPQ		
@WMMTGX GLRP?TGRPC?J QMJSRGML .,3 KE-.,.3KJ &*ranibizumab-nuna*'	LD	
AGKCPJG GLRP?TGRPC?J QMJSRGML .,1 KE-.,.3KJ* .,3 KE-.,.3KJ &*ranibizumab-eqrn*'	LD	
CWJC? GLRP?TGRPC?J QMJSRGML 0 KE-.,.3KJ &*aflibercept*'	NQN	N?
CWJC? GLRP?TGRPC?J QMJSRGML NPCDGJJCB QWPGLEC 0 KE-.,.3KJ &*aflibercept*'	NQN	N?
JSACLRGQ GLRP?TGRPC?J QMJSRGML .,1 KE-.,.3KJ &*ranibizumab*'	NQN	N?
JSACLRGQ GLRP?TGRPC?J QMJSRGML NPCDGJJCB QWPGLEC .,1 KE-.,.3KJ* .,3 KE-.,.3KJ &*ranibizumab*'	NQN	N?
MRFCP		
GPPGE?RGML QMJSRGMLQ		
sterile water for irrigation irrigation solution	LN	QRV
PCQNGP?RMPW+ BPSEQ RM RPC?R @PC?RFGLE BGQMPBCPQ		
?JNF?+/ ?LRGRPWNQGL BCDGAGCLAW ?ECLRQ+ BPSEQ DMP PCNJ?ACKCLR* KMBGDGA?RGML* RPC?RKCLR		
?P?J?QR LN GLRP?TCLMSQ QMJSRGML PCAMLQRGRSRCB /... KE*3.. KE &*alpha1-proteinase inhibitor*'	LD	
EJ?QQG? GLRP?TCLMSQ QMJSRGML /... KE-3.KJ &*alpha1-proteinase inhibitor*'	LD	
NPMJ?QRGL+A GLRP?TCLMSQ QMJSRGML /... KE-0.KJ &*alpha1-proteinase inhibitor*'	NQN	N?
NPMJ?QRGL+A GLRP?TCLMSQ QMJSRGML PCAMLQRGRSRCB /... KE &*alpha1-proteinase inhibitor*'	NQN	N?
XCK?GP? GLRP?TCLMSQ QMJSRGML PCAMLQRGRSRCB /... KE &*alpha1-proteinase inhibitor*'	NQN	N?
?L?NFWJ?VGQ RPC?RKCLR?ECLRQ		
?STG+O GLHCARGML QMJSRGML ?SRM+GLHCARMP .,/ KE-.,/KJ* .,/3 KE-.,/3KJ* .,1 KE-.,1KJ &*epinephrine*'	N@	OJ &2 GLHCARGMLQ ncp 03 b_wq'

0.01 Nf_pk_aw Bpse Esgbc+?bt_lacb Amlrpmj Nj_l+?crl_Qrsbclr Fc_jrf

Rfc dmpksj_pwgq snb_rcb _llsjjwgl HsjwK

.5-./-0.01

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
epinephrine injection solution auto-injector 0.15 mg/0.15ml	NE	OJ &2 GLHCARGMLQ ncp 03 B?Wq'
epinephrine injection solution auto-injector 0.15 mg/0.3ml, 0.3 mg/0.3ml	NE	OJ &2 QMJSRGML ?SRM+ GLHCARMP ncp 03 b_wq'
CNGLCNFPGLCQL?N+T GLHCARGML IGR/ KE-KJ &*epinephrine*'	LD	
CNGNCL 0+N?I GLHCARGML QMJSRGML ?SRM+ GLHCARMP .,1 KE-.,1KJ &*epinephrine*'	N@	OJ &2 GLHCARGMLQ ncp 03 B?Wq'
CNGNCL HP 0+N?I GLHCARGML QMJSRGML ?SRM+ GLHCARMP .,/3 KE-.,1KJ &*epinephrine*'	N@	OJ &2 GLHCARGMLQ ncp 03 B?Wq'
QWKHCNG GLHCARGML QMJSRGML NPCDGJJCB QWPGLEC .,/3 KE-.,1KJ* .,1 KE-.,1KJ &*epinephrine*'	LD	
?LRGAFMJGLCPEGA-@CR? ?EMLGQR AMK@GL?RGMLQ+ BPSEQRM RPC?R AMNB		
?GPBSM PCQNGAJGAI //1-/2 GLF?J?RGML ?CPMQMJ NMUBCP @PC?RF ?ARGT?RCB //1+/2 KAE-?AR &*fluticasone-salmeterol*'	LD	
?GPBSM PCQNGAJGAI 010-/2 GLF?J?RGML ?CPMQMJ NMUBCP @PC?RF ?ARGT?RCB 010+/2 KAE-?AR &*fluticasone-salmeterol*'	LD	
?GPBSM PCQNGAJGAI 33-/2 GLF?J?RGML ?CPMQMJ NMUBCP @PC?RF ?ARGT?RCB 33+/2 KAE-?AR &*fluticasone-salmeterol*'	LD	
?LMPM CJJGNR? GLF?J?RGML ?CPMQMJ NMUBCP @PC?RF ?ARGT?RCB 40,3+03 KAE-?AR &*umeclidinium-vilanterol*'	N@	OJ &/ n_ai_ec ncp 03 b_wq'
@CTCQNG ?CPMQNFCPC GLF?J?RGML ?CPMQMJ 7+2,6 KAE-?AR &*glycopyrrolate-formoterol*'	LD	
@PCXRPG ?CPMQNFCPC GLF?J?RGML ?CPMQMJ /4.+ 7+2,6 KAE-?AR &*budeson-glycopyrrol-formoterol*'	N@	OJ &/ N?AI?EC ncp 03 b_wq'
AMK@GTCLR PCQNGK?RGLF?J?RGML ?CPMQMJ QMJSRGML 0.+/.. KAE-?AR &*ipratropium-albuterol*'	LN	OJ &0 N?AI?ECQ ncp 03 b_wq'
fluticasone-salmeterol inhalation aerosol powder breath activated 113-14 mcg/act, 232-14 mcg/act, 55-14 mcg/act	LD	
/a t l' l' ð ¼5 w S (0 @ 0 0w N @ 0 *ipratropium-albuterol inhalation solution* l'ŞŞÓl'	Ð • e 0S ð Ð P P P Ñ/B à P P 0	

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq _lb Jgkgrq
QRGMJRM PCQNGK?RGLF?J?RGML ?CPMQMJ QMJSRGML 0,3+0,3 KAE-?AR &*tiotropium bromide-olodaterol*'	N@	OJ &/ N?AI?EC ncp 03 b_wq'
?LRGAFMJGLCPEGA-@CR? ?EMLGQR-QRCPMGB AMK@GL?RGMLQ+BPSEQRMRPC?R ?QRFK? ?LB AMNB		
RPCJCEWCJJGNR? GLF?J?RGML ?CPMQMJ NMUBCP @PC?RF ?ARGT?RCB /..+40,3+03 KAE-?AR* 0..+40,3+03 KAE-?AR &*fluticasone-umeclidin-vilant*'	N@	OJ &/ n_ai_ec ncp 03 b_wq'
?LRGAFMJGLCPEGAQ		
?RPMTCLR FD? GLF?J?RGML ?CPMQMJ QMJSRGML /5 KAE-?AR &*ipratropium bromide hfa*'	LD	
GLAPSQC CJJGNR? GLF?J?RGML ?CPMQMJ NMUBCP @PC?RF ?ARGT?RCB 40,3 KAE-?AR &*umeclidinium bromide*'	LD	
ipratropium bromide inhalation solution 0.02 %	NE	OJ &3 KJ ncp 03 b_wq'
ipratropium bromide nasal solution 0.03 %, 0.06 %	NE	
JMLF?J? K?EL?GP PCDGJJ IGRGLF?J?RGML QMJSRGML 03 KAE-KJ &*glycopyrrolate*'	LD	
JMLF?J? K?EL?GP QR?PRCP IGRGLF?J?RGML QMJSRGML 03 KAE-KJ &*glycopyrrolate*'	LD	
QNGPGT? F?LBGF?JCP GLF?J?RGML A?NQSJC /6 KAE &*tiotropium bromide monohydrate*'	N@	OJ &/ N?AI?EC ncp 03 B?Wq'
QNGPGT? PCQNGK?RGLF?J?RGML ?CPMQMJ QMJSRGML /,03 KAE-?AR &*tiotropium bromide monohydrate*'	N@	OJ &/ N?AI?EC ncp 03 B?Wq'
QNGPGT? PCQNGK?RGLF?J?RGML ?CPMQMJ QMJSRGML 0,3 KAE-?AR &*tiotropium bromide monohydrate*'	N@	OJ &/ N?AI?EC ncp 03 b_wq'
RSBMPX? NPCQQ?GP GLF?J?RGML ?CPMQMJ NMUBCP @PC?RF ?ARGT?RCB 2.. KAE-?AR &*aclidinium bromide*'	LD	
WSNCJPG GLF?J?RGML QMJSRGML /53 KAE-1KJ &*revefenacin*'	N@	OJ &1. KJ ncp 03 b_wq'
?LRGFGQR?KGLC AMK@GL?RGMLQ		
azelastine-fluticasone nasal suspension 137-50 mcg/act	NE	OJ &/ EK ncp 03 B?Wq'

0.01 Nf_pk_aw Bpse Esgbc+?bt_lacb Amlrpmj Nj_l+?crl_Qrsbclr Fc_jrf

Rfc dmpksj_pwgq snb_rcb _llsjjwgl HsjwK

.5-./-0.01

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
desloratadine oral tablet dispersible 2.5 mg, 5 mg	LN	
eq loratadine childrens oral tablet chewable 5 mg	NE	Qcjcar MRA
fexofenadine hcl oral tablet 180 mg	NE	Qcjcar MRA
hydroxyzine hcl oral syrup 10 mg/5ml	NE	
hydroxyzine hcl oral tablet 10 mg, 25 mg, 50 mg	NE	L6 &Jgqrgle bmcq lmrglajsbc acpr_gl LBAq'
hydroxyzine pamoate oral capsule 100 mg, 25 mg, 50 mg	NE	
I?P@GL?J CP MP?J QSQNCLQGML CVRCLBCB PCJC?QC 2 KE-3KJ &*carbinoxamine maleate*'	LN	QR
kp fexofenadine hcl oral tablet 60 mg	NE	Qcjcar MRA
levocetirizine dihydrochloride oral tablet 5 mg	NE	Qcjcar MRA
loratadine oral capsule 10 mg	NE	Qcjcar MRA
loratadine oral tablet 10 mg	NE	Qcjcar MRA
olopatadine hcl nasal solution 0.6 %	LN	OJ &/ @MRRJC ncp 03 b_wq'
N?R?L?QC L?Q?J QMJSRGML .,4 # &*olopatadine hcl*'	LN	OJ &/ @MRRJC ncp 03 b_wq'
PWAJMP? MP?J QMJSRGML 0 KE-3KJ &*dexchlorpheniramine maleate*'	LD	
PWTCLR MP?J R?@JCR 4 KE &*carbinoxamine maleate*'	LD	
sm loratadine allergy relief oral tablet dispersible 10 mg	NE	Qcjcar MRA
sm loratadine oral solution 5 mg/5ml	NE	Qcjcar MRA
VWX?J ?JJCPEW 02FP MP?J R?@JCR 3 KE &*levocetirizine dihydrochloride*'	NE	Qcjcar MRA
XWPRCA ?JJCPEW MP?J A?NQSJC /. KE &*cetirizine hcl*'	NE	Qcjcar MRA
XWPRCA ?JJCPEW MP?J R?@JCR /. KE &*cetirizine hcl*'	NE	Qcjcar MRA
XWPRCA AFGJBPCLQ ?JJCPEW MP?J QMJSRGML / KE-KJ &*cetirizine hcl*'	NE	Qcjcar MRA
XWPRCA AFGJBPCLQ ?JJCPEW MP?J R?@JCR AFCU?@JC 0,3 KE &*cetirizine hcl*'	NE	JEA9 Qcjcar MRA

0.01 Nf_pk_aw Bpse Esgbc+?bt_lacb Amlrpmj Nj_l+?crl_Qrsbclr Fc_jrf

Rfc dmpksj_pwgq snb_rcb _llsjjwgl HsjwK

.5-./-0.01

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
@CR? ?EMLGQRQ+BPSEQRMRPC?R ?QRFK? ?LB AMNB		
albuterol sulfate hfa inhalation aerosol solution 108 (90 base) mcg/act	NE	L6 &Jgqrgle bmcq lmrglajsbc acpr_gl LBAq'9OJ &0 EK ncp 03 B?Wq'
albuterol sulfate inhalation nebulization solution (2.5 mg/3ml) 0.083%, 0.63 mg/3ml	NE	OJ &3 @MVCQ ncp 03 B?Wq'
albuterol sulfate inhalation nebulization solution 1.25 mg/3ml	NE	OJ &3 @MVCQ ncp 03 b_wq'
albuterol sulfate inhalation nebulization solution 2.5 mg/0.5ml	NE	OJ &4. KJ ncp 03 b_wq'
albuterol sulfate oral syrup 2 mg/5ml	NE	
albuterol sulfate oral tablet 2 mg, 4 mg	NE	
arformoterol tartrate inhalation nebulization solution 15 mcg/2ml	LD	
@PMT?L?GLF?J?RGML LC@SJGX?RGML QMJSRGML /3 KAE-0KJ &*arformoterol tartrate*'	LD	
formoterol fumarate inhalation nebulization solution 20 mcg/2ml	NE	OJ &0 @MVCQ ncp 03 B?Wq'
levalbuterol hcl inhalation nebulization solution 0.31 mg/3ml, 0.63 mg/3ml, 1.25 mg/3ml	NE	OJ &1.. KJ ncp 03 b_wq'
levalbuterol hcl inhalation nebulization solution 1.25 mg/0.5ml	NE	OJ &23 LC@SJGX?RGML QMJSRGML ncp 03 b_wq'
levalbuterol tartrate inhalation aerosol 45 mcg/act	LN	OJ &0 GLF?JCPQ ncp 03 B?Wq'
NCPDMPMKGQRGLF?J?RGML LC@SJGX?RGML QMJSRGML 0. KAE-0KJ &*formoterol fumarate*'	LN	OJ &4. TG?JQ ncp 03 b_wq'
NPM?GP BGEGF?JCP GLF?J?RGML ?CPMQMJ NMUBCP @PC?RF ?ARGT?RCB /.6&7. @?QC' KAE-?AR &*albuterol sulfate (sensor)*'	LD	
NPM?GP PCQNGAJGAI GLF?J?RGML ?CPMQMJ NMUBCP @PC?RF ?ARGT?RCB /.6&7. @?QC' KAE-?AR &*albuterol sulfate*'	LD	
NPMTCLRGJ FD? GLF?J?RGML ?CPMQMJ QMJSRGML /.6&7. @?QC' KAE-?AR &*albuterol sulfate*'	LD	
QCPCTCLR BGQISQGLF?J?RGML ?CPMQMJ NMUBCP @PC?RF ?ARGT?RCB 3. KAE-?AR &*salmeterol xinafoate*'	LD	

0.01 Nf_pk_aw Bpse Esgbc+?bt_lacb Amlrpmj Nj_l+?crl_Qrsbclr Fc_jrf

Rfc dmpksj_pwgq snb_rcb _llsjjwgl HsjwK

.5-./-0.01
0..

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
MP I ? K @G MP ? J R ? @JCR / . . +/03 K E* 0 . . +/03 K E &*lumacaftor-ivacaftor*'	L NQN	N ?9 OJ &/ / 0 R ? @JCRQ ncp 06 b_wq'
NSJ K MXW K C GL F ? J ? RGML QMJSRGML 0,3 K E-0,3 K J &*dornase alfa*'	L NQN	N ?9 OJ &/ 3 . K J ncp 1 . B_wq'
QW K BC I M MP ? J R ? @JCR RFCP ? NW N ? A I / . . +/3 . $ /3 . K E* 3 . +53 $ 53 K E &*tezacaftor-ivacaftor*'	L NQN	N ?9 OJ &34 R ? @JCRQ ncp 06 b_wq'
RM@G GL F ? J ? RGML LC@SJGX ? RGML QMJSRGML 1 . . K E-3 K J &*tobramycin*'	L D	
RM@G NMB F ? JCP GL F ? J ? RGML A ? NQSJC 06 K E &*tobramycin*'	L D	
tobramycin inhalation nebulization solution 300 mg/4ml	NQN	N ?9 OJ &002 K J ncp 06 B ? Wq'
tobramycin inhalation nebulization solution 300 mg/5ml	NQN	N ?9 OJ &06 . K J ncp 06 b_wq'
RPG I ? DR ? MP ? J R ? @JCR RFCP ? NW N ? A I / . . +3 . +53 $ / 3 . K E* 3 . +03+15,3 $ 53 K E &*elexacaftor-tezacaftor-ivacaft*'	L NQN	N ?9 OJ &62 R ? @JCRQ ncp 06 b_wq'
RPG I ? DR ? MP ? J RFCP ? NW N ? A I / . . +3 . +53 $ 53 K E* 6 . +2 . +4 . $ 37,3 K E &*elexacaftor-tezacaftor-ivacaft*'	L NQN	N ?
JCS I MRPGCLC K MBGDGCPQ		
zileuton er oral tablet extended release 12 hour 600 mg	L D	L / . &LN'
XWDJM MP ? J R ? @JCR 4 . . K E &*zileuton*'	L D	
JCS I MRPGCLC PCACNRMP ? LR ? EML GQRQ + BPSEQ RM RPC ? R ? QRF K ? ? L B ? JJCPEGCQ		
montelukast sodium oral packet 4 mg	NE	
montelukast sodium oral tablet 10 mg	NE	
montelukast sodium oral tablet chewable 4 mg, 5 mg	NE	
QGL E SJ ? GP MP ? J N ? A I CR 2 K E &*montelukast sodium*'	L D	
QGL E SJ ? GP MP ? J R ? @JCR / . K E &*montelukast sodium*'	L D	
QGL E SJ ? GP MP ? J R ? @JCR AFCU ? @JC 2 K E* 3 K E &*montelukast sodium*'	L D	
zafirlukast oral tablet 10 mg, 20 mg	NE	
K ? QR ACJJ QR ? @GJGXCPQ + BPSEQ RM RPC ? R ? JJCPEGCQ		
cromolyn sodium inhalation nebulization solution 20 mg/2ml	NE	OJ &0 @MVCQ ncp 03 B ? Wq'

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
KGQACJJ?LCMSQ		
acetylcysteine inhalation solution 10 %, 20 %	NE	
B?JGPCQN MP?J R?@JCR 03. KAE*3.. KAE *&roflumilast'*	LD	
roflumilast oral tablet 250 mcg, 500 mcg	NE	
sodium chloride inhalation nebulization solution 10 %, 3 %	NE	
L?Q?J QRCPMGBQ+BPSEQ RM RPC?R ?JJCPEGCQ		
@CAML?QC ?O L?Q?J QSQNCLQGML 20 KAE-QNP?W *&beclomethasone diprop monohyd'*	LD	
budesonide nasal suspension 32 mcg/act	NE&	
GE-QNQC??JO CPEGC ĺ ĺ ĺ NE *32mcg, ct*	T í wr& *100 ig/a*	
.*""4"0/*"4"- 4641&/4*0/ N(41 " *be, ŭ ¢t*		/ '

/ '
NE

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
?PKML?GP BGEGF?JCP GLF?J?RGML ?CPMQMJ NMUBCP @PC?RF ?ARGT?RCB //1 KAE-?AR*010 KAE-?AR*33 KAE-?AR &*fluticasone propionate(sensor)*'	LD	
?PLSGRW CJJGNR? GLF?J?RGML ?CPMQMJ NMUBCP @PC?RF ?ARGT?RCB /.. KAE-?AR*0.. KAE-?AR*3. KAE-?AR &*fluticasone furoate*'	LD	
?QK?LCV &/0. KCRCPCB BMQCQ' GLF?J?RGML ?CPMQMJ NMUBCP @PC?RF ?ARGT?RCB 00. KAE-?AR &*mometasone furoate*'	LD	
?QK?LCV &1. KCRCPCB BMQCQ' GLF?J?RGML ?CPMQMJ NMUBCP @PC?RF ?ARGT?RCB //. KAE-?AR*00. KAE-?AR &*mometasone furoate*'	LD	
?QK?LCV &4. KCRCPCB BMQCQ' GLF?J?RGML ?CPMQMJ NMUBCP @PC?RF ?ARGT?RCB 00. KAE-?AR &*mometasone furoate*'	LD	
?QK?LCV FD? GLF?J?RGML ?CPMQMJ /.. KAE-?AR*0.. KAE-?AR*3. KAE-?AR &*mometasone furoate*'	LD	
budesonide inhalation suspension 0.25 mg/2ml	NE	OJ &1 KJ ncp 03 b_wq'
budesonide inhalation suspension 0.5 mg/2ml	NE	OJ &0 KJ ncp 03 b_wq'
budesonide inhalation suspension 1 mg/2ml	NE	OJ &/ KJ ncp 03 b_wq'
DJMTCLR BGQISQ GLF?J?RGML ?CPMQMJ NMUBCP @PC?RF ?ARGT?RCB /.. KAE-?AR*03. KAE-?AR*3. KAE-?AR &*fluticasone propionate (inhal)*'	LD	
DJMTCLR FD? GLF?J?RGML ?CPMQMJ //. KAE-?AR*00. KAE-?AR*22 KAE-?AR &*fluticasone propionate hfa*'	LD	
fluticasone propionate hfa inhalation aerosol 110 mcg/act, 220 mcg/act, 44 mcg/act	LD	
NSJKGAMPR DJCVF?JCP GLF?J?RGML ?CPMQMJ NMUBCP @PC?RF ?ARGT?RCB /6. KAE-?AR &*budesonide*'	N@	OJ &0 ?CPMQMJ NMUBCP @PC?RF ?ARGT?RCB ncp 03 b_wq'
NSJKGAMPR DJCVF?JCP GLF?J?RGML ?CPMQMJ NMUBCP @PC?RF ?ARGT?RCB 7. KAE-?AR &*budesonide*'	N@	OJ &1 ?CPMQMJ NMUBCP @PC?RF ?ARGT?RCB ncp 03 b_wq'
NSJKGAMPR GLF?J?RGML QSQNCLQGML .,03 KE-0KJ*.,3 KE-0KJ*/ KE-0KJ &*budesonide*'	LD	

0.01 Nf_pk_aw Bpse Esgbc+?bt_lacb Amlrpmj Nj_l+?crl_Qrsbclr Fc_jrf

Rfc dmpksj_pwgq snb_rcb _llsjjwgl HsjwK

.5-./-0.01
0.4

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
V?LRFGLCQ+BPSEQRMRPC?RAMNB		
RFCM+02MP?JA?NQSJCCVRCLBCBPCJC?QC02 FMSP/..KE*0..KE*1..KE*2..KE &*theophylline*'	LD	
theophylline er oral tablet extended release 12 hour 300 mg, 450 mg	NE	
theophylline er oral tablet extended release 24 hour 400 mg, 600 mg	NE	
theophylline oral elixir 80 mg/15ml	NE	
theophylline oral solution 80 mg/15ml	NE	
RMNGA?J+BPSEQRMRPC?RC?P?LBQIGL AMLBGRGMLQ		
BCPK?RMJMEW*?ALC		
?@QMPGA?JBMP?JA?NQSJC/4KE*02KE*10KE*6KE &*isotretinoin micronized*'	LD	
?@QMPGA?MP?JA?NQSJC/.KE*0.KE*03KE*1.KE*13KE*2.KE &*isotretinoin*'	LD	
?A?LW?CVRCPL?JECJ/,0+0,3 # &*clindamycin phos-benzoyl perox*'	LD	
isotretinoin &?aasr_lcMp_jA_nqsjc0.Ke*1.Ke*2.Ke'	LN	N?
?AXMLCCVRCPL?JECJ3#*5,3 # &*dapsone*'	LD	
adapalene external cream 0.1 %	LN	N?9OJ &23 Encp03b_wq'9?J&K_v13Wc_pq'
adapalene external gel 0.1 %	NE	N?9QcjcarMRA9OJ &23 Encp03b_wq'9?J&K_v13Wc_pq'
adapalene external gel 0.3 %	LN	N?9OJ &23 Encp03b_wq'9?J&K_v13Wc_pq'
adapalene external pad 0.1 %	LD	
adapalene external solution 0.1 %	LD	
adapalene-benzoyl peroxide external gel 0.1-2.5 %, 0.3-2.5 %	NE	N?9?J&K_v13Wc_pq'
?IJGCDCVRCPL?JAPC?K .,..3 # &*trifarotene*'	N@	N?
?JRPCLMCVRCPL?JJMRGML .,.3 # &*tretinoin*'	LD	
isotretinoin &?klcqrcckMp_jA_nqsjc/.Ke*0.Ke*2.Ke'	LN	N?
?KXCCOCVRCPL?JDM?K2 # &*minocycline hcl micronized*'	LD	

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
?P?XJM CVRCP L?J JMRGML .,.23 # &*tazarotene*'	N@	N?9 ?J &K_v 13 Wc_pq'
?RP?JGL CVRCP L?J ECJ .,.3 # &*tretinoin*'	LD	
tretinoin &?tgr_ Cvrcpl_j Ecj .,.03 #'	NE	N?9 ?J &K_v 13 Wc_pq'
?XCJCV CVRCP L?J APC?K 0. # &*azelaic acid*'	LD	
benzoyl peroxide-erythromycin external gel 5-3 %	NE	
isotretinoin &Aj_p_tgq Mp_j A_nqsjc /. Ke*0. Ke*1. Ke*2. Ke'	LN	N?
AJCMAGL+R CVRCP L?J JMRGML / # &*clindamycin phosphate*'	LN	OJ &4. KJ ncp 03 B?Wq'
clindamycin phosphate &Ajglb_agl+N Cvrcpl_j Qu_` / #'	NE	
AJGLB?ECJ CVRCP L?J ECJ / # &*clindamycin phosphate*'	LD	
clindamycin phos-benzoyl perox external gel 1.2-2.5 %	NE	
clindamycin phos-benzoyl perox external gel 1-5 %, 1.2-5 %	LN	
clindamycin phosphate external foam 1 %	LN	L6 &Jgqrgle bmcq lmr glajsbc acpr_gl LBAq'
clindamycin phosphate external gel 1 %	LN	L6 &Jgqrgle bmcq lmr glajsbc acpr_gl LBAq'9 OJ &53 E ncp 03 b_wq'
clindamycin phosphate external lotion 1 %	LN	OJ &4. KJ ncp 03 b_wq'
clindamycin phosphate external solution 1 %	LN	OJ &4. KJ ncp 03 b_wq'
clindamycin-tretinoin external gel 1.2-0.025 %	LN	N?9 L6 &Jgqrgle bmcq lmr glajsbc acpr_gl LBAq'9 ?J &K_v 13 Wc_pq'
dapsone external gel 5 %, 7.5 %	NE	
BGDDCPGL CVRCP L?J APC?K .,/ # &*adapalene*'	LN	N?9 OJ &23 E ncp 03 b_wq'9 ?J &K_v 13 Wc_pq'
BGDDCPGL CVRCP L?J ECJ .,/ # &*adapalene*'	NE	N?9 Qcjcar MRA9 OJ &23 E ncp 03 b_wq'9 ?J &K_v 13 Wc_pq'
BGDDCPGL CVRCP L?J ECJ .,1 # &*adapalene*'	LN	N?9 OJ &23 E ncp 03 b_wq'9 ?J &K_v 13 Wc_pq'
BGDDCPGL CVRCP L?J JMRGML .,/ # &*adapalene*'	LD	
CNGBSM CVRCP L?J ECJ .,/+0,3 # &*adapalene-benzoyl peroxide*'	N@	N?9 ?J &K_v 13 Wc_pq'

0.01 Nf_pk_aw Bpse Esgbc+?bt_lacb Amlrpmj Nj_l+?crl_Qrsbclr Fc_jrf

Rfc dmpksj_pwgq snb_rcb _llsjjwgl HsjwK

.5-./-0.01

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
CNGBSM DMPRC CVRCPL?J ECJ .,1+0,3 # &*adapalene-benzoyl peroxide*'	N@	N?9?J&K_v 13 Wc_pq'
ery external pad 2 %	NE	
CPWECJ CVRCPL?J ECJ 0 # &*erythromycin*'	LN	OJ &4. E ncp 03 B?Wq'
erythromycin external gel 2 %	NE	OJ &4. E ncp 03 b_wq'
erythromycin external solution 2 %	NE	OJ &4. KJ ncp 03 b_wq'
D?@GMP CVRCPL?J DM?K .,/ # &*tazarotene*'	LD	
isotretinoin oral capsule 10 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg	LN	N?
IJ?PML CVRCPL?J JMRGML /. # &*sulfacetamide sodium (acne)*'	LN	QR
MLCVRML CVRCPL?J ECJ /,0+1,53 # &*clindamycin phos-benzoyl perox*'	N@	
PCRGL+? CVRCPL?J APC?K .,.03 #* .,.3 #* .,/ # &*tretinoin*'	LN	N?9?J&K_v 13 Wc_pq'
PCRGL+? CVRCPL?J ECJ .,./ #* .,.03 # &*tretinoin*'	LN	N?9?J&K_v 13 Wc_pq'
PCRGL+? KGAPM CVRCPL?J ECJ .,.2 #* .,/ # &*tretinoin microsphere*'	LN	N?9?J&K_v 13 Wc_pq'
PCRGL+? KGAPM NSKN CVRCPL?J ECJ .,.2 #* .,.4 #* .,.6 #* .,/ # &*tretinoin microsphere*'	LN	N?9?J&K_v 13 Wc_pq'
sulfacetamide sodium (acne) external lotion 10 %	NE	
tazarotene external foam 0.1 %	LD	
tretinoin external cream 0.025 %, 0.05 %, 0.1 %	NE	N?9?J&K_v 13 Wc_pq'
tretinoin external gel 0.01 %	NE	N?9?J&K_v 13 Wc_pq'
tretinoin external gel 0.05 %	LN	N?9?J&K_v 13 Wc_pq'
tretinoin microsphere external gel 0.04 %, 0.1 %	NE	N?9?J&K_v 13 Wc_pq'
RUWLCM CVRCPL?J APC?K .,/+1 # &*tretinoin-benzoyl peroxide*'	N@	
TCJRGL CVRCPL?J ECJ /,0+.,.03 # &*clindamycin-tretinoin*'	LD	
UGLJCTG CVRCPL?J APC?K / # &*clascoterone*'	N@	N?
isotretinoin &Xcl_r_lc Mp_j A_nqsjc /. Ke*0. Ke*1. Ke*2. Ke'	LN	N?
XG?L? CVRCPL?J ECJ /,0+.,.03 # &*clindamycin-tretinoin*'	LD	

0.01 Nf_pk_aw Bpse Esgbc+?bt_lacb Amlrpmj Nj_l+?crl_Qrsbclr Fc_jrf

Rfc dmpksj_pwgq snb_rcb _llsjjwgl HsjwK

.5-./-0.01
0/.

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
BCP K ?RMJMEW* ?ARGLGA ICP?RMQGQ		
A?P?A CVRCP L ?J APC? K .,3 # &*fluorouracil*'	LD	
fluorouracil external cream 0.5 %	LD	
fluorouracil external cream 5 %	NE	
fluorouracil external solution 2 %, 5 %	NE	
imiquimod external cream 5 %	NE	OJ &0 @MVCQ ncp 0/ b_wq'
imiquimod pump external cream 3.75 %	LN	N?
I JGQWPG CVRCP L ?J MGLRKCLR / # &*tirbanibulin*'	LD	
XWAJ?P? CVRCP L ?J APC? K 1,53 # &*imiquimod*'	LD	
XWAJ?P? NS KN CVRCP L ?J APC? K 0,3 #* 1,53 # &*imiquimod*'	LD	
BCP K ?RMJMEW* ?LRG@GMRGAQ		
gentamicin sulfate external cream 0.1 %	NE	OJ &/0. E ncp 03 b_wq'
gentamicin sulfate external ointment 0.1 %	NE	OJ &/0. E ncp 03 b_wq'
mafenide acetate external packet 5 %	NE	
mupirocin calcium external cream 2 %	LD	
mupirocin external ointment 2 %	NE	OJ &1. E K ncp 03 B ?Wq'
LCM+QWL ?J ?P CVRCP L ?J APC? K .,3+.,.03 # &*neomycin-fluocinolone*'	LD	
silver sulfadiazine external cream 1 %	NE	
silver sulfadiazine &Qqb Cvrcp l_j Apc_k / #'	NE	
VCNG CVRCP L ?J APC? K / # &*ozenoxacin*'	LN	N?9 OJ &1. E ncp 03 B ?Wq'
BCP K ?RMJMEW* ?LRGDSLE?JQ		
ciclopirox external gel 0.77 %	LN	
ciclopirox external shampoo 1 %	LN	
ciclopirox external solution 8 %	NE	N?9 QRV9 OJ &4,4 K J ncp 0/ b_wq'
ciclopirox olamine external cream 0.77 %	NE	
ciclopirox olamine external suspension 0.77 %	LN	
clotrimazole-betamethasone external cream 1-0.05 %	NE	QRV9 OJ &4. E K ncp 03 b_wq'
clotrimazole-betamethasone external lotion 1-0.05 %	NE	QRV9 OJ &4. K J ncp 03 b_wq'

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq _lb Jgkgrq
sulconazole nitrate external solution 1 %	NE	OJ &4. K J ncp 03 b_wq'
tavaborole external solution 5 %	LD	
TSQGML CVRCPL?J MGLRKCLR .,03+/3+6/,13 # &*miconazole-zinc oxide-petrolat*'	LD	
BCPK?RMJMEW* ?LRGNPSPGRGA		
doxepin hcl external cream 5 %	LD	
NPSBMVGL CVRCPL?J APC?K 3 # &*doxepin hcl (antipruritic)*'	LN	QR9 OJ &23 E ncp 03 b_wq'
XML?JML CVRCPL?J APC?K 3 # &*doxepin hcl (antipruritic)*'	LN	QR9 OJ &23 E ncp 03 b_wq'
BCPK?RMJMEW* ?LRGNQMPG?RGAQ		
acitretin oral capsule 10 mg, 17.5 mg, 25 mg	NE	N?9 OJ &4. A?NQSJCQ ncp 03 b_wq'
calcipotriene external cream 0.005 %	LD	
calcipotriene external foam 0.005 %	LD	
calcipotriene external ointment 0.005 %	LN	QR9 OJ &4. E K ncp 03 b_wq'
calcipotriene external solution 0.005 %	LN	QR9 OJ &4. K J ncp 03 b_wq'
calcitriol external ointment 3 mcg/gm	LD	
methoxsalen rapid oral capsule 10 mg	NE	
QMPGJSV CVRCPL?J DM?K .,..3 # &*calcipotriene*'	LD	
QMRWIRS MP?J R?@JCR 4 K E &*deucravacitinib*'	LD	
tazarotene external cream 0.1 %	NE	N?9 ?J &K_v 13 Wc_pq'
tazarotene external gel 0.05 %, 0.1 %	LD	
R?XMP?A CVRCPL?J APC?K .,.3 #* .,/ # &*tazarotene*'	LD	
R?XMP?A CVRCPL?J ECJ .,.3 #* .,/ # &*tazarotene*'	LD	
TCARGA?J CVRCPL?J MGLRKCLR1 KAE-EK &*calcitriol*'	LD	
TR?K? CVRCPL?J APC?K / # &*tapinarof*'	LD	
UWLXMP? CVRCPL?J APC?K .,..3+.,.42 # &*calcipotriene-betameth diprop*'	LD	
XMPWTC CVRCPL?J APC?K .,1 # &*roflumilast*'	LD	
BCPK?RMJMEW* ?LRGQC@MPPFCGAQ		
ketoconazole external shampoo 2 %	NE	

0.01 Nf_pk_aw Bpse Esgbc+?bt_lacb Amlrpmj Nj_l+?crl_Qrsbclr Fc_jrf

Rfc dmpksj_pwgq snb_rcb _llsjjwgl HsjwK

.5-./-0.01

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
BCPK?RMJMEW* ?RMNGA BCPK?RGRGQ		
?B@PWQS@ASR?LCMSQQMJSRGML NPCDGJJCB QWPGLEC /3. KE-KJ &*tralokinumab-ldrm*'	NQN	N?9OJ &2 QWPGLECQ ncp 06 b_wq'
AG@GLOMMP?JR?@JCR /.. KE*0.. KE*3. KE &*abrocitinib*'	NQN	N?9OJ &1. R?@JCRQ ncp 1. b_wq'
BSNGVCLRQS@ASR?LCMSQQMJSRGML NCL+ GLHCARMP 0.. KE-/,/2KJ &*dupilumab*'	NQN	N?9OJ &0 NCLQ ncp 06 B_wq'
BSNGVCLRQS@ASR?LCMSQQMJSRGML NCL+ GLHCARMP 1.. KE-0KJ &*dupilumab*'	NQN	N?9OJ &2 NCLQ ncp 06 B_wq'
BSNGVCLRQS@ASR?LCMSQQMJSRGML NPCDGJJCB QWPGLEC 0.. KE-/,/2KJ &*dupilumab*'	NQN	N?9OJ &0 QWPGLECQ ncp 06 B_wq'
BSNGVCLRQS@ASR?LCMSQQMJSRGML¾` γ.	∃. NQN Î	B[illegible] σ k@A[illegible] *dupil ɔ mab*'

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb
halobetasol propionate	N@	
calcipo iene-betameth diprop exte l'		
calcipo iene-betameth diprop exte l'	*0.005-0.064*	
fluoc ˛ ˚ ˛ γ / acetonide		
clobetasol propionate e exte l' 0.05 %	LN	
clobetasol propionate emulsion exte l' 0.05 %		
clobetasol propionate exte l' 0.05 %	LN	
clobetasol propionate exte l' 0.05 %	LN	
clobetasol propionate exte l' 0.05 %	LN	
clobetasol propionate exte l' 0.05 %		
clobetasol propionate exte l' ˛ 0.05 %	LN	
clobetasol propionate exte l' 0.05 %	LN	
clobetasol propionate exte l' 0.05 %	LN	
clobetasol propionate exte l' 0.05 %	LN LN	
propionate propionate	LN	
clocortolone ɹ ȳ m ʒ˚ ʒ D γ / γ ɲ D Ч γ ʒ`	*0.1 %*	
pivalate flurandM γ˛ ˚ ȳ ƙ γ	LN	
flurandM γ˛ ˚ ȳ ƙ γ		
flurandM γ˛ ˚ ȳ ƙ γ		
fluocinolone ʒ p γ B ˛ ȳ ƙ γ de ʒ ƒ γ ˚˛ nal c γ	LN LN LN	

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
desonide external gel 0.05 %	LD	
desonide external lotion 0.05 %	LN	ON&/0

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
SJRP?T?RC CVRCP L?J JMRGML .,.3 # &*halobetasol propionate*'	LD	
T?LMQ CVRCP L?J APC?K .,/ # &*fluocinonide*'	LD	
TCP BCQM CVRCP L?J DM?K .,.3 # &*desonide*'	LD	
BCP K?RMJMEW* JMA?J ?LCQRFCRGAQ		
lidocaine external ointment 5 %	LN	OJ &3. E K ncp 03 B?Wq'
lidocaine external patch 5 %	LN	N?9 OJ &7. N?RAFCQ ncp 03 B?Wq'
lidocaine hcl external solution 4 %	NE	OJ &3. K J ncp 03 B?Wq'
lidocaine-prilocaine external cream 2.5-2.5 %	NE	OJ &1. E ncp 03 b_wq'
JGBMBCP K CVRCP L?J N?RAF 3 # &*lidocaine*'	LN	N?9 OJ &7. N?RAFCQ ncp 03 B?Wq'
NJG?EJGQ CVRCP L?J APC?K 5+5 # &*lidocaine-tetracaine*'	LD	
	LD	

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
KCRPMAPC?K CVRCPL?J APC?K .,53 # &*metronidazole*'	LN	QR9 OJ &4. E ncp 03 b_wq'
KCRPMECJ CVRCPL?J ECJ / # &*metronidazole*'	LD	
KCRPMJMRGML CVRCPL?J JMRGML .,53 # &*metronidazole*'	LN	OJ &4. KJ ncp 03 B?Wq'
metronidazole external cream 0.75 %	NE	OJ &4. E ncp 03 b_wq'
metronidazole external gel 0.75 %	NE	OJ &4. E ncp 03 b_wq'
metronidazole external gel 1 %	LN	OJ &4. E ncp 03 b_wq'
metronidazole external lotion 0.75 %	NE	OJ &4. KJ ncp 03 b_wq'
KGPT?QM CVRCPL?J ECJ .,11 # &*brimonidine tartrate*'	LD	
LMPGR?RC CVRCPL?J APC?K / # &*metronidazole*'	LD	
MP?AC? MP?J A?NQSJC BCJ?WCB PCJC?QC 2. KE &*doxycycline*'	N@	
PFMD?BC CVRCPL?J APC?K / # &*oxymetazoline hcl*'	LD	
QMMJ?LRP? CVRCPL?J APC?K / # &*ivermectin*'	N@	
XGJVG CVRCPL?J DM?K /,3 # &*minocycline hcl micronized*'	LD	
BCPK?RMJMEW* QA?@GAGBCQ ?LB NCBGASJGAGBCQ		
APMR?L CVRCPL?J JMRGML /. # &*crotamiton*'	NE	
malathion external lotion 0.5 %	NE	
permethrin external cream 5 %	NE	
spinosad external suspension 0.9 %	NE	
BCPK?RMJMEW* UMSLB A?PC ?ECLRQ		
acetic acid irrigation solution 0.25 %	NE	
PCEP?LCV CVRCPL?J ECJ .,./ # &*becaplermin*'	LN	N?9 OJ &1. E ncp 03 b_wq'
KMSRF-RFPM?R-BCLR?J ?ECLRQ		
cevimeline hcl oral capsule 30 mg	NE	
chlorhexidine gluconate mouth/throat solution 0.12 %	NE	
clotrimazole mouth/throat troche 10 mg	NE	OJ &7. JMXCL ECQ ncp 03 b_wq'
lidocaine viscous hcl mouth/throat solution 2 %	NE	
nystatin mouth/throat suspension 100000 unit/ml	NE	
MP?TGE @SAA?JR?@JCR 3. KE &*miconazole*'	LN	OJ &/2 R?@JCRQ ncp 03 b_wq'

0.01 Nf_pk_aw Bpse Esgbc+?bt_lacb Amlrpmj Nj_l+?crl_Qrsbclr Fc_jrf

Rfc dmpksj_pwgq snb_rcb _llsjjwgl HsjwK

.5-./-0.01

Npcqapgnrgml Bpse L_kc	Bpse Rgcp	Amtcp_ec Pcosgpckclrq_lb Jgkgrq
pilocarpine hcl oral tablet 5 mg, 7.5 mg	NE	
triamcinolone acetonide mouth/throat paste 0.1 %	NE	
MRGA + BPSEQ RM RPC?R AML BGRGMLQ MD RFC C?P		
acetic acid otic solution 2 %	NE	
AGNPM FA MRGA QSQNCLQGML .,0+/ # &*ciprofloxacin-hydrocortisone*'	LD	L/.&LN'
AGNPMBCV MRGA QSQNCLQGML .,1+.,/ # &*ciprofloxacin-dexamethasone*'	LD	
ciprofloxacin hcl otic solution 0.2 %	LN	
ciprofloxacin-dexamethasone otic suspension 0.3-0.1 %	NE	
ciprofloxacin-fluocinolone pf otic solution 0.3-0.025 %	LD	L/.&LN'
fluocinolone acetonide otic oil 0.01 %	LN	
hydrocortisone-acetic acid otic solution 1-2 %	NE	
neomycin-polymyxin-hc otic solution 1 %	NE	
neomycin-polymyxin-hc otic suspension 3.5-10000-1	NE	
ofloxacin otic solution 0.3 %	NE	
MRMTCJ MRGA QMJSRGML .,1+.,.03 # &*ciprofloxacin-fluocinolone*'	LD	

0.01 Nf_pk_aw Bpse Esgbc + ?bt_lacb Amlrpmj Nj_l + ?crl_Qrsbclr Fc_jrf

Rfc dmpksj_pwgq snb_rcb _llsjjwgl Hsjwk

.5-./-0.01
000

abacavir sulfate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,06
abacavir sulfate-lamivudine,,,,,,10
?@GJGDW,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,56
?@GJGDW ?QGKRSDGG,,,,,,,,,,,56
?@GJGDW K?GLRCL?,,,,,,,,,56
abiraterone acetate,,,,,,,,,,,,,,,,,,,,21
?@PCT?,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0/7
?@QMPGA?,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.6
?@QMPGA? JB,,,,,,,,,,,,,,,,,,,,,,,,,0.6
acamprosate calcium,,,,,,,,,,,,,,,,,46
?A?LW?,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.6
acarbose,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,/.7
?AAPSDCP,,,,,,,,,,,,,,,,,,,,,,,,,,,,/66
?AAS+AFCI ?TGT? NJSQ
,,/04
?AAS+AFCI D?QRAJGV
J?LACRQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,/04
?AAS+AFCI ESGBC,,,,,,,,,/04
?AAS+AFCI
QK?PRTGCU,,,,,,,,,,,,,,,,,,,,,,,,,,,,,/04
?AAS+AFCI QMDRAJGV
J?LACRQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,/04
?aasr_lc,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.6
?AASRPCLB EJSAMQC,,/04
acebutolol hcl,,,,,,,,,,,,,,,,,,,,,,,,,,,,4.
acetaminophen-codeine,,,,,,,,,,,,,/6
acetazolamide,,,,,,,,,,,,,,,,,,,,,,,,,,,,41
acetazolamide er,,,,,,,,,,,,,,,,,,,,,,,,41
acetic acid,,,,,,,,,,,,,,,,,,,,,,,,,,00/* 000
acetylcysteine,,,,,,,,,,,,,,,,,,,,,,,,,,0.2
?AGNFCV,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,/33
acitretin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0/1
?ARCKP?,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,/5/
?ARCKP? ?ARNCL,,,,,,,,,,/5/
?ARF?P,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,/23
?ARGK KSLC,,,,,,,,,,,,,,,,,,,,,,,,/6/
?ARGO,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,/6
?ARMLCJ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,//6
?ARMQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,//4
?AST?GJ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,/70
acyclovir,,,,,,,,,,,,,,,,,,,,,,,,,,,,12* 0/7
?AXMLC,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.6
adapalene,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.6
adapalene-benzoyl peroxide,,,,0.6
?B@PW,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0/2
?BAGPA?,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,44
?BBCP?JJ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,65
?BBCP?JJ VP,,,,,,,,,,,,,,,,,,,,,,,,,,,,65
?BBWG,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,/.3
adefovir dipivoxil,,,,,,,,,,,,,,,,,,,,,,,12
?BCKN?Q,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,44
?BGNCV+N,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,//6
?BJ?PGRW,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,47
?BKCJME,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,///
?BKCJME QMJMQR?P,,,,,///
?BRFWX?,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,/25
?BT?GP BGQISQ,,,,,,,,,,,,,,,,,0.5
?BT?GP FD?,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.5
?BT?LACGLRSGRGML
RCQR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,/05
?BT?LAC KGAPM+BP?U
RCQR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,/05
?BT?RC,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,/44
?BTMA?RC PCBG+AMBC,,/05
?BTMA?RC PCBG+AMBC)
RCQR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,/05
?BTMA?RC RCQR,,,,,,,,,,,,,,,,/05
adynovate,,,,,,,,,,,,,,,,,,,

amiloride hcl ,,,,,,,,,,,,,,,,,,,,,,,,,,,,, 41
amiloride-hydrochlorothiazide ,, 41
aminocaproic acid ,,,,,,,,,,,,,,,,,,,, / 46
amiodarone hcl ,,,,,,,,,,,,,,,,,,,,,,,,,,,, 34
? K GRGX ? ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, / 30
amitriptyline hcl ,,,,,,,,,,,,,,,,, 5.*
? لم

carbamazepine er ,,,

colesevelam hcl ,,,,,,,,,,,,,,,,,,,,,,,,,35
colestipol hcl ,,,,,,,,,,,,,,,,,,,,,,,,,,,, 35
colistimethate sodium (cba) ,,,,, 17
AMK@GE?L ,,,,,,,,,,,,,,,,,,,,,,,, /7.
AMK@GN?RAF ,,,,,,,,,,,,,,,,,,,, /16
AMK@GTCLR PCQNGK?R,, /74
AMK@GTGP ,,,,,,,,,,,,,,,,,,,,,,,,,,,, 10
AMKCRPGO&/.. KE
B?GJW BMQC' ,,,,,,,,,,,,,,,,,,,,,,,24
AMKCRPGO&/2. KE
B?GJW BMQC' ,,,,,,,,,,,,,,,,,,,,,,,24
AMKCRPGO&4. KE B?GJW
BMQC' ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,24
comfort assured lancets 28g ,,,, /07
comfort assured lancets 33g ,,,, /07
AMKDMPR RMSAF
J?LACRQ1/E ,,,,,,,,,,,,,,,,,,,, /07
AMKDMPR RMSAF NJSQ
J?LACRQ1.E ,,,,,,,,,,,,,,,,,,,, /07
AMKNJCP? ,,,,,,,,,,,,,,,,,,,,,,,,,, 10
complete natal dha ,,,,,,,,,,,,,,,,,, /62
completenate ,,,,,,,,,,,,,,,,,,,,,,,,, /62
Amknpm ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, /3.
AMLACNR M@ ,,,,,,,,,,,,,,,,,,,,,, /62
AMLACPR? ,,,,,,,,,,,,,,,,,,,,,,,,,, 66
condoms ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, /00 /,,k,,,,,,,,,,,,,,,, ,,,,,,,,,

,,,,,,,,,,,,,,,,,,,,,,,,
/ /

dexmethylphenidate hcl er ,,,66* 67
dextroamphetamine sulfate ,,,,,,67
dextroamphetamine sulfate er ,,,67
BFGTW ,,,,,,

DPCCQRWJC GLQSJGLV
RCQR,,,

GQMPBGJ RGRP?BMQC,,,,,,,,,43
isosorb dinitrate-hydralazine,,,,,42
isosorbide dinitrate,,,,,,,,,,,,,,,,,,,43
isosorbide mononitrate,,,,,,,,,,,,, 43
isosorbide mononitrate er,,,,,,,,,43
isotretinoin,,,,,,,,,,,,,,,,,,,,,,,,,,,,0/.
isradipine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, 40
GQR?JMJ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,/7.
GQRSPGQ?,,,,,,,,,,,,,,,,,,,,,,,,,,,, /04
itraconazole,,,,,,,,,,,,,,,,,,,,,,,,,,,,, 05
ivermectin,,,,,,,,,,,,,,,,,,,,,,,,04* 00.
GVGLGRW,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,/46
H?BCLS,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, /0.
H?BCLS QNPGL I JC,,,,,,,,,/0.
H?I?DG,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,26
H?JWL ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,/36
H?LSKCR,,,,,,,,,,,,,,,,,,,,,,,,,, //.
H?LSKCR VP,,,,,,,,,,,,,,,,,,,,,//.
H?LSTG?,,,,,,,,,,,,,,,,,,,,,,,,,,,,,//.
H?PBG?LAC,,,,,,,,,,,,,,,,,,,,,,,,//5
H?RCLXM,,,,,,,,,,,,,,,,,,,,,,,,,,,,/.6
H?WNGPA?,,,,,,,,,,,,,,,,,,,,,,,,,,,,,26
jenliva prenatal/postnatal,,,,,,,,/63
HCLR?BSCRM,,,,,,,,,,,,,,,,,,,,,//.
HCLR?BSCRM VP,,,,,,,,,,,,, //.
HgIrcjg,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,/17
HGTG,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, /44
HMCLH?,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,/6/
HMPL?WNK,,,,,,,,,,,,,,,,,,,,,,,, 67
HS@JG?,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0/0

0/0

0/0

/44

0/0 ļ 23 3

خم 0/0

ļ ļ ļ ļ ļ ļ ,,,π ļ ļ ļ ļ ļ ļ ļ بج ļ ,n ļ ḃ ļ ,,,,,

,,,,

leucovorin calcium ,,,,,,,,,,,,,,,,,,,,,31
JCS I CP? L ,,,,,,,,,,,,,,,,,,,,,,,,,,,20
JCS I GLC,,,,,,,,,,,,,,,,,,,,,,,,,,,, /42
leuprolide acetate ,,,,,,,,,,,,,,,,,,,,22
levalbuterol hcl ,,,,,,,,,,,,,,,,,,,,,0. .
levalbuterol tartrate,,,,,,,,,,,,,,,,0. .
levamlodipine maleate,,,,,,,,,,,,,, 40
JCTCKGP ,,,,,,,,,,,,,,,,,,,,,,,,,,,, / /2
JCTCKGP DJCVNCL ,,,,,,,,,/ /2
levetiracetam,,,,,,,,,,,,,,,,,,,,,,,,,,62
levetiracetam er,,,,,,,,,,,,,,,,,,,,,,62
levobunolol hcl,,,,,,,,,,,,,,,,,,,,,,/7.
levocarnitine,,,,,,,,,,,,,,,,,,,,,,,,/0.
levocetirizine dihydrochloride,,/77
levofloxacin,,,,,,,,,,,,,,,,,,,,, 15* /70
levonorgest-eth estrad 91-day, /01
levonorgestrel-ethinyl estrad,,, /01
levorphanol tartrate,,,,,,,,,,,,,,,,,0.
levothyroxine sodium,,,,,,,,,,,,,, /26
JCTSJ?L ICP?QRGA I ,,,,00.
JCV?NPM,,,,,,,,,,,,,,,,,,,,,,,,,,,,,51
JCVCRRC,,,,,,,,,,,,,,,,,,,,,,,,,,,,0/5
JCVGT? ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.
JG?JB? ,,,,,,,,,,,,,,,,,,,,,,,,,,,,, /3/
JG@CPRW LCVR
ECLCP?RGML RCQR,,,,,,,,,/11
liberty test,,,,,,,,,,,,,,,,,,,,,,,,,,/11
JG@P?V ,,,,,,,,,,,,,,,,,,,,,,,,,,,,, /3/
JGA?PR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,00.
lidocaine,,,,,,,,,,,,,,,,,,,

KCIRMTG,,,,,,,,,,,,,,,,,,,,,,,,,,,,,27
meloxicam,,,,,,,,,,,,,,,,,,,,,,,,,,,,,/5
melphalan,,,,,,,,,,,,,,,,,,,,,,,,,,,,,20
memantine hcl,,,,,,,,,,,,,,,,,,,,,,,,,5.

L ?R? JTGR,,,,,,,,,,,,,,,,,,,,,,,,,,,, /63
L ?R? XG? ,,,,,,,,,,,,,,,,,,,,,,,,,,,,, /02
nateglinide,,,,,,,,,,,,,,,,,,,

/53

MBMKXM,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30
MDCT,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.3
ofloxacin,,,,,,,,,,,,,,,,,,,,,,,,,/70* 000
olanzapine,,,,,,,,,,,,,,,,,,,,,,,,,,,,6.
olanzapine-fluoxetine hcl,,,,,,,, /.3
olmesartan medoxomil,,,,,,,,,,,,, 34
olmesartan medoxomil-hctz,,,,,,33
olmesartan-amlodipine-hctz,,,,,,33
olopatadine hcl,,,,,,,,,,,,,,,,,,,,,, /77
MJSKG?LR,,,,,,,,,,,,,,,,,,,,,,,,,/53
MJSV+C,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, 0/6
omega-3-acid ethyl esterp rp (

/77

MJSV+=

MJSV+=

MJSV+=

MJSV+C

C olmesartan

/53
MJSV+C

/53
MJSV+C

/53
MJSV+C

/77
MJSV+C

/53
MJSV+C

/53
MJSV+C

N?VGJ ,,,

NPMAWQ@G,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,/4.
NPMBGEW LM AMBGL E
@JMMB EJSA,,,,,,,,,,,,,,,,,,,,,,,,,/13
NPMDGJ LGL C,,,,,,,,,,,,,,,,,,,,,,,,,/46
progesterone,,,,,,,,,,,,,,,,,,,,,,,,,,,,/25
NPMEP?D,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,/60
NPMJ?QRGL+A,,,,,,,,,,,,,,,,,,,,,,,,,/73
NPMJ?RC,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,01
NPMJCLQ?,,,,,,,,,,,,,,,,,,,,,,,,,,,,/72
NPMJG?,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,/24
NPMK?AR?,,,,,,,,,,,,,,,,,,,,,,,,,,,/43
promethazine hcl,,,,,,,,,,,,,,,,,,,,,,/3.
promethazine vc,,,,,,,,,,,,,,,,,,,,,,,0.0
promethazine vc/codeine,,,,,,,,,0.0
promethazine-codeine,,,,,,,,,,,,,,0.0
promethazine-dm,,,,,,,,,,,,,,,,,,,,,0.0
NPMKCRFCE?L,,,,,,,,,,,,,,,,,/3.
NPMKCRPGSK,,,,,,,,,,,,,,,,,,,,,,,/25
propafenone hcl,,,,,,,,,,,,,,,,,,,,,,,34
propafenone hcl er,,,,,,,,,,,,,,,,,,,,34
propranolol hcl,,,,,,,,,,,,,,,,,,,,,,,4/
propranolol hcl er,,,,,,,,,,,,,,,,,,,,4/
propylthiouracil,,,,,,,,,,,,,,,,,,,,,,/26
NPMQA?P,,,,,,,,,,,,,,,,,,,,,,,,,,,,,/36
NPMRMLGV,,,,,,,,,,,,,,,,,,,,,,,,,,,,/34
protriptyline hcl,,,,,,,,,,,,,,,,,,,,,,53
NPMTCLRGJ FD?,,,,,,,,,,,,,,,0..
NPMTGB? M@,,,,,,,,,,,,,,,,,,,,,,,,/64
NPMTGEGJ,,,,,,,,,,,,,,,,,,,,,,,,,,,,/.1
NPMX?A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,53
NPSBMVGL,,,,,,,,,,,,,,,,,,,,,,,,,,0/1
pseudoeph-bromphen-dm,,,,,,,,0.0
NRQN?LCJQCEJS RCQR,/13
NSJKGAMPR,,,,,,,,,,,,,,,,,,,,,,,,,,0.4
NSJKGAMPR
DJCVF?JCP,,,,,,,,,,,,,,,,,,,,,,,,0.4
NSJKMXWKC,,,,,,,,,,,,,,,,,,,,,,,,0.1
NSPGV?L,,,,,,,,,,,,,,,,,,,,,,,,,,,,,20
NWJCP?,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,/35
pyrazinamide,,,,,,,,,,,,,,,,,,,,,,,,,,12
pyridostigmine bromide,,,,,,,,,,,,75
pyridostigmine bromide er,,,,,,,,75
pyrimethamine,,,,,,,,,,,,,,,,,,,,,,,,17
NWPSIWLB,,,,,,,,,,,,,,,,,,,,,,,,,,/46
NWPSIWLB R?NCP
N?AI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,/46
qc lansoprazole,,,,,,,,,,,,,,,,,,,,,,/34
OBMJM,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,01
OCJ@PCC,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,7/
OGLJMAI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,27
OL?QJ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.2
OL?QJ AFGJBPCLQ,,,,,,,,,0.2
OQWKG?,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,//6
ORCPL,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,//5
quad-mix,,,,,,,,,,,,,,,,,,,,,,,,,,,,/37
OS?PRCRRC,,,,,,,,,,,,,,,,,,,,,,,,,,/02
quazepam,,,,,,,,,,,,,,,,,,,,,,,,,,,,,71
OSBCVW VP,,,,,,,,,,,,,,,,,,,,,,,,,,,63
quetiapine fumarate,,,,,,,,,,,,,,,,,6.
quetiapine fumarate er,,,,,,,,,,,,,,- ă Ŏ

PCXTMEJ?P IUGINCL,,//3
PFMD?BC,,,,,,,,,,,,,,,,,,,,,,,,,,,,00/
PFME?K SJRP?+
DGJRCPCB NJSQ,,,,,,,,,,,,,,,,,/6/
PFMNFWJ?A,,,,,,,,,,,,,,,,,,,,,/6/
PFMNPCQQ?,,,,,,,,,,,,,,,,,,,,,,/7.
PG?QR?N,,,,,,,,,,,,,,,,,,,,,,,,,/41
ribavirin,,,,,,,,,,,,,,,,,,,,,,,,,,,,16
rifabutin,,,,,,,,,,,,,,,,,,,,,,,,,,,,12
rifampin,,,,,,,,,,,,,,,,,,,,,,,,,,,,12
PGEFRCQR EQ/..@JMMB
EJSAMQC,,,,,,,,,,,,,,,,,,,,,,,,,/13
PGEFRCQR EQ33.@JMMB
EJSAMQC,,,,,,,,,,,,,,,,,,,,,,,,,/13
riluzole,,,,,,,,,,,,,,,,,,,,,,,,,,,,75
rimantadine hcl,,,,,,,,,,,,,,,,,,,,,,13
PGLTMO,,,,,,,,,,,,,,,,,,,,,,/53*/54
PGMKCR,,,,,,,,,,,,,,,,,,,,,,,,,,,,/.7
risedronate sodium,,,,,,,,,,,,,,,,,,//7
risperidone,,,,,,,,,,,,,,,,,,,,,,,,,,6.
PGR?JGL,,,,,,,,,,,,,,,,,,,,,,,,,,,,,7/
PGR?JGL J?,,,,,,,,,,,,,,,,,,,,,,,,7/
ritonavir,,,,,,,,,,,,,,,,,,,,,,,,,,,,1/
rivastigmine,,,,,,,,,,,,,,,,,,,,,,,,,5.
rivastigmine tartrate,,,,,,,,,,,,,,,,,5.
Pgtcjq_,,,,,,,,,,,,,,,,,,,,,,,,,,,,,/03
rixubis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,/46
rizatriptan benzoate,,,,,,,,,,,,,,,,,74
PM@GLSJ,,,,,,,,,,,,,,,,,,,,,,,,,,,/27
PM@GLSJ+DMPRC,,,,,,,,,,,,,,,,/27
PMAIJ?R?L,,,,,,,,,,,,,,,,,,,,,,/7.
roflumilast,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.2
PMJTCBML,,,,,,,,,,,,,,,,,,,,,,,,/43
ropinirole hcl,,,,,,,,,,,,,,,,,,,,,,,,,56
ropinirole hcl er,,,,,,,,,,,,,,,,,,,,,,56
rosuvastatin calcium,,,,,,,,,,,,,,,,,,36
PMQXCR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,37
PMU?Q?,,,,,,,,,,,,,,,,,,,,,,,,,,,,/30
PMVGAMBMLC,,,,,,,,,,,,,,,,,,,,,,,,,01
PMVW@MLB,,,,,,,,,,,,,,,,,,,,,,,,,,,02
PMXCPCK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,71
PMXJWRPCI,,,,,,,,,,,,,,,,,,,,,,,,,,,3.
PS@P?A?,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30
PSAMLCQR,,,,,,,,,,,,,,,,,,,,,,,,,,,/57
rufinamide,,,,,,,,,,,,,,,,,,,,,,,,,,,,63
PSIM@G?,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1/
PW?JRPGQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,/76
PW@CJQSQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,///
PWAJMP?,,,,,,,,,,,,,,,,,,,,,,,,,,,,,/77
PWB?NR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.
PWR?PW,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,56
PWTCLR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,/77
Q?@PGJ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,63
Q?DWP?J,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Q?GXCL,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,/22
Q?GXCLNPCN,,,,,,,,,,,,,,,,,,,,,,,,,,/22
Q?KQQ?G,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Q?PLA?SQM,,,,,,,,,,,,,,,,,,,,,,,,,,,/3.
Q?LBGKKSLC,,,,,,,,,,,,,,,,,,,,,,,,,/60
Q?LBMQR?RGL,,,,,,,,,,,,,,,,,,,,,,,,/.5
Q?LBMQR?RGL J?P
BCNMR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,/.5
Q?LRWJ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,00.
Q?NFPGQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6.
sapropterin dihydrochloride,,,,/16
sapscare twist top lancets,,,,,,,,/13
Q?T?WQ?,,,,,,,,,,,,,,,,,,,,,,,,,,,,/40
Q?TCJJ?,,,,,,,,,,,,,,,,,,,,,,,,,,,,,70
Q?TCJJ? RGRP?RGML
N?AI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,70
Q?VCLB?,,,,,,,,,,,,,,,,,,,,,,,,,,,,//6
QACK@JGV,,,,,,,,,,,,,,,,,,,,,,,,,,,3.
scopolamine,,,,,,,,,,,,,,,,,,,,,,,,,/3/
QC?QMLGOSC,,,,,,,,,,,,,,,,,,,,,,,,/03
QCAS?BM,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6.
QCEJCLRGQ,,,,,,,,,,,,,,,,,,,,,,,,,,,02
QCEJSPMKCR,,,,,,,,,,,,,,,,,,,,,,,//5
QCJCAR+M@,,,,,,,,,,,,,,,,,,,,,/64*/65
QCJCAR+M@)BF?,,,,,,,,,,,,,,,/65
selegiline hcl,,,,,,,,,,,,,,,,,,,,,,,,,,56
QCJXCLRPW,,,,,,,,,,,,,,,,,,,,,,,,,,1/
QCKEJCC&WDEL',,,,,,//3*//4
QCLQGN?P,,,,,,,,,,,,,,,,,,,,,,,,,,,,//7
QCPCTCLR BGQISQ,,,,,,,,,,0..
QCPLGTM,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0/6
QCPMOSCJ VP,,,,,,,,,,,,,,,,,,,,,,,,,6.
QCPMQRGK,,,,,,,,,,,,,,,,,,,,,,,,,,,,/22
sertraline hcl,,,,,,,,,,,,,,,,,,,,,,,,,,53
sevelamer carbonate,,,,,,,,,,,,,,,,,,/25
sevelamer hcl,,,,,,,,,,,,,,,,,,,,,,,,,/25
QCTCLD?AR,,,,,,,,,,,,,,,,,,,,,,,,,,,/41
QCWQ?P?,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2/
QDPMU?Q?,,,,,,,,,,,,,,,,,,,,,,,,,,,,/30
QFSP+QC?J
AMLRP?ACNRGTC,,,,,,,,,,,,,,,,/36
QGELGDMP,,,,,,,,,,,,,,,,,,,,,,,,,,,,/24
QGELGDMP J?P,,,,,,,,,,,,,,,,,,,,,,,/24
QGIJMQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,/47
sildenafil citrate,,,,,,,,,,,,,,,,,,45*/37
QGJCLMP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,71
QGJGO,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,/54
silodosin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,/36
silver sulfa^ ƒ.a....ite.....8
.....?.....11 1
R 1P 8

sotalol hcl (af) ,,,,,,,,,,,,,,,,,,,,,,,,,,,34
QMRW I RS ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0/1
QMT?JBG,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,16
spinosad,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, 00/
QNGPGT? F?LBGF?JCP,,, /75
QNGPGT? PCQNGK?R,,,,,,,,, /75
spironolactone,,,,,,,,,,,,,,,,,,,,,,,,,,,42
spironolactone-hctz,,,,,,,,,,,,,,,,,, 42
QNMP?LMV,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,06
QNP?T?RM&34 K E BMQC', 53
QNP?T?RM&62 K E BMQC', 53
QNPGR?K ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,63
QNPGV,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,/5
QNPWACJ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.
QNQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, /0/
Qqb,,0//
stavudine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1/
QRCEJ?RPM,,,,,,,,,,,,,,,,,,,,,,,, //5
QRCEJSH?L ,,,,,,,,,,,,,,,,,,,,,,,, //5
QRCJ?P? ,,,,,,,,,,,,,,,,,,,,,, /54* /55
QRCLBP? ,,,,,,,,,,,,,,,,,,,,,,,,,,,,/37
sterile water for im 117 ļ ļ ļ ļ ļ ļ ļ ļ ļ ļ

. B P...2...ļ 159 31

Q R C J ? ž

31 C J ? b 1 <

1q7

T?JAWRC,,,,,,,,,,,,,,,,,,,,,,,,,,,,,13
valganciclovir hcl,,,,,,,,,,,,,,,,,,,,,13
T?JGSK ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,64
valproic acid,,,,,,,,,,,,,,,,,,,,,,,,,,64
valsartan,,,,,,,,,,,,,,,,,,,,,,,,,,,,,34
valsartan-hydrochlorothiazide,,,33
T?JRMAM/. KE BMQC,,,,,,64
T?JRMAM/3 KE BMQC,,,,,,64
T?JRMAM0. KE BMQC,,,,,,64
T?JRMAM3 KE BMQC,,,,,,,64
T?JRPCV,,,,,,,,,,,,,,,,,,,,,,,,,,,,,13
T?LAMAGL ,,,,,,,,,,,,,,,,,,,,,,,,,,,17
vancomycin hcl,,,,,,,,,,,,,,,,,,,,,,17
T?LMQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0/7
vardenafil hcl,,,,,,,,,,,,,,,,,,,,,,,/37
varenicline tartrate,,,,,,,,,,,,,,,, /.5
T?PGXGE ,,,,,,,,,,,,,,,,,,,,,,,,,,,,/6/
T?PS@G&/6. KE BMQC',,, /3/
T?QACN? ,,,,,,,,,,,,,,,,,,,,,,,,,,,,, 37
TAD T?EGL?J
AMLRP?ACNRGTC,,,,,,,,,,,, /36
TCA?KWJ ,,,,,,,,,,,,,,,,,,,,,,,,,,,,43
TCARGA?J ,,,,,,,,,,,,,,,,,,,,,,,,,,0/1
TCJCRPG,,,,,,,,,,,,,,,,,,,,,,,,,,,,, 46
TCJGTCR,,,,,,,,,,,,,,,,,,,,,,,,,,,,/03
TCJNFMPM,,,,,,,,,,,,,,,,,,,,,,,,,/25
TCJR?QQ? ,,,,,,,,,,,,,,,,,,,,,,,,,,/0/
TCJRGL ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0/.
TCKJGBW,,,,,,,,,,,,,,,,,,,,,,,,,,,,13
TCLAJCVR?,,,,,,,,,,,,,,,,,,20* 21
TCLAJCVR? QR?PRGLE
N?AI ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, 21
venlafaxine besylate er,,,,,,,,,,,,, 54
venlafaxine hcl,,,,,,,,,,,,,,,,,,,,,,, 54
venlafaxine hcl er,,,,,,,,,,,,,,,,,,,, 54
TCLMDCP ,,,,,,,,,,,,,,,,,,,,,,,,,,,/67
TCLR?TGQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,46
TCLRMJGL FD?,,,,,,,,,,,,,,,,,0./
verapamil hcl,,,,,,,,,,,,,,,,,,,,,,,,41
verapamil hcl er,,,,,,,,,,,,,,,,,, 40* 41
verasens blood glucose test,,,,,,/14
TCPBCQM,,,,,,,,,,,,,,,,,,,,,,,,,,,0/7
TCPCECL ,,,,,,,,,,,,,,,,,,,,,,,,,,, 00.
TCPI?XG?,,,,,,,,,,,,,,,,,,,,,,,,,/72, - ,, ,,,,E ξ ϰᵛ ʎ ϰ/Ø2
TCPI?XG?

JN N ,, ,,,,,Ď ĺ Ä ĺ Ķ ĺ ĺ ĺ IJ Ţ t
- ,, ,,,, ϰ ´Y ₂ ,,,,,, s]] ĺ ĺ ĺ ĺ ĺ ĺ ,,,,,Ď ĺ Ä ĺ Ķ ĺ ĺ ĺ IJ
00. æĞæî Ğ .....Ď ĺ Ä ĺ Ķ ĺ ĺ ĺ IJ

VCJH?LXVP,,,,,,,,,,,,,,,,,,,,,,,,,/56
VCJMB?,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,20
VCJNPMQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,/7/
VCJQRPWK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,70
VCK@GDW,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,/6/
VCL?XGLC,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,76
VCLGA?J,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,//6
VCMKGL,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,/.1
VCNG,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0//
VCPCQC,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,13
VCPKCJM,,,,,,,,,,,,,,,,,,,,,,,,,,,,,/32
VECT?,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,/24
VF?LAC,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.2
VGD?V?L,,,,,,,,,,,,,,,,,,,,,,,,,,17*2.
VGEBSMVP,,,,,,,,,,,,,,,,,,,,,,,,,,,//5
VGGBP?,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,/72
VGKGLM,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2/
VMDJSX?&2.KEBMQC',,,13
VMDJSX?&6.KEBMQC',,,13
VMJ?GP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.3
VMNCLCVFD?,,,,,,,,,,,,,,,,,,,,,,,,,,0./
VMQN?R?,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3/
VNMTGM&/..KEMLAC
UCCIJW',,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30
VNMTGM&2.KEMLAC
UCCIJW',,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30
VNMTGM&2.KERUGAC
UCCIJW',,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30
VNMTGM&4.KEMLAC
UCCIJW',,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30
VNMTGM&4.KERUGAC
UCCIJW',,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30
VNMTGM&6.KEMLAC
UCCIJW',,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30
VNMTGM&6.KERUGAC
UCCIJW',,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30
VR?KNX?CP,,,,,,,,,,,,,,,,,,,,,,,,,,,02
VR?LBG,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,23
Vsj_Ic,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,/04
VSJRMNFW,,,,,,,,,,,,,,,,,,,,,,,,,,,///
VSPGBCL,,,,,,,,,,,,,,,,,,,,,,,,,,,,,/24
VWLRF?,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,/45
VWLRF?QMJMDSQC,,,,,,,,/45
VWMQRCB,,,,,,,,,,,,,,,,,,,,,,,,,,,,,/.7
VWPCK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,/.1
VWU?T,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,/.1
VWX?J?JJCPEW02FP,,,/77
W?QKGL06,,,,,,,,,,,,,,,,,,,,,,,,,,,,/04
W?X,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,/04 /04 /04,,,,,,,,,/75,,,,,,,,,/,,,,6[4&&?,,,,A[5,& / [6